

Disclaimer

The following report(s) provides findings from an FDA-initiated query using its Mini-Sentinel pilot. While Mini-Sentinel queries may be undertaken to assess potential medical product safety risks, they may also be initiated for various other reasons. Some examples include determining a rate or count of an identified health outcome of interest, examining medical product use, exploring the feasibility of future, more detailed analyses within Mini-Sentinel, and seeking to better understand the capabilities of the Mini-Sentinel pilot.

Data obtained through Mini-Sentinel are intended to complement other types of evidence such as preclinical studies, clinical trials, postmarket studies, and adverse event reports, all of which are used by FDA to inform regulatory decisions regarding medical product safety. The information contained in this report is provided as part of FDA's commitment to place knowledge acquired from the Mini-Sentinel pilot in the public domain as soon as possible. Any public health actions taken by FDA regarding products involved in Mini-Sentinel queries will continue to be communicated through existing channels.

FDA wants to emphasize that the fact that FDA has initiated a query involving a medical product and is reporting findings related to that query does not mean that FDA is suggesting health care practitioners should change their prescribing practices for the medical product or that patients taking the medical product should stop using it. Patients who have questions about the use of an identified medical product should contact their health care practitioners.

The following report contains a description of the request, request specifications, and results from the modular program run(s).

If you are using a web page screen reader and are unable to access this document, please contact the Mini-Sentinel Operations Center for assistance at info@mini-sentinel.org.

Overview

Request Description FDA has requested execution of Modular Program #3 (MP3) to investigate exposure of two anticoagulant medications (dabigatran and warfarin) among members with a pre-existing condition of atrial fibrillation and among members with various pre-existing exclusions. This involved one run of MP3. The time window for the request was October 19, 2010 to December 31, 2012. The package was distributed to 18 Data Partners on October 15, 2013.

Results provide counts of new anticoagulant users, dispensings, total days supplied, eligible members, and member-years for patients. 64 scenarios were examined in total. Please see the Specifications tab for more details on each scenario.

Request ID msy5_mpr05_v1, Report 1 of 1

Specifications Program parameter inputs and scenarios

Glossary List of Terms found in this Report and their Definitions

Table 1a Table displaying the Number of New Dabigatran Users, New Episodes, Dispensings, Total Days Supplied, Years at Risk, Eligible Members, Member-Years, New Users per 1,000 Eligible Members, Days Supplied per User, Dispensings per User, and Days Supplied per Dispensing by Pre-Existing Condition Criteria between October 19, 2010 and December 31, 2012

Table 1b Table displaying the Number of New Warfarin Users, New Episodes, Dispensings, Total Days Supplied, Years at Risk, Eligible Members, Member-Years, New Users per 1,000 Eligible Members, Days Supplied per User, Dispensings per User, and Days Supplied per Dispensing by Pre-Existing Condition Criteria between October 19, 2010 and December 31, 2012

Table 2a Table displaying the Number of New Dabigatran Users, New Episodes, Dispensings, Total Days Supplied, Years at Risk, Eligible Members, Member-Years, New Users per 1,000 Eligible Members, Days Supplied per User, Dispensings per User, and Days Supplied per Dispensing by Pre-Existing Condition Criteria and Age Group between October 19, 2010 and December 31, 2012

Table 2b Table displaying the Number of New Warfarin Users, New Episodes, Dispensings, Total Days Supplied, Years at Risk, Eligible Members, Member-Years, New Users per 1,000 Eligible Members, Days Supplied per User, Dispensings per User, and Days Supplied per Dispensing by Pre-Existing Condition Criteria and Age Group between October 19, 2010 and December 31, 2012

Table 3a Table displaying the Number of New Dabigatran Users, New Episodes, Dispensings, Total Days Supplied, Years at Risk, Eligible Members, Member-Years, New Users per 1,000 Eligible Members, Days Supplied per User, Dispensings per User, and Days Supplied per Dispensing by Pre-Existing Condition Criteria and Sex between October 19, 2010 and December 31, 2012

Table 3b Table displaying the Number of New Warfarin Users, New Episodes, Dispensings, Total Days Supplied, Years at Risk, Eligible Members, Member-Years, New Users per 1,000 Eligible Members, Days Supplied per User, Dispensings per User, and Days Supplied per Dispensing by Pre-Existing Condition Criteria and Sex between October 19, 2010 and December 31, 2012

Table 4a Table displaying the Number of New Dabigatran Users, New Episodes, Dispensings, Total Days Supplied, Years at Risk, Eligible Members, Member-Years, New Users per 1,000 Eligible Members, Days Supplied per User, Dispensings per User, and Days Supplied per Dispensing by Pre-Existing Condition Criteria and Year between October 19, 2010 and December 31, 2012

Table 4b Table displaying the Number of New Warfarin Users, New Episodes, Dispensings, Total Days Supplied, Years at Risk, Eligible Members, Member-Years, New Users per 1,000 Eligible Members, Days Supplied per User, Dispensings per User, and Days Supplied per Dispensing by Pre-Existing Condition Criteria and Year between October 19, 2010 and December 31, 2012

Table 5 Table displaying Pre-existing Conditions and Prescription Drug Dispensings among Incident Dabigatran and Warfarin Users with Atrial Fibrillation.

Appendix A Table of Procedure and Diagnosis Codes for Pre-existing conditions in this request.

Notes: Please contact the Mini-Sentinel Operations Center (MSOC_Requests@harvardpilgrim.org) for questions and to provide comments/suggestions for future enhancements to this document.

Modular Program Specifications for Query MSY5_MPR05_v1

Modular Program #3 will be used to new dabigatran and warfarin episodes among patients with differing groups of pre-existing conditions. In total, 134 different scenarios will be examined in this request with differing exposures of interest and pre-existing conditions. See below for a description of each of these scenarios. **In all scenarios, the members included in the cohort have a pre-existing condition of atrial fibrillation. For the scenarios with the word "Exclude" in the Pre-Existing Condition column, each member in the cohort has to have a pre-existing condition of atrial fibrillation and cannot have a pre-existing condition of whatever is excluded (e.g. anemia, COPD, diabetes, etc.). For example, the pre-existing condition criteria in scenario 3 is "Afib Exclude Anemia." This means that people in this cohort have a pre-existing condition of Afib AND they do not have a pre-existing condition of anemia. If we subtract the users in scenario 3 from the users in scenario 1, we get dabigatran users who have a pre-existing condition of BOTH Afib and anemia. This information is presented in Table 5.**

Coverage Requirement	Drug and Medical
Query Period	October 19, 2010 to December 31, 2012.
Enrollment Gap	45 Days
Enrollment Days	183
Age Stratifications	0-40, 41-54, 55-64, 65-74, 75-84, and 85+

Scenario	Drug/Exposure				Pre-Existing Condition							Event/Outcome		
	Incident exposure	Incident w/ respect to:	Ep. Gap	Ep. Ext. Period	Min. Ep. Duration	Min. Days Supplied	Washout (days)	Incidence Type*	Pre-Existing Condition**	Include/Exclude	Lookback Start	Lookback End	Care Setting PDX	Event/Outcome
1	Dabigatran	Dabigatran/Warfarin	10	10	1	1	183	SING	Atrial Fibrillation	Include	-183	-1	All	Dummy
2	Warfarin	Dabigatran/Warfarin	10	10	1	1	183	SING	Atrial Fibrillation	Include	-183	-1	All	Dummy
3	Dabigatran	Dabigatran/Warfarin	10	10	1	1	183	SING	Afib Exclude Anemia	Include	-183	-1	All	Dummy
4	Warfarin	Dabigatran/Warfarin	10	10	1	1	183	SING	Afib Exclude Anemia	Include	-183	-1	All	Dummy
5	Dabigatran	Dabigatran/Warfarin	10	10	1	1	183	SING	Afib Exclude COPD	Include	-183	-1	All	Dummy
6	Warfarin	Dabigatran/Warfarin	10	10	1	1	183	SING	Afib Exclude COPD	Include	-183	-1	All	Dummy
7	Dabigatran	Dabigatran/Warfarin	10	10	1	1	183	SING	Afib Exclude Diabetes	Include	-183	-1	All	Dummy
8	Warfarin	Dabigatran/Warfarin	10	10	1	1	183	SING	Afib Exclude Diabetes	Include	-183	-1	All	Dummy
9	Dabigatran	Dabigatran/Warfarin	10	10	1	1	183	SING	Afib Exclude Hypertension	Include	-183	-1	All	Dummy
10	Warfarin	Dabigatran/Warfarin	10	10	1	1	183	SING	Afib Exclude Hypertension	Include	-183	-1	All	Dummy
11	Dabigatran	Dabigatran/Warfarin	10	10	1	1	183	SING	Afib Exclude Chronic Kidney Failure	Include	-183	-1	All	Dummy
12	Warfarin	Dabigatran/Warfarin	10	10	1	1	183	SING	Afib Exclude Chronic Kidney Failure	Include	-183	-1	All	Dummy

Scenario	Drug/Exposure								Pre-Existing Condition				Event/Outcome	
	Incident exposure	Incident w/ respect to:	Ep. Gap	Ep. Ext. Period	Min. Ep. Duration	Min. Days Supplied	Washout (days)	Incidence Type*	Pre-Existing Condition**	Include/Exclude	Lookback Start	Lookback End	Care Setting PDX	Event/Outcome
13	Dabigatran	Dabigatran/Warfarin	10	10	1	1	183	SING	Afib Exclude Acute Kidney Failure	Include	-183	-1	All for AFIB, IP* for AKF	Dummy
14	Warfarin	Dabigatran/Warfarin	10	10	1	1	183	SING	Afib Exclude Acute Kidney Failure	Include	-183	-1	All for AFIB, IP* for AKF	Dummy
15	Dabigatran	Dabigatran/Warfarin	10	10	1	1	183	SING	Afib Exclude Peptic Ulcer Disease	Include	-183	-1	All	Dummy
16	Warfarin	Dabigatran/Warfarin	10	10	1	1	183	SING	Afib Exclude Peptic Ulcer Disease	Include	-183	-1	All	Dummy
17	Dabigatran	Dabigatran/Warfarin	10	10	1	1	183	SING	Afib Exclude AMI	Include	-183	-1	All for AFIB, IP* for AMI	Dummy
18	Warfarin	Dabigatran/Warfarin	10	10	1	1	183	SING	Afib Exclude AMI	Include	-183	-1	All for AFIB, IP* for AMI	Dummy
19	Dabigatran	Dabigatran/Warfarin	10	10	1	1	183	SING	Afib Exclude Heart Failure	Include	-183	-1	All	Dummy
20	Warfarin	Dabigatran/Warfarin	10	10	1	1	183	SING	Afib Exclude Heart Failure	Include	-183	-1	All	Dummy
21	Dabigatran	Dabigatran/Warfarin	10	10	1	1	183	SING	Afib Exclude Peripheral Vascular Disease	Include	-183	-1	All	Dummy
22	Warfarin	Dabigatran/Warfarin	10	10	1	1	183	SING	Afib Exclude Peripheral Vascular Disease	Include	-183	-1	All	Dummy
23	Dabigatran	Dabigatran/Warfarin	10	10	1	1	183	SING	Afib Exclude Hospitalized Stroke	Include	-183	-1	All for AFIB, IPP for Stroke	Dummy
24	Warfarin	Dabigatran/Warfarin	10	10	1	1	183	SING	Afib Exclude Hospitalized Stroke	Include	-183	-1	All for AFIB, IPP for Stroke	Dummy
25	Dabigatran	Dabigatran/Warfarin	10	10	1	1	183	SING	Afib Exclude Urinary Catheter	Include	-183	-1	All	Dummy
26	Warfarin	Dabigatran/Warfarin	10	10	1	1	183	SING	Afib Exclude Urinary Catheter	Include	-183	-1	All	Dummy
27	Dabigatran	Dabigatran/Warfarin	10	10	1	1	183	SING	Afib Exclude Hospitalized Bleed	Include	-183	-1	All for AFIB, IPP for Bleed	Dummy
28	Warfarin	Dabigatran/Warfarin	10	10	1	1	183	SING	Afib Exclude Hospitalized Bleed	Include	-183	-1	All for AFIB, IPP for Bleed	Dummy
29	Dabigatran	Dabigatran/Warfarin	10	10	1	1	183	SING	Afib Exclude NSAIDs	Include	-183	-1	All	Dummy
30	Warfarin	Dabigatran/Warfarin	10	10	1	1	183	SING	Afib Exclude NSAIDs	Include	-183	-1	All	Dummy
31	Dabigatran	Dabigatran/Warfarin	10	10	1	1	183	SING	Afib Exclude PPIs	Include	-183	-1	All	Dummy
32	Warfarin	Dabigatran/Warfarin	10	10	1	1	183	SING	Afib Exclude PPIs	Include	-183	-1	All	Dummy

Scenario	Drug/Exposure								Pre-Existing Condition					Event/Outcome
	Incident exposure	Incident w/ respect to:	Ep. Gap	Ep. Ext. Period	Min. Ep. Duration	Min. Days Supplied	Washout (days)	Incidence Type*	Pre-Existing Condition**	Include/Exclude	Lookback Start	Lookback End	Care Setting PDX	Event/Outcome
33	Dabigatran	Dabigatran/Warfarin	10	10	1	1	183	SING	Afib Exclude SSRIs	Include	-183	-1	All	Dummy
34	Warfarin	Dabigatran/Warfarin	10	10	1	1	183	SING	Afib Exclude SSRIs	Include	-183	-1	All	Dummy
35	Dabigatran	Dabigatran/Warfarin	10	10	1	1	183	SING	Afib Exclude Thyroid Replacement	Include	-183	-1	All	Dummy
36	Warfarin	Dabigatran/Warfarin	10	10	1	1	183	SING	Afib Exclude Thyroid Replacement	Include	-183	-1	All	Dummy
37	Dabigatran	Dabigatran/Warfarin	10	10	1	1	183	SING	Afib Exclude Insulin	Include	-183	-1	All	Dummy
38	Warfarin	Dabigatran/Warfarin	10	10	1	1	183	SING	Afib Exclude Insulin	Include	-183	-1	All	Dummy
39	Dabigatran	Dabigatran/Warfarin	10	10	1	1	183	SING	Afib Exclude Metformin	Include	-183	-1	All	Dummy
40	Warfarin	Dabigatran/Warfarin	10	10	1	1	183	SING	Afib Exclude Metformin	Include	-183	-1	All	Dummy
41	Dabigatran	Dabigatran/Warfarin	10	10	1	1	183	SING	Afib Exclude Sulfonylureas	Include	-183	-1	All	Dummy
42	Warfarin	Dabigatran/Warfarin	10	10	1	1	183	SING	Afib Exclude Sulfonylureas	Include	-183	-1	All	Dummy
43	Dabigatran	Dabigatran/Warfarin	10	10	1	1	183	SING	Afib Exclude Other Diabetes Med	Include	-183	-1	All	Dummy
44	Warfarin	Dabigatran/Warfarin	10	10	1	1	183	SING	Afib Exclude Other Diabetes Med	Include	-183	-1	All	Dummy
45	Dabigatran	Dabigatran/Warfarin	10	10	1	1	183	SING	Afib Exclude ACEI Exclude ARB	Include	-183	-1	All	Dummy
46	Warfarin	Dabigatran/Warfarin	10	10	1	1	183	SING	Afib Exclude ACEI Exclude ARB	Include	-183	-1	All	Dummy
47	Dabigatran	Dabigatran/Warfarin	10	10	1	1	183	SING	Afib Exclude Anti-arrhythmics	Include	-183	-1	All	Dummy
48	Warfarin	Dabigatran/Warfarin	10	10	1	1	183	SING	Afib Exclude Anti-arrhythmics	Include	-183	-1	All	Dummy
49	Dabigatran	Dabigatran/Warfarin	10	10	1	1	183	SING	Afib Exclude IV Anticoagulants	Include	-183	-1	All	Dummy
50	Warfarin	Dabigatran/Warfarin	10	10	1	1	183	SING	Afib Exclude IV Anticoagulants	Include	-183	-1	All	Dummy
51	Dabigatran	Dabigatran/Warfarin	10	10	1	1	183	SING	Afib Exclude Anti-platelets	Include	-183	-1	All	Dummy
52	Warfarin	Dabigatran/Warfarin	10	10	1	1	183	SING	Afib Exclude Anti-platelets	Include	-183	-1	All	Dummy

Scenario	Drug/Exposure								Pre-Existing Condition				Event/Outcome	
	Incident exposure	Incident w/ respect to:	Ep. Gap	Ep. Ext. Period	Min. Ep. Duration	Min. Days Supplied	Washout (days)	Incidence Type*	Pre-Existing Condition**	Include/Exclude	Lookback Start	Lookback End	Care Setting PDX	Event/Outcome
53	Dabigatran	Dabigatran/Warfarin	10	10	1	1	183	SING	Afib Exclude Beta Blockers	Include	-183	-1	All	Dummy
54	Warfarin	Dabigatran/Warfarin	10	10	1	1	183	SING	Afib Exclude Beta Blockers	Include	-183	-1	All	Dummy
55	Dabigatran	Dabigatran/Warfarin	10	10	1	1	183	SING	Afib Exclude Calcium Channel Blockers	Include	-183	-1	All	Dummy
56	Warfarin	Dabigatran/Warfarin	10	10	1	1	183	SING	Afib Exclude Calcium Channel Blockers	Include	-183	-1	All	Dummy
57	Dabigatran	Dabigatran/Warfarin	10	10	1	1	183	SING	Afib Exclude Digoxin	Include	-183	-1	All	Dummy
58	Warfarin	Dabigatran/Warfarin	10	10	1	1	183	SING	Afib Exclude Digoxin	Include	-183	-1	All	Dummy
59	Dabigatran	Dabigatran/Warfarin	10	10	1	1	183	SING	Afib Exclude Loop Diuretics	Include	-183	-1	All	Dummy
60	Warfarin	Dabigatran/Warfarin	10	10	1	1	183	SING	Afib Exclude Loop Diuretics	Include	-183	-1	All	Dummy
61	Dabigatran	Dabigatran/Warfarin	10	10	1	1	183	SING	Afib Exclude Potassium-Sparing Diuretics	Include	-183	-1	All	Dummy
62	Warfarin	Dabigatran/Warfarin	10	10	1	1	183	SING	Afib Exclude Potassium-Sparing Diuretics	Include	-183	-1	All	Dummy
63	Dabigatran	Dabigatran/Warfarin	10	10	1	1	183	SING	Afib Exclude Thiazides	Include	-183	-1	All	Dummy
64	Warfarin	Dabigatran/Warfarin	10	10	1	1	183	SING	Afib Exclude Thiazides	Include	-183	-1	All	Dummy
65	Dabigatran	Dabigatran/Warfarin	10	10	1	1	183	SING	Afib Exclude Amiodarone	Include	-183	-1	All	Dummy
66	Warfarin	Dabigatran/Warfarin	10	10	1	1	183	SING	Afib Exclude Amiodarone	Include	-183	-1	All	Dummy
67	Dabigatran	Dabigatran/Warfarin	10	10	1	1	183	SING	Afib Exclude Dronedarone	Include	-183	-1	All	Dummy
68	Warfarin	Dabigatran/Warfarin	10	10	1	1	183	SING	Afib Exclude Dronedarone	Include	-183	-1	All	Dummy

NDC codes checked against First Data Bank's "National Drug Data File (NDDF®) Plus"
 ICD-9-CM diagnosis and procedure codes checked against "Ingenix 2012 ICD-9-CM Data File" provided by OptumInsight
 HCPCS codes checked against "Optum 2012 HCPCS Level II Data File" provided by OptumInsight
 CPT codes checked against "Optum 2012 Current Procedure Codes & Relative Values Data File" provided by OptumInsight

Glossary of Terms in Modular Program 3*

- Blackout Period** - number of days at the beginning of a treatment episode that events are to be ignored. If an event occurs during the blackout period, the episode is excluded.
- Care Setting** - type of medical encounter or facility where the exposure, event, or condition code was recorded. Possible care settings include: Inpatient Hospital Stay (IP), Non-Acute Institutional Stay (IS), Emergency Department (ED), Ambulatory Visit (AV), and Other
- Days at Risk** - number of days supplied plus any episode gaps and exposure extension periods.
- Eligible Members** - number of members eligible for an incident treatment episode (defined by the drug/exposure and event washout periods) with drug and medical coverage during the query period.
- Enrollment Days** - irrespective of what query incidence type (WASHTYP) is specified, this is an optional parameter to further restrict the number of days of continuous enrollment prior to start of new incident treatment episode to reach a certain minimum. This parameter is used to ensure that appropriate enrollment requirements are met. Since at least washout period days of enrollment must be found prior to index date this minimum enrollment days requirement can only be binding if enrollment days > washout period days
- Enrollment Gap** - number of days allowed between two consecutive enrollment periods without breaking a "continuously enrolled"
- Episode Gap** - number of days allowed between two (or more) consecutive exposures (dispensings/procedures) to be considered the same
- Exposure Extension Period** - number of days post treatment period in which the outcomes/events are counted for a treatment episode.
- Lookback Period (pre-existing condition)** - number of days wherein a member is required to have evidence of pre-existing condition (diagnosis/procedure/drug dispensing).
- Member-Days** - sum of all days of enrollment with medical and drug coverage** in the query period preceded by an exposure washout
- Minimum Days Supplied** - specifies a minimum number of days in length of the days supplied for the episode to be considered
- Minimum Episode Duration** - specifies a minimum number of days in length of the episode for it to be considered
- New Episodes** - new treatment episodes; length of episode is determined by days supplied in one dispensing (or consecutive dispensings
- New Users** - number of members with incident exposure during the query period. Member must have no evidence of exposure (s) of interest (defined by incidence criteria) in the prior washout period. A user may only be counted once in a query period.
- Principal Diagnosis** - diagnosis or condition established to be chiefly responsible for admission of the patient to the hospital. YES will only consider diagnoses flagged as Principal
- Query Period** - period in which the modular program looks for exposures and outcomes of interest.
- Total Days Supplied** - number of days supplied for all dispensings in qualifying treatment episodes.
- Washout Period (drug/exposure)**** - number of days a user is required to have no evidence of prior exposure (drug dispensing/procedure) and continuous drug and medical coverage prior to an incident treatment episode.
- Washout Period (event/outcome)**** - number of days a user is required to have no evidence of a prior event (procedure/diagnosis) and continuous drug and medical coverage prior to an incident treatment episode.
- Washout Type (drug/exposure)**- *Minimum washout type* will consider the first treatment episode in the query period as long as it is the first treatment episode in the user's entire available history. *Single* and *Multiple washout types* will use the washout period to establish incidence, however *Single* will only consider the first treatment episode whereas *Multiple* will consider all qualifying incident treatment
- Washout Type (event/outcome)**- *Minimum washout type* considers the first event in a valid episode as long as it is the first event in the user's entire available history. *Multiple washout type* uses the washout period to establish incidence and considers all qualifying incident treatment episodes. The program will only consider one event per episode, but the *Multiple washout type* will consider more than one

*all terms may not be used in this report

**incident treatment episodes must be incident to both the exposure and the event

Table 1a. Summary of Incident Dabigatran Use in the MSDD between October 19, 2010 and December 31, 2012, by Pre-Existing Condition Criteria

	New Users	New Episodes	New Dispensings	Total Days Supplied	Years at Risk	Eligible Members	Member-Years	New Users / 1K Eligible Members	Days Supplied/ User	Dispensings / User	Days Supplied/ Dispensing
Exposure of Dabigatran, Pre-Existing Inclusion of Atrial Fibrillation	29,157	29,157	109,201	4,003,593	11,463.8	774,330	481,354.1	37.65	137.31	3.75	36.66
Exposure of Dabigatran, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Anemia	25,197	25,197	95,691	3,517,369	10,060.4	682,166	417,220.9	36.94	139.59	3.80	36.76
Exposure of Dabigatran, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of COPD	24,954	24,954	94,252	3,458,070	9,899.1	695,577	430,121.9	35.88	138.58	3.78	36.69
Exposure of Dabigatran, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Diabetes	21,183	21,183	79,076	2,879,912	8,252.2	629,511	393,921.3	33.65	135.95	3.73	36.42
Exposure of Dabigatran, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Hypertension	7,239	7,239	25,708	916,970	2,649.0	505,415	346,589.6	14.32	126.67	3.55	35.67
Exposure of Dabigatran, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Chronic Kidney Failure	26,403	26,403	99,432	3,644,024	10,438.0	704,664	436,291.3	37.47	138.02	3.77	36.65
Exposure of Dabigatran, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Acute Kidney Failure	27,811	27,811	104,600	3,843,837	11,000.9	735,565	456,140.0	37.81	138.21	3.76	36.75
Exposure of Dabigatran, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Peptic Ulcer Disease	29,063	29,063	108,883	3,992,597	11,431.8	770,887	477,436.3	37.70	137.38	3.75	36.67
Exposure of Dabigatran, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Hospitalized AMI	28,235	28,235	105,887	3,886,630	11,129.8	752,930	467,201.3	37.50	137.65	3.75	36.71
Exposure of Dabigatran, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Heart Failure	22,266	22,266	83,496	3,083,785	8,829.8	669,597	417,387.9	33.25	138.50	3.75	36.93
Exposure of Dabigatran, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Peripheral Vascular Disease	26,688	26,688	99,870	3,663,277	10,484.9	730,912	445,924.7	36.51	137.26	3.74	36.68
Exposure of Dabigatran, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Stroke	28,119	28,119	104,237	3,822,826	10,956.3	762,648	473,192.6	36.87	135.95	3.71	36.67
Exposure of Dabigatran, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Urinary Catheter	28,861	28,861	108,117	3,964,394	11,350.8	764,328	470,985.6	37.76	137.36	3.75	36.67
Exposure of Dabigatran, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Hospitalized Bleeding	28,512	28,512	106,918	3,925,099	11,236.6	754,202	462,548.0	37.80	137.66	3.75	36.71
Exposure of Dabigatran, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of NSAID Use	25,197	25,197	94,337	3,463,209	9,918.0	736,883	450,204.6	34.19	137.45	3.74	36.71
Exposure of Dabigatran, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of PPI Use	23,692	23,692	88,786	3,238,380	9,286.8	676,185	409,707.2	35.04	136.69	3.75	36.47

	New Users	New Episodes	New Dispensings	Total Days Supplied	Years at Risk	Eligible Members	Member-Years	New Users / 1K Eligible Members	Days Supplied/ User	Dispensings / User	Days Supplied/ Dispensing
Exposure of Dabigatran, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of SSRI Antidepressants Use	26,181	26,181	98,063	3,601,970	10,313.3	712,127	437,647.2	36.76	137.58	3.75	36.73
Exposure of Dabigatran, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Thyroid Replacement Use	25,213	25,213	94,203	3,439,781	9,857.3	689,409	423,486.1	36.57	136.43	3.74	36.51
Exposure of Dabigatran, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Insulin Use	27,594	27,594	103,441	3,787,276	10,847.3	741,828	461,914.8	37.20	137.25	3.75	36.61
Exposure of Dabigatran, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Metformin Use	25,617	25,617	95,565	3,494,634	10,012.6	729,286	454,601.9	35.13	136.42	3.73	36.57
Exposure of Dabigatran, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Sulfonylureas Use	27,016	27,016	100,923	3,695,197	10,582.5	737,175	458,434.6	36.65	136.78	3.74	36.61
Exposure of Dabigatran, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Other Diabetes Management Medication Use	27,755	27,755	103,326	3,779,720	10,828.6	757,875	470,610.4	36.62	136.18	3.72	36.58
Exposure of Dabigatran, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of ACEI/ARB Use	15,129	15,129	53,681	1,917,193	5,528.9	564,871	346,040.6	26.78	126.72	3.55	35.71
Exposure of Dabigatran, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Anti-arrhythmic Use	23,248	23,248	88,173	3,246,751	9,277.3	717,443	416,039.1	32.40	139.66	3.79	36.82
Exposure of Dabigatran, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of IV Anticoagulant Use	27,543	27,543	103,615	3,809,506	10,900.0	756,766	462,353.5	36.40	138.31	3.76	36.77
Exposure of Dabigatran, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Antiplatelet Use	25,972	25,972	95,979	3,498,642	10,032.7	719,593	439,019.9	36.09	134.71	3.70	36.45
Exposure of Dabigatran, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Beta Blocker Use	12,637	12,637	46,215	1,670,673	4,804.4	524,084	302,921.0	24.11	132.20	3.66	36.15
Exposure of Dabigatran, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Calcium Channel Blocker Use	19,774	19,774	73,089	2,652,649	7,609.8	643,838	383,897.9	30.71	134.15	3.70	36.29
Exposure of Dabigatran, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Digoxin Use	26,287	26,287	98,658	3,613,373	10,346.5	732,584	440,472.9	35.88	137.46	3.75	36.63
Exposure of Dabigatran, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Loop Diuretic Use	23,956	23,956	90,139	3,299,267	9,448.8	683,711	415,073.7	35.04	137.72	3.76	36.60
Exposure of Dabigatran, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Potassium-Sparing Diuretic Use	28,162	28,162	105,314	3,864,027	11,063.8	757,704	467,623.7	37.17	137.21	3.74	36.69
Exposure of Dabigatran, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Thiazide Diuretic Use	22,477	22,477	82,385	2,993,841	8,597.6	687,397	423,471.7	32.70	133.20	3.67	36.34
Exposure of Dabigatran, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Amiodarone Use	27,281	27,281	102,609	3,762,993	10,767.1	751,660	453,215.4	36.29	137.93	3.76	36.67
Exposure of Dabigatran, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Dronedrone Use											

New Users	New Episodes	Dispensings	Total Days Supplied	Years at Risk	Eligible Members	Member-Years	New Users / 1K Eligible Members	Days Supplied/ User	Dispensings / User	Days Supplied/ Dispensing
27,756	27,756	103,860	3,813,673	10,914.6	768,479	472,483.1	36.12	137.40	3.74	36.72

Table 1b. Summary of Incident Warfarin Use in the MSDD between October 19, 2010 and December 31, 2012, by Pre-Existing Condition Criteria

	New Users	New Episodes	New Dispensings	Total Days Supplied	Years at Risk	Eligible Members	Member-Years	New Users / 1K Eligible Members	Days Supplied/ User	Dispensings / User	Days Supplied/ Dispensing
Exposure of Warfarin Pre-Existing Inclusion of Atrial Fibrillation	106,858	106,858	350,859	14,222,737	40,031.0	774,330	476,765.2	138.00	133.10	3.28	40.54
Exposure of Warfarin, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Anemia	79,081	79,081	256,776	10,717,705	30,150.3	682,154	414,571.3	115.93	135.53	3.25	41.74
Exposure of Warfarin, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of COPD	84,296	84,296	272,476	11,233,504	31,624.8	695,569	426,783.7	121.19	133.26	3.23	41.23
Exposure of Warfarin, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Diabetes	70,099	70,099	226,164	9,200,326	25,939.1	629,506	391,040.1	111.36	131.25	3.23	40.68
Exposure of Warfarin, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Hypertension	21,300	21,300	63,883	2,672,401	7,571.3	505,409	345,839.8	42.14	125.46	3.00	41.83
Exposure of Warfarin, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Chronic Kidney Failure	84,536	84,536	275,899	11,270,944	31,741.8	704,658	433,034.8	119.97	133.33	3.26	40.85
Exposure of Warfarin, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Acute Kidney Failure	94,917	94,917	308,794	12,726,518	35,810.7	735,562	452,373.1	129.04	134.08	3.25	41.21
Exposure of Warfarin, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Peptic Ulcer Disease	106,075	106,075	347,837	14,122,326	39,747.8	770,885	472,950.3	137.60	133.14	3.28	40.60
Exposure of Warfarin, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Hospitalized AMI	100,434	100,434	328,517	13,415,790	37,755.8	752,919	463,028.9	133.39	133.58	3.27	40.84
Exposure of Warfarin, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Heart Failure	68,928	68,928	219,467	9,193,503	25,890.5	669,587	414,852.3	102.94	133.38	3.18	41.89
Exposure of Warfarin, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Peripheral Vascular Disease	91,814	91,814	296,140	12,198,590	34,338.4	730,907	442,339.7	125.62	132.86	3.23	41.19
Exposure of Warfarin, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Stroke	101,228	101,228	326,550	13,377,444	37,674.6	762,644	468,849.5	132.73	132.15	3.23	40.97
Exposure of Warfarin, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Urinary Catheter	104,199	104,199	341,143	13,885,081	39,080.6	764,326	466,654.0	136.33	133.26	3.27	40.70
Exposure of Warfarin, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Hospitalized Bleeding	101,858	101,858	333,397	13,645,600	38,380.8	754,198	458,566.3	135.05	133.97	3.27	40.93
Exposure of Warfarin, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of NSAID Use	94,774	94,774	309,863	12,630,050	35,546.3	736,874	446,405.2	128.62	133.26	3.27	40.76
Exposure of Warfarin, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of PPI Use	85,225	85,225	278,215	11,383,773	32,027.6	676,178	406,555.3	126.04	133.57	3.26	40.92

	New Users	New Episodes	New Dispensings	Total Days Supplied	Years at Risk	Eligible Members	Member-Years	New Users / 1K Eligible Members	Days Supplied/ User	Dispensings / User	Days Supplied/ Dispensing
Exposure of Warfarin, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of SSRI Antidepressants Use											
	94,643	94,643	308,787	12,636,380	35,562.9	712,127	433,832.0	132.90	133.52	3.26	40.92
Exposure of Warfarin, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Thyroid Replacement Use											
	90,661	90,661	296,170	11,982,340	33,747.1	689,405	419,737.5	131.51	132.17	3.27	40.46
Exposure of Warfarin, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Insulin Use											
	98,163	98,163	321,141	13,057,719	36,762.3	741,827	457,768.2	132.33	133.02	3.27	40.66
Exposure of Warfarin, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Metformin Use											
	94,850	94,850	309,040	12,494,072	35,207.6	729,284	450,542.5	130.06	131.72	3.26	40.43
Exposure of Warfarin, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Sulfonylureas Use											
	96,792	96,792	316,008	12,770,792	35,968.0	737,172	454,347.6	131.30	131.94	3.26	40.41
Exposure of Warfarin, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Other Diabetes Management Medication Use											
	102,403	102,403	334,898	13,595,721	38,268.2	757,873	466,287.2	135.12	132.77	3.27	40.60
Exposure of Warfarin, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of ACEI/ARB Use											
	56,462	56,462	182,494	7,241,588	20,468.1	564,859	343,928.7	99.96	128.26	3.23	39.68
Exposure of Warfarin, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Anti-arrhythmic Use											
	93,092	93,092	309,766	12,543,699	35,265.8	717,427	412,717.2	129.76	134.75	3.33	40.49
Exposure of Warfarin, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of IV Anticoagulant Use											
	100,166	100,166	327,232	13,358,803	37,590.1	756,761	458,266.3	132.36	133.37	3.27	40.82
Exposure of Warfarin, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Antiplatelet Use											
	96,304	96,304	313,528	12,783,618	35,995.0	719,587	435,040.5	133.83	132.74	3.26	40.77
Exposure of Warfarin, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Beta Blocker Use											
	48,690	48,690	162,349	6,362,025	17,975.0	524,070	301,375.8	92.91	130.66	3.33	39.19
Exposure of Warfarin, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Calcium Channel Blocker Use											
	74,816	74,816	242,813	9,792,390	27,580.9	643,826	381,154.9	116.21	130.89	3.25	40.33
Exposure of Warfarin, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Digoxin Use											
	95,650	95,650	316,371	12,710,868	35,789.9	732,586	436,842.3	130.56	132.89	3.31	40.18
Exposure of Warfarin, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Loop Diuretic Use											
	79,802	79,802	261,843	10,596,575	29,859.0	683,703	412,228.4	116.72	132.79	3.28	40.47
Exposure of Warfarin, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Potassium-Sparing Diuretic Use											
	102,191	102,191	336,446	13,627,457	38,345.4	757,701	463,367.6	134.87	133.35	3.29	40.50
Exposure of Warfarin, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Thiazide Diuretic Use											
	83,778	83,778	272,257	10,961,467	30,903.0	687,383	419,989.9	121.88	130.84	3.25	40.26
Exposure of Warfarin, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Amiodarone Use											
	100,422	100,422	332,388	13,469,803	37,892.3	751,655	449,524.9	133.60	134.13	3.31	40.52
Exposure of Warfarin, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Dronedarone Use											

New Users	New Episodes	Dispensings	Total Days Supplied	Years at Risk	Eligible Members	Member-Years	New Users / 1K Eligible Members	Days Supplied/ User	Dispensings / User	Days Supplied/ Dispensing
105,060	105,060	344,867	13,989,026	39,369.6	768,473	467,998.0	136.71	133.15	3.28	40.56

Table 2a. Summary of Incident Dabigatran Use in the MSDD between October 19, 2010 and December 31, 2012, by Pre-Existing Condition Criteria and Age Group

	New Users	New Episodes	Dispensings	Total Days Supplied	Years at Risk	Eligible Members	Member-Years	New Users / 1K Eligible Members	Days Supplied/ User	Dispensings / User	Days Supplied/ Dispensing
Exposure of Dabigatran, Pre-Existing Inclusion of Atrial Fibrillation											
00 to 40 Years	560	560	1,258	39,185	120.7	28,960	13,073.1	19.34	69.97	2.25	31.15
41 to 54 Years	3,755	3,755	11,677	382,313	1,127.9	86,626	44,044.7	43.35	101.81	3.11	32.74
55 to 64 Years	8,069	8,069	31,362	1,099,861	3,146.1	154,002	83,187.7	52.40	136.31	3.89	35.07
65 to 74 Years	8,064	8,064	30,687	1,167,636	3,324.1	197,821	113,971.5	40.76	144.80	3.81	38.05
75 to 84 Years	6,533	6,533	25,889	1,009,450	2,872.1	213,751	132,710.9	30.56	154.52	3.96	38.99
85+ Years	2,176	2,176	8,328	305,148	872.9	141,129	94,366.3	15.42	140.23	3.83	36.64
Exposure of Dabigatran, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Anemia											
00 to 40 Years	532	532	1,178	36,808	113.5	27,192	12,188.7	19.56	69.19	2.21	31.25
41 to 54 Years	3,498	3,498	10,836	354,793	1,046.8	80,838	40,875.9	43.27	101.43	3.10	32.74
55 to 64 Years	7,394	7,394	28,993	1,015,547	2,903.4	140,718	75,403.7	52.54	137.35	3.92	35.03
65 to 74 Years	6,915	6,915	26,963	1,030,814	2,929.5	174,669	99,524.0	39.59	149.07	3.90	38.23
75 to 84 Years	5,254	5,254	21,338	843,081	2,392.1	182,496	111,626.3	28.79	160.46	4.06	39.51
85+ Years	1,604	1,604	6,383	236,326	675.2	117,417	77,602.3	13.66	147.34	3.98	37.02
Exposure of Dabigatran, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of COPD											
00 to 40 Years	554	554	1,249	38,975	120.0	28,630	12,882.6	19.35	70.35	2.25	31.20
41 to 54 Years	3,581	3,581	11,092	363,255	1,070.9	83,813	42,551.1	42.73	101.44	3.10	32.75
55 to 64 Years	7,290	7,290	28,508	1,001,797	2,862.9	143,763	77,870.6	50.71	137.42	3.91	35.14
65 to 74 Years	6,674	6,674	25,737	985,015	2,799.2	174,230	100,761.0	38.31	147.59	3.86	38.27
75 to 84 Years	5,135	5,135	20,928	819,568	2,333.7	184,486	114,459.9	27.83	159.60	4.08	39.16
85+ Years	1,720	1,720	6,738	249,460	712.4	123,159	81,596.7	13.97	145.03	3.92	37.02
Exposure of Dabigatran, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Diabetes											
00 to 40 Years	501	501	1,110	34,385	106.1	27,580	12,443.1	18.17	68.63	2.22	30.98
41 to 54 Years	3,072	3,072	9,295	301,248	893.2	78,087	40,044.4	39.34	98.06	3.03	32.41
55 to 64 Years	5,884	5,884	22,442	776,881	2,227.5	129,027	71,113.7	45.60	132.03	3.81	34.62
65 to 74 Years	5,452	5,452	21,024	797,963	2,268.0	151,456	88,838.4	36.00	146.36	3.86	37.95
75 to 84 Years	4,602	4,602	18,736	731,928	2,077.6	164,829	103,151.4	27.92	159.05	4.07	39.07
85+ Years	1,672	1,672	6,469	237,507	679.9	117,112	78,330.2	14.28	142.05	3.87	36.71

	New Users	New Episodes	Dispensings	Total Days Supplied	Years at Risk	Eligible Members	Member-Years	New Users / 1K Eligible Members	Days Supplied/ User	Dispensings / User	Days Supplied/ Dispensing
Exposure of Dabigatran, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Hypertension											
00 to 40 Years	355	355	759	23,493	72.6	25,344	11,464.5	14.01	66.18	2.14	30.95
41 to 54 Years	1,617	1,617	4,813	154,195	459.8	67,955	36,738.9	23.80	95.36	2.98	32.04
55 to 64 Years	2,423	2,423	8,866	304,326	877.2	110,075	65,683.6	22.01	125.60	3.66	34.33
65 to 74 Years	1,510	1,510	5,828	223,229	635.3	125,317	81,708.8	12.05	147.83	3.86	38.30
75 to 84 Years	1,026	1,026	4,346	171,158	487.2	127,295	89,257.4	8.06	166.82	4.24	39.38
85+ Years	308	308	1,096	40,569	116.9	80,998	61,736.3	3.80	131.72	3.56	37.02
Exposure of Dabigatran, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Chronic Kidney Failure											
00 to 40 Years	553	553	1,248	38,910	119.8	28,483	12,854.0	19.42	70.36	2.26	31.18
41 to 54 Years	3,648	3,648	11,371	371,903	1,096.8	84,056	42,752.2	43.40	101.95	3.12	32.71
55 to 64 Years	7,709	7,709	30,003	1,051,351	3,008.5	146,045	78,874.6	52.79	136.38	3.89	35.04
65 to 74 Years	7,277	7,277	27,990	1,066,671	3,035.9	180,460	103,867.4	40.32	146.58	3.85	38.11
75 to 84 Years	5,508	5,508	22,177	869,953	2,476.4	187,603	116,727.2	29.36	157.94	4.03	39.23
85+ Years	1,708	1,708	6,643	245,236	700.6	120,879	81,215.8	14.13	143.58	3.89	36.92
Exposure of Dabigatran, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Acute Kidney Failure											
00 to 40 Years	549	549	1,218	37,985	117.0	28,508	12,899.1	19.26	69.19	2.22	31.19
41 to 54 Years	3,658	3,658	11,383	373,395	1,100.9	84,545	43,105.4	43.27	102.08	3.11	32.80
55 to 64 Years	7,784	7,784	30,354	1,067,326	3,050.6	148,400	80,411.6	52.45	137.12	3.90	35.16
65 to 74 Years	7,686	7,686	29,538	1,127,335	3,206.7	188,011	108,285.3	40.88	146.67	3.84	38.17
75 to 84 Years	6,116	6,116	24,347	952,755	2,710.8	200,583	124,177.0	30.49	155.78	3.98	39.13
85+ Years	2,018	2,018	7,760	285,041	814.9	131,086	87,261.7	15.39	141.25	3.85	36.73
Exposure of Dabigatran, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Peptic Ulcer Disease											
00 to 40 Years	559	559	1,257	39,155	120.6	28,940	13,050.8	19.32	70.04	2.25	31.15
41 to 54 Years	3,747	3,747	11,659	381,773	1,126.2	86,474	43,895.7	43.33	101.89	3.11	32.74
55 to 64 Years	8,048	8,048	31,295	1,097,671	3,139.7	153,546	82,719.2	52.41	136.39	3.89	35.07
65 to 74 Years	8,037	8,037	30,590	1,164,563	3,315.2	196,928	113,075.0	40.81	144.90	3.81	38.07
75 to 84 Years	6,509	6,509	25,817	1,006,357	2,863.2	212,450	131,254.8	30.64	154.61	3.97	38.98
85+ Years	2,163	2,163	8,265	303,078	867.0	140,255	93,440.8	15.42	140.12	3.82	36.67
Exposure of Dabigatran, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Hospitalized AMI											
00 to 40 Years	555	555	1,228	38,285	118.1	28,761	12,973.1	19.30	68.98	2.21	31.18
41 to 54 Years	3,673	3,673	11,367	372,444	1,099.3	85,079	43,265.2	43.17	101.40	3.09	32.77
55 to 64 Years	7,833	7,833	30,540	1,070,416	3,061.8	150,343	81,242.2	52.10	136.65	3.90	35.05

	New Users	New Episodes	Dispensings	Total Days Supplied	Years at Risk	Eligible Members	Member-Years	New Users / 1K Eligible Members	Days Supplied/ User	Dispensings / User	Days Supplied/ Dispensing
65 to 74 Years	7,780	7,780	29,812	1,135,572	3,233.9	192,085	110,578.3	40.50	145.96	3.83	38.09
75 to 84 Years	6,296	6,296	24,965	976,472	2,777.2	207,077	128,210.7	30.40	155.09	3.97	39.11
85+ Years	2,098	2,098	7,975	293,441	839.4	136,338	90,931.7	15.39	139.87	3.80	36.80
Exposure of Dabigatran, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Heart Failure											
00 to 40 Years	468	468	968	30,218	93.9	27,928	12,586.3	16.76	64.57	2.07	31.22
41 to 54 Years	3,161	3,161	9,442	309,488	916.9	81,234	41,541.1	38.91	97.91	2.99	32.78
55 to 64 Years	6,558	6,558	25,533	900,032	2,573.4	140,358	76,562.6	46.72	137.24	3.89	35.25
65 to 74 Years	6,177	6,177	23,880	913,582	2,599.1	172,990	100,325.4	35.71	147.90	3.87	38.26
75 to 84 Years	4,625	4,625	18,792	745,815	2,119.4	178,585	111,792.1	25.90	161.26	4.06	39.69
85+ Years	1,277	1,277	4,881	184,650	527.1	109,648	74,580.3	11.65	144.60	3.82	37.83
Exposure of Dabigatran, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Peripheral Vascular Disease											
00 to 40 Years	553	553	1,242	38,525	118.7	28,793	12,971.8	19.21	69.67	2.25	31.02
41 to 54 Years	3,694	3,694	11,499	376,692	1,111.0	85,459	43,225.8	43.23	101.97	3.11	32.76
55 to 64 Years	7,725	7,725	30,040	1,055,682	3,018.5	149,644	80,233.8	51.62	136.66	3.89	35.14
65 to 74 Years	7,296	7,296	27,865	1,060,390	3,015.9	187,349	106,832.5	38.94	145.34	3.82	38.05
75 to 84 Years	5,647	5,647	22,333	876,509	2,490.9	197,383	120,322.6	28.61	155.22	3.95	39.25
85+ Years	1,773	1,773	6,891	255,479	729.9	126,508	82,338.2	14.01	144.09	3.89	37.07
Exposure of Dabigatran, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Stroke											
00 to 40 Years	557	557	1,237	38,555	118.9	28,841	13,014.0	19.31	69.22	2.22	31.17
41 to 54 Years	3,690	3,690	11,403	373,433	1,102.7	85,995	43,782.3	42.91	101.20	3.09	32.75
55 to 64 Years	7,865	7,865	30,280	1,062,102	3,041.5	152,549	82,456.1	51.56	135.04	3.85	35.08
65 to 74 Years	7,805	7,805	29,519	1,123,174	3,199.1	195,182	112,397.2	39.99	143.90	3.78	38.05
75 to 84 Years	6,177	6,177	24,165	946,075	2,693.3	209,591	129,824.1	29.47	153.16	3.91	39.15
85+ Years	2,025	2,025	7,633	279,487	800.9	137,779	91,718.9	14.70	138.02	3.77	36.62
Exposure of Dabigatran, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Urinary Catheter											
00 to 40 Years	560	560	1,258	39,185	120.7	28,878	13,013.2	19.39	69.97	2.25	31.15
41 to 54 Years	3,744	3,744	11,640	381,203	1,124.5	86,314	43,797.9	43.38	101.82	3.11	32.75
55 to 64 Years	8,016	8,016	31,149	1,092,931	3,126.6	153,059	82,349.8	52.37	136.34	3.89	35.09
65 to 74 Years	7,976	7,976	30,430	1,158,569	3,297.3	195,638	111,947.4	40.77	145.26	3.82	38.07
75 to 84 Years	6,430	6,430	25,464	992,960	2,824.8	210,014	129,021.6	30.62	154.43	3.96	38.99
85+ Years	2,135	2,135	8,176	299,546	856.8	137,553	90,855.7	15.52	140.30	3.83	36.64

	New Users	New Episodes	Dispensings	Total Days Supplied	Years at Risk	Eligible Members	Member-Years	New Users / 1K Eligible Members	Days Supplied/ User	Dispensings / User	Days Supplied/ Dispensing
Exposure of Dabigatran, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Hospitalized Bleeding											
00 to 40 Years	554	554	1,242	38,705	119.2	28,675	12,918.3	19.32	69.86	2.24	31.16
41 to 54 Years	3,705	3,705	11,514	377,332	1,113.3	85,379	43,308.3	43.39	101.84	3.11	32.77
55 to 64 Years	7,927	7,927	30,799	1,081,271	3,091.8	151,115	81,195.7	52.46	136.40	3.89	35.11
65 to 74 Years	7,925	7,925	30,216	1,151,314	3,276.8	193,111	110,048.8	41.04	145.28	3.81	38.10
75 to 84 Years	6,319	6,319	25,151	983,013	2,796.1	206,573	126,041.9	30.59	155.56	3.98	39.08
85+ Years	2,082	2,082	7,996	293,464	839.4	135,627	89,035.0	15.35	140.95	3.84	36.70
Exposure of Dabigatran, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of NSAID Use											
00 to 40 Years	497	497	1,139	35,248	108.3	27,757	12,113.9	17.91	70.92	2.29	30.95
41 to 54 Years	3,279	3,279	10,261	336,056	991.5	82,034	40,705.9	39.97	102.49	3.13	32.75
55 to 64 Years	6,865	6,865	26,621	936,434	2,680.0	144,322	76,371.5	47.57	136.41	3.88	35.18
65 to 74 Years	6,907	6,907	26,241	999,692	2,845.5	186,806	106,117.1	36.97	144.74	3.80	38.10
75 to 84 Years	5,688	5,688	22,531	879,848	2,502.5	204,397	125,316.6	27.83	154.68	3.96	39.05
85+ Years	1,961	1,961	7,544	275,931	790.3	136,167	89,579.6	14.40	140.71	3.85	36.58
Exposure of Dabigatran, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of PPI Use											
00 to 40 Years	512	512	1,167	36,445	112.2	27,434	12,083.3	18.66	71.18	2.28	31.23
41 to 54 Years	3,280	3,280	10,187	333,917	985.0	78,408	38,884.3	41.83	101.80	3.11	32.78
55 to 64 Years	6,772	6,772	26,272	917,622	2,627.7	134,779	71,075.6	50.25	135.50	3.88	34.93
65 to 74 Years	6,420	6,420	24,675	935,900	2,668.5	170,774	96,595.4	37.59	145.78	3.84	37.93
75 to 84 Years	5,041	5,041	20,139	780,559	2,224.4	184,251	112,426.6	27.36	154.84	4.00	38.76
85+ Years	1,667	1,667	6,346	233,937	669.0	121,100	78,641.9	13.77	140.33	3.81	36.86
Exposure of Dabigatran, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of SSRI Antidepressants Use											
00 to 40 Years	518	518	1,170	36,390	111.9	27,145	11,961.1	19.08	70.25	2.26	31.10
41 to 54 Years	3,422	3,422	10,589	346,813	1,022.9	80,141	40,162.1	42.70	101.35	3.09	32.75
55 to 64 Years	7,332	7,332	28,463	997,258	2,853.6	141,303	75,607.3	51.89	136.01	3.88	35.04
65 to 74 Years	7,179	7,179	27,499	1,049,673	2,985.8	181,901	104,290.9	39.47	146.21	3.83	38.17
75 to 84 Years	5,829	5,829	23,058	904,152	2,573.5	196,988	121,238.8	29.59	155.11	3.96	39.21
85+ Years	1,901	1,901	7,284	267,684	765.6	128,102	84,387.0	14.84	140.81	3.83	36.75
Exposure of Dabigatran, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Thyroid Replacement Use											
00 to 40 Years	545	545	1,233	38,435	118.3	28,059	12,616.0	19.42	70.52	2.26	31.17
41 to 54 Years	3,512	3,512	10,791	353,158	1,042.7	81,479	41,124.4	43.10	100.56	3.07	32.73
55 to 64 Years	7,285	7,285	28,425	993,306	2,843.7	141,117	75,464.9	51.62	136.35	3.90	34.94

	New Users	New Episodes	Dispensings	Total Days Supplied	Years at Risk	Eligible Members	Member-Years	New Users / 1K Eligible Members	Days Supplied/ User	Dispensings / User	Days Supplied/ Dispensing
65 to 74 Years	6,952	6,952	26,400	1,007,029	2,864.5	177,306	101,541.6	39.21	144.85	3.80	38.15
75 to 84 Years	5,283	5,283	21,135	820,378	2,336.0	185,881	114,914.1	28.42	155.29	4.00	38.82
85+ Years	1,636	1,636	6,219	227,475	652.0	117,733	77,825.0	13.90	139.04	3.80	36.58
Exposure of Dabigatran, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Insulin Use											
00 to 40 Years	550	550	1,244	38,645	118.9	28,621	12,902.4	19.22	70.26	2.26	31.07
41 to 54 Years	3,633	3,633	11,286	369,309	1,089.9	84,052	42,736.1	43.22	101.65	3.11	32.72
55 to 64 Years	7,597	7,597	29,420	1,028,157	2,943.3	146,279	79,232.4	51.94	135.34	3.87	34.95
65 to 74 Years	7,496	7,496	28,629	1,089,021	3,100.8	186,846	108,051.7	40.12	145.28	3.82	38.04
75 to 84 Years	6,204	6,204	24,729	964,268	2,741.8	204,553	127,189.9	30.33	155.43	3.99	38.99
85+ Years	2,114	2,114	8,133	297,876	852.6	137,357	91,802.4	15.39	140.91	3.85	36.63
Exposure of Dabigatran, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Metformin Use											
00 to 40 Years	533	533	1,174	36,485	112.7	28,535	12,861.5	18.68	68.45	2.20	31.08
41 to 54 Years	3,385	3,385	10,350	337,192	998.1	82,560	41,878.0	41.00	99.61	3.06	32.58
55 to 64 Years	6,963	6,963	26,838	935,330	2,679.0	142,697	77,321.8	48.80	134.33	3.85	34.85
65 to 74 Years	6,867	6,867	26,122	993,461	2,827.0	181,980	105,412.6	37.73	144.67	3.80	38.03
75 to 84 Years	5,795	5,795	23,188	902,392	2,566.8	201,431	125,542.3	28.77	155.72	4.00	38.92
85+ Years	2,074	2,074	7,893	289,774	829.0	137,104	91,585.7	15.13	139.72	3.81	36.71
Exposure of Dabigatran, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Sulfonylureas Use											
00 to 40 Years	552	552	1,243	38,615	118.9	28,809	12,988.4	19.16	69.95	2.25	31.07
41 to 54 Years	3,586	3,586	11,079	361,749	1,069.1	84,652	43,013.1	42.36	100.88	3.09	32.65
55 to 64 Years	7,541	7,541	29,276	1,022,802	2,926.8	147,503	79,790.9	51.12	135.63	3.88	34.94
65 to 74 Years	7,355	7,355	27,906	1,062,742	3,024.7	185,949	107,487.9	39.55	144.49	3.79	38.08
75 to 84 Years	5,941	5,941	23,563	922,148	2,621.4	200,917	125,085.6	29.57	155.22	3.97	39.14
85+ Years	2,041	2,041	7,856	287,141	821.5	134,847	90,068.6	15.14	140.69	3.85	36.55
Exposure of Dabigatran, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Other Diabetes Management Medication Use											
00 to 40 Years	551	551	1,244	38,705	119.1	28,838	13,005.2	19.11	70.25	2.26	31.11
41 to 54 Years	3,639	3,639	11,250	367,494	1,085.7	85,255	43,235.3	42.68	100.99	3.09	32.67
55 to 64 Years	7,597	7,597	29,330	1,023,842	2,931.1	149,346	80,554.5	50.87	134.77	3.86	34.91
65 to 74 Years	7,611	7,611	28,624	1,089,875	3,104.2	192,659	110,889.5	39.51	143.20	3.76	38.08
75 to 84 Years	6,250	6,250	24,787	964,018	2,742.0	209,364	129,867.2	29.85	154.24	3.97	38.89
85+ Years	2,107	2,107	8,091	295,786	846.5	139,274	93,058.6	15.13	140.38	3.84	36.56

	New Users	New Episodes	Dispensings	Total Days Supplied	Years at Risk	Eligible Members	Member-Years	New Users / 1K Eligible Members	Days Supplied/ User	Dispensings / User	Days Supplied/ Dispensing
Exposure of Dabigatran, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of ACEI/ARB Use											
00 to 40 Years	441	441	946	29,120	90.9	26,662	11,735.0	16.54	66.03	2.15	30.78
41 to 54 Years	2,468	2,468	7,463	240,555	715.3	69,165	34,229.6	35.68	97.47	3.02	32.23
55 to 64 Years	4,403	4,403	16,293	558,898	1,608.8	109,944	58,222.1	40.05	126.94	3.70	34.30
65 to 74 Years	3,717	3,717	13,646	509,456	1,458.2	136,785	79,028.5	27.17	137.06	3.67	37.33
75 to 84 Years	2,995	2,995	11,404	438,300	1,250.7	151,704	94,751.2	19.74	146.34	3.81	38.43
85+ Years	1,105	1,105	3,929	140,864	404.9	104,118	68,074.1	10.61	127.48	3.56	35.85
Exposure of Dabigatran, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Anti-arrhythmic Use											
00 to 40 Years	412	412	927	29,110	89.7	27,459	11,607.0	15.00	70.66	2.25	31.40
41 to 54 Years	2,810	2,810	8,724	287,393	845.9	78,925	36,571.3	35.60	102.28	3.10	32.94
55 to 64 Years	6,225	6,225	24,610	867,599	2,475.6	137,631	67,325.4	45.23	139.37	3.95	35.25
65 to 74 Years	6,414	6,414	24,782	946,314	2,688.0	181,092	96,928.4	35.42	147.54	3.86	38.19
75 to 84 Years	5,487	5,487	21,883	852,754	2,423.8	199,374	117,317.7	27.52	155.41	3.99	38.97
85+ Years	1,900	1,900	7,247	263,581	754.2	134,038	86,289.4	14.18	138.73	3.81	36.37
Exposure of Dabigatran, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of IV Anticoagulant Use											
00 to 40 Years	517	517	1,175	36,635	112.5	28,460	12,646.9	18.17	70.86	2.27	31.18
41 to 54 Years	3,490	3,490	10,985	360,407	1,061.8	84,855	42,549.1	41.13	103.27	3.15	32.81
55 to 64 Years	7,635	7,635	29,824	1,046,532	2,992.0	150,357	80,014.3	50.78	137.07	3.91	35.09
65 to 74 Years	7,585	7,585	28,966	1,106,178	3,147.7	192,229	108,687.3	39.46	145.84	3.82	38.19
75 to 84 Years	6,214	6,214	24,549	961,438	2,733.5	208,587	127,155.5	29.79	154.72	3.95	39.16
85+ Years	2,102	2,102	8,116	298,316	852.6	138,584	91,300.4	15.17	141.92	3.86	36.76
Exposure of Dabigatran, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Antiplatelet Use											
00 to 40 Years	553	553	1,244	38,825	119.5	28,740	12,919.1	19.24	70.21	2.25	31.21
41 to 54 Years	3,619	3,619	11,277	369,038	1,088.9	83,549	42,072.9	43.32	101.97	3.12	32.72
55 to 64 Years	7,380	7,380	28,520	994,093	2,847.6	144,073	76,743.8	51.22	134.70	3.86	34.86
65 to 74 Years	7,080	7,080	26,953	1,024,087	2,917.6	182,657	103,749.3	38.76	144.65	3.81	38.00
75 to 84 Years	5,524	5,524	21,331	830,669	2,364.7	195,368	119,335.9	28.27	150.37	3.86	38.94
85+ Years	1,816	1,816	6,654	241,930	694.4	128,837	84,198.9	14.10	133.22	3.66	36.36
Exposure of Dabigatran, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Beta Blocker Use											
00 to 40 Years	299	299	631	19,265	60.7	23,833	9,406.8	12.55	64.43	2.11	30.53
41 to 54 Years	1,875	1,875	5,598	183,421	543.0	61,664	27,358.0	30.41	97.82	2.99	32.77
55 to 64 Years	3,679	3,679	14,316	491,808	1,411.6	100,415	48,625.0	36.64	133.68	3.89	34.35

	New Users	New Episodes	Dispensings	Total Days Supplied	Years at Risk	Eligible Members	Member-Years	New Users / 1K Eligible Members	Days Supplied/ User	Dispensings / User	Days Supplied/ Dispensing
65 to 74 Years	3,211	3,211	12,007	451,671	1,289.8	128,495	70,252.0	24.99	140.66	3.74	37.62
75 to 84 Years	2,664	2,664	10,242	399,857	1,141.7	142,885	86,689.8	18.64	150.10	3.84	39.04
85+ Years	909	909	3,421	124,651	357.6	95,720	60,589.5	9.50	137.13	3.76	36.44
Exposure of Dabigatran, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Calcium Channel Blocker Use											
00 to 40 Years	481	481	1,082	33,750	103.9	27,230	11,629.6	17.66	70.17	2.25	31.19
41 to 54 Years	2,876	2,876	8,904	290,579	859.0	76,146	36,567.5	37.77	101.04	3.10	32.63
55 to 64 Years	5,629	5,629	21,415	744,240	2,131.9	128,532	65,952.4	43.79	132.22	3.80	34.75
65 to 74 Years	5,231	5,231	19,691	744,520	2,121.0	161,574	90,181.6	32.38	142.33	3.76	37.81
75 to 84 Years	4,204	4,204	16,927	655,902	1,867.1	173,793	105,504.9	24.19	156.02	4.03	38.75
85+ Years	1,353	1,353	5,070	183,658	526.8	114,364	74,061.9	11.83	135.74	3.75	36.22
Exposure of Dabigatran, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Digoxin Use											
00 to 40 Years	525	525	1,180	36,810	113.5	28,530	12,748.1	18.40	70.11	2.25	31.19
41 to 54 Years	3,495	3,495	10,824	354,251	1,045.8	83,966	41,882.6	41.62	101.36	3.10	32.73
55 to 64 Years	7,364	7,364	28,549	999,956	2,859.1	147,062	77,368.6	50.07	135.79	3.88	35.03
65 to 74 Years	7,237	7,237	27,669	1,050,751	2,990.6	187,061	104,865.0	38.69	145.19	3.82	37.98
75 to 84 Years	5,818	5,818	23,468	914,401	2,601.6	200,106	120,550.5	29.07	157.17	4.03	38.96
85+ Years	1,848	1,848	6,968	257,204	735.8	129,756	83,058.1	14.24	139.18	3.77	36.91
Exposure of Dabigatran, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Loop Diuretic Use											
00 to 40 Years	524	524	1,182	36,545	113.1	28,449	12,776.7	18.42	69.74	2.26	30.92
41 to 54 Years	3,374	3,374	10,326	337,187	995.5	82,357	41,537.9	40.97	99.94	3.06	32.65
55 to 64 Years	7,041	7,041	27,348	960,096	2,746.2	141,330	75,596.4	49.82	136.36	3.88	35.11
65 to 74 Years	6,579	6,579	25,430	963,797	2,741.9	175,864	100,120.4	37.41	146.50	3.87	37.90
75 to 84 Years	4,980	4,980	20,279	795,938	2,263.2	183,571	112,323.6	27.13	159.83	4.07	39.25
85+ Years	1,458	1,458	5,574	205,704	588.9	113,468	72,718.7	12.85	141.09	3.82	36.90
Exposure of Dabigatran, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Potassium-Sparing Diuretic Use											
00 to 40 Years	545	545	1,217	37,835	116.9	28,708	12,931.4	18.98	69.42	2.23	31.09
41 to 54 Years	3,645	3,645	11,242	367,372	1,084.5	85,167	43,138.6	42.80	100.79	3.08	32.68
55 to 64 Years	7,821	7,821	30,434	1,067,517	3,053.0	150,547	80,912.5	51.95	136.49	3.89	35.08
65 to 74 Years	7,767	7,767	29,540	1,125,871	3,205.0	193,053	110,543.7	40.23	144.96	3.80	38.11
75 to 84 Years	6,299	6,299	24,890	972,291	2,766.0	208,883	128,711.2	30.16	154.36	3.95	39.06
85+ Years	2,085	2,085	7,991	293,141	838.5	137,969	91,386.4	15.11	140.60	3.83	36.68

	New Users	New Episodes	Dispensings	Total Days Supplied	Years at Risk	Eligible Members	Member-Years	New Users / 1K Eligible Members	Days Supplied/ User	Dispensings / User	Days Supplied/ Dispensing
Exposure of Dabigatran, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Thiazide Diuretic Use											
00 to 40 Years	515	515	1,141	35,390	109.3	28,055	12,539.3	18.36	68.72	2.22	31.02
41 to 54 Years	3,189	3,189	9,724	316,490	937.8	79,446	39,898.5	40.14	99.24	3.05	32.55
55 to 64 Years	6,330	6,330	24,223	840,856	2,413.2	135,159	72,244.6	46.83	132.84	3.83	34.71
65 to 74 Years	5,956	5,956	22,212	844,232	2,406.2	170,978	98,083.1	34.83	141.74	3.73	38.01
75 to 84 Years	4,813	4,813	18,828	730,305	2,080.4	188,268	116,681.7	25.56	151.74	3.91	38.79
85+ Years	1,674	1,674	6,257	226,568	650.7	127,211	84,024.6	13.16	135.35	3.74	36.21
Exposure of Dabigatran, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Amiodarone Use											
00 to 40 Years	534	534	1,194	37,305	114.9	28,808	12,925.6	18.54	69.86	2.24	31.24
41 to 54 Years	3,593	3,593	11,161	365,183	1,076.5	85,181	42,575.9	42.18	101.64	3.11	32.72
55 to 64 Years	7,610	7,610	29,885	1,049,645	2,999.2	149,602	78,598.8	50.87	137.93	3.93	35.12
65 to 74 Years	7,480	7,480	28,652	1,090,412	3,102.4	191,010	106,402.8	39.16	145.78	3.83	38.06
75 to 84 Years	6,044	6,044	23,982	937,539	2,665.1	205,629	123,699.4	29.39	155.12	3.97	39.09
85+ Years	2,020	2,020	7,735	282,909	808.9	136,446	89,013.0	14.80	140.05	3.83	36.58
Exposure of Dabigatran, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Dronedaronone Use											
00 to 40 Years	537	537	1,205	37,595	115.7	28,840	12,905.9	18.62	70.01	2.24	31.20
41 to 54 Years	3,501	3,501	10,795	353,441	1,042.3	85,738	42,837.9	40.83	100.95	3.08	32.74
55 to 64 Years	7,608	7,608	29,367	1,031,459	2,950.3	151,959	80,550.8	50.07	135.58	3.86	35.12
65 to 74 Years	7,669	7,669	29,324	1,115,472	3,172.8	196,007	111,653.0	39.13	145.45	3.82	38.04
75 to 84 Years	6,320	6,320	25,093	979,535	2,786.2	212,499	130,952.7	29.74	154.99	3.97	39.04
85+ Years	2,121	2,121	8,076	296,171	847.2	140,582	93,582.9	15.09	139.64	3.81	36.67

Table 2b. Summary of Incident Warfarin Use in the MSDD between October 19, 2010 and December 31, 2012, by Pre-Existing Condition Criteria and Age Group

	New Users	New Episodes	Dispensings	Total Days Supplied	Years at Risk	Eligible Members	Member-Years	New Users / 1K Eligible Members	Days Supplied/ User	Dispensings / User	Days Supplied/ Dispensing
Exposure of Warfarin Pre-Existing Inclusion of Atrial Fibrillation											
00 to 40 Years	1,062	1,062	3,418	115,592	332.1	28,960	13,052.6	36.67	108.84	3.22	33.82
41 to 54 Years	7,429	7,429	23,851	818,568	2,345.6	86,611	43,851.5	85.77	110.19	3.21	34.32
55 to 64 Years	18,880	18,880	59,703	2,237,829	6,334.2	153,853	82,443.7	122.71	118.53	3.16	37.48
65 to 74 Years	30,344	30,344	96,633	4,187,791	11,754.5	197,562	112,760.1	153.59	138.01	3.18	43.34
75 to 84 Years	34,933	34,933	115,865	4,933,599	13,850.0	213,283	131,106.1	163.79	141.23	3.32	42.58
85+ Years	14,210	14,210	51,389	1,929,358	5,414.6	140,652	93,551.1	101.03	135.77	3.62	37.54
Exposure of Warfarin, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Anemia											
00 to 40 Years	893	893	2,853	98,554	282.4	27,192	12,177.6	32.84	110.36	3.19	34.54
41 to 54 Years	6,108	6,108	19,609	673,661	1,932.2	80,828	40,759.6	75.57	110.29	3.21	34.35
55 to 64 Years	15,032	15,032	47,670	1,805,657	5,107.6	140,613	74,906.3	106.90	120.12	3.17	37.88
65 to 74 Years	22,725	22,725	72,338	3,223,853	9,035.9	174,500	98,776.5	130.23	141.86	3.18	44.57
75 to 84 Years	24,677	24,677	80,162	3,563,862	9,994.0	182,202	110,761.3	135.44	144.42	3.25	44.46
85+ Years	9,646	9,646	34,144	1,352,118	3,798.4	117,141	77,190.0	82.35	140.17	3.54	39.60
Exposure of Warfarin, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of COPD											
00 to 40 Years	1,023	1,023	3,308	111,948	321.8	28,630	12,863.2	35.73	109.43	3.23	33.84
41 to 54 Years	6,727	6,727	21,635	746,216	2,137.8	83,800	42,395.3	80.27	110.93	3.22	34.49
55 to 64 Years	15,931	15,931	49,906	1,889,436	5,351.0	143,648	77,267.1	110.90	118.60	3.13	37.86
65 to 74 Years	23,224	23,224	72,533	3,232,444	9,063.3	174,010	99,883.2	133.46	139.19	3.12	44.57
75 to 84 Years	26,415	26,415	85,920	3,755,681	10,542.3	184,157	113,339.5	143.44	142.18	3.25	43.71
85+ Years	10,976	10,976	39,174	1,497,779	4,208.5	122,848	81,035.3	89.35	136.46	3.57	38.23
Exposure of Warfarin, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Diabetes											
00 to 40 Years	931	931	2,988	100,294	289.9	27,580	12,427.3	33.76	107.73	3.21	33.57
41 to 54 Years	5,578	5,578	17,556	601,900	1,728.9	78,066	39,903.3	71.45	107.91	3.15	34.28
55 to 64 Years	12,228	12,228	37,972	1,410,192	4,004.3	128,916	70,619.4	94.85	115.32	3.11	37.14
65 to 74 Years	18,116	18,116	56,195	2,459,773	6,914.2	151,316	88,164.2	119.72	135.78	3.10	43.77
75 to 84 Years	22,847	22,847	74,135	3,214,587	9,030.3	164,562	102,166.1	138.84	140.70	3.24	43.36
85+ Years	10,399	10,399	37,318	1,413,580	3,971.6	116,768	77,760.0	89.06	135.93	3.59	37.88

	New Users	New Episodes	Dispensings	Total Days Supplied	Years at Risk	Eligible Members	Member-Years	New Users / 1K Eligible Members	Days Supplied/ User	Dispensings / User	Days Supplied/ Dispensing
Exposure of Warfarin, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Hypertension											
00 to 40 Years	652	652	2,142	71,761	207.8	25,344	11,452.5	25.73	110.06	3.29	33.50
41 to 54 Years	2,841	2,841	8,896	311,040	894.8	67,937	36,676.4	41.82	109.48	3.13	34.96
55 to 64 Years	5,011	5,011	14,993	565,693	1,609.7	110,024	65,506.8	45.54	112.89	2.99	37.73
65 to 74 Years	5,484	5,484	16,055	737,046	2,072.9	125,254	81,509.5	43.78	134.40	2.93	45.91
75 to 84 Years	5,245	5,245	15,154	712,704	2,009.6	127,222	89,047.5	41.23	135.88	2.89	47.03
85+ Years	2,067	2,067	6,643	274,157	776.5	80,940	61,647.0	25.54	132.64	3.21	41.27
Exposure of Warfarin, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Chronic Kidney Failure											
00 to 40 Years	999	999	3,256	110,466	317.3	28,483	12,835.5	35.07	110.58	3.26	33.93
41 to 54 Years	6,742	6,742	21,641	743,119	2,130.3	84,042	42,588.3	80.22	110.22	3.21	34.34
55 to 64 Years	16,347	16,347	51,585	1,932,525	5,472.7	145,927	78,271.0	112.02	118.22	3.16	37.46
65 to 74 Years	24,316	24,316	76,899	3,364,380	9,442.2	180,265	103,007.1	134.89	138.36	3.16	43.75
75 to 84 Years	26,074	26,074	85,876	3,728,496	10,470.2	187,278	115,648.1	139.23	143.00	3.29	43.42
85+ Years	10,058	10,058	36,642	1,391,958	3,909.2	120,556	80,685.0	83.43	138.39	3.64	37.99
Exposure of Warfarin, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Acute Kidney Failure											
00 to 40 Years	981	981	3,129	106,606	306.5	28,508	12,882.4	34.41	108.67	3.19	34.07
41 to 54 Years	6,774	6,774	21,490	742,329	2,128.9	84,531	42,945.8	80.14	109.59	3.17	34.54
55 to 64 Years	16,924	16,924	53,192	2,009,056	5,687.8	148,271	79,771.7	114.14	118.71	3.14	37.77
65 to 74 Years	26,954	26,954	84,971	3,755,503	10,530.7	187,803	107,274.7	143.52	139.33	3.15	44.20
75 to 84 Years	30,793	30,793	101,096	4,395,829	12,337.4	200,201	122,886.2	153.81	142.75	3.28	43.48
85+ Years	12,491	12,491	44,916	1,717,195	4,819.4	130,698	86,612.3	95.57	137.47	3.60	38.23
Exposure of Warfarin, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Peptic Ulcer Disease											
00 to 40 Years	1,060	1,060	3,409	115,345	331.5	28,940	13,030.8	36.63	108.82	3.22	33.84
41 to 54 Years	7,397	7,397	23,694	813,228	2,331.0	86,459	43,705.6	85.56	109.94	3.20	34.32
55 to 64 Years	18,755	18,755	59,317	2,224,344	6,295.6	153,400	81,987.2	122.26	118.60	3.16	37.50
65 to 74 Years	30,125	30,125	95,835	4,157,267	11,668.4	196,668	111,885.4	153.18	138.00	3.18	43.38
75 to 84 Years	34,643	34,643	114,781	4,895,955	13,744.2	211,996	129,694.8	163.41	141.33	3.31	42.65
85+ Years	14,095	14,095	50,801	1,916,187	5,377.2	139,788	92,646.5	100.83	135.95	3.60	37.72
Exposure of Warfarin, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Hospitalized AMI											
00 to 40 Years	1,017	1,017	3,256	110,750	318.2	28,761	12,956.0	35.36	108.90	3.20	34.01
41 to 54 Years	7,030	7,030	22,452	773,144	2,217.4	85,063	43,085.9	82.64	109.98	3.19	34.44
55 to 64 Years	17,775	17,775	55,976	2,107,341	5,964.0	150,203	80,542.5	118.34	118.56	3.15	37.65

	New Users	New Episodes	Dispensings	Total Days Supplied	Years at Risk	Eligible Members	Member-Years	New Users / 1K Eligible Members	Days Supplied/ User	Dispensings / User	Days Supplied/ Dispensing
65 to 74 Years	28,385	28,385	90,016	3,935,631	11,041.9	191,840	109,491.5	147.96	138.65	3.17	43.72
75 to 84 Years	32,867	32,867	108,612	4,665,341	13,095.2	206,650	126,761.5	159.05	141.95	3.30	42.95
85+ Years	13,360	13,360	48,205	1,823,583	5,119.1	135,888	90,191.6	98.32	136.50	3.61	37.83
Exposure of Warfarin, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Heart Failure											
00 to 40 Years	803	803	2,481	83,461	241.8	27,928	12,575.0	28.75	103.94	3.09	33.64
41 to 54 Years	5,319	5,319	16,510	572,907	1,646.1	81,222	41,415.2	65.49	107.71	3.10	34.70
55 to 64 Years	13,128	13,128	40,289	1,524,360	4,325.3	140,263	76,087.5	93.60	116.12	3.07	37.84
65 to 74 Years	19,983	19,983	61,879	2,772,614	7,771.5	172,824	99,627.9	115.63	138.75	3.10	44.81
75 to 84 Years	21,950	21,950	71,247	3,166,228	8,890.1	178,316	110,928.0	123.10	144.25	3.25	44.44
85+ Years	7,745	7,745	27,061	1,073,933	3,015.7	109,414	74,218.7	70.79	138.66	3.49	39.69
Exposure of Warfarin, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Peripheral Vascular Disease											
00 to 40 Years	1,032	1,032	3,308	112,331	322.5	28,793	12,952.7	35.84	108.85	3.21	33.96
41 to 54 Years	7,012	7,012	22,437	771,377	2,210.9	85,442	43,053.4	82.07	110.01	3.20	34.38
55 to 64 Years	17,241	17,241	54,484	2,049,885	5,800.0	149,512	79,586.4	115.32	118.90	3.16	37.62
65 to 74 Years	26,257	26,257	82,560	3,634,743	10,199.2	187,123	105,858.8	140.32	138.43	3.14	44.03
75 to 84 Years	29,018	29,018	94,220	4,112,121	11,540.5	197,017	119,130.8	147.29	141.71	3.25	43.64
85+ Years	11,254	11,254	39,131	1,518,133	4,265.4	126,147	81,757.7	89.21	134.90	3.48	38.80
Exposure of Warfarin, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Stroke											
00 to 40 Years	1,024	1,024	3,250	110,405	317.7	28,841	12,994.7	35.51	107.82	3.17	33.97
41 to 54 Years	7,139	7,139	22,737	783,790	2,247.9	85,980	43,600.1	83.03	109.79	3.18	34.47
55 to 64 Years	18,104	18,104	56,554	2,131,085	6,037.4	152,404	81,739.1	118.79	117.71	3.12	37.68
65 to 74 Years	28,930	28,930	90,455	3,962,183	11,128.3	194,932	111,241.9	148.41	136.96	3.13	43.80
75 to 84 Years	32,871	32,871	106,946	4,609,900	12,946.1	209,136	128,314.7	157.18	140.24	3.25	43.10
85+ Years	13,160	13,160	46,608	1,780,081	4,997.3	137,332	90,959.0	95.83	135.26	3.54	38.19
Exposure of Warfarin, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Urinary Catheter											
00 to 40 Years	1,053	1,053	3,397	114,786	329.7	28,878	12,993.7	36.46	109.01	3.23	33.79
41 to 54 Years	7,340	7,340	23,563	809,641	2,320.1	86,299	43,607.9	85.05	110.31	3.21	34.36
55 to 64 Years	18,595	18,595	58,731	2,203,141	6,236.4	152,915	81,629.5	121.60	118.48	3.16	37.51
65 to 74 Years	29,682	29,682	94,352	4,101,812	11,509.9	195,385	110,795.0	151.92	138.19	3.18	43.47
75 to 84 Years	33,895	33,895	112,280	4,800,975	13,479.1	209,568	127,523.0	161.74	141.64	3.31	42.76
85+ Years	13,634	13,634	48,820	1,854,726	5,205.3	137,116	90,104.8	99.43	136.04	3.58	37.99

	New Users	New Episodes	Dispensings	Total Days Supplied	Years at Risk	Eligible Members	Member-Years	New Users / 1K Eligible Members	Days Supplied/ User	Dispensings / User	Days Supplied/ Dispensing
Exposure of Warfarin, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Hospitalized Bleeding											
00 to 40 Years	1,018	1,018	3,270	111,323	319.5	28,675	12,897.9	35.50	109.35	3.21	34.04
41 to 54 Years	7,093	7,093	22,576	779,591	2,233.4	85,364	43,144.7	83.09	109.91	3.18	34.53
55 to 64 Years	18,067	18,067	56,902	2,147,177	6,077.1	150,984	80,510.6	119.66	118.85	3.15	37.73
65 to 74 Years	29,049	29,049	92,386	4,036,771	11,324.3	192,881	108,980.0	150.61	138.96	3.18	43.69
75 to 84 Years	33,209	33,209	110,015	4,732,798	13,271.8	206,176	124,685.0	161.07	142.52	3.31	43.02
85+ Years	13,422	13,422	48,248	1,837,940	5,154.6	135,221	88,348.1	99.26	136.93	3.59	38.09
Exposure of Warfarin, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of NSAID Use											
00 to 40 Years	936	936	3,060	103,837	298.2	27,757	12,098.3	33.72	110.94	3.27	33.93
41 to 54 Years	6,505	6,505	20,807	716,107	2,053.3	82,016	40,558.5	79.31	110.09	3.20	34.42
55 to 64 Years	16,192	16,192	50,918	1,921,125	5,436.3	144,204	75,811.8	112.29	118.65	3.14	37.73
65 to 74 Years	26,556	26,556	84,185	3,671,230	10,303.6	186,607	105,111.3	142.31	138.24	3.17	43.61
75 to 84 Years	31,484	31,484	103,681	4,440,349	12,467.3	203,995	123,961.5	154.34	141.04	3.29	42.83
85+ Years	13,101	13,101	47,212	1,777,402	4,987.5	135,746	88,863.7	96.51	135.67	3.60	37.65
Exposure of Warfarin, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of PPI Use											
00 to 40 Years	943	943	2,994	101,029	290.3	27,434	12,070.0	34.37	107.14	3.17	33.74
41 to 54 Years	6,345	6,345	20,348	696,266	1,998.5	78,396	38,737.4	80.94	109.73	3.21	34.22
55 to 64 Years	15,493	15,493	49,120	1,845,395	5,221.9	134,666	70,554.4	115.05	119.11	3.17	37.57
65 to 74 Years	24,045	24,045	76,556	3,343,791	9,378.7	170,580	95,767.9	140.96	139.06	3.18	43.68
75 to 84 Years	27,274	27,274	89,747	3,873,475	10,863.3	183,941	111,347.1	148.28	142.02	3.29	43.16
85+ Years	11,125	11,125	39,450	1,523,817	4,274.8	120,772	78,078.5	92.12	136.97	3.55	38.63
Exposure of Warfarin, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of SSRI Antidepressants Use											
00 to 40 Years	947	947	3,026	102,340	294.3	27,145	11,949.2	34.89	108.07	3.20	33.82
41 to 54 Years	6,650	6,650	21,458	738,105	2,113.4	80,127	40,009.0	82.99	110.99	3.23	34.40
55 to 64 Years	16,626	16,626	52,419	1,969,831	5,575.2	141,180	74,971.9	117.76	118.48	3.15	37.58
65 to 74 Years	26,562	26,562	84,590	3,684,633	10,343.6	181,691	103,281.0	146.19	138.72	3.18	43.56
75 to 84 Years	31,264	31,264	102,474	4,424,868	12,418.8	196,591	119,911.2	159.03	141.53	3.28	43.18
85+ Years	12,594	12,594	44,820	1,716,603	4,817.7	127,699	83,709.6	98.62	136.30	3.56	38.30
Exposure of Warfarin, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Thyroid Replacement Use											
00 to 40 Years	1,024	1,024	3,323	112,503	323.2	28,059	12,596.4	36.49	109.87	3.25	33.86
41 to 54 Years	6,940	6,940	22,299	765,791	2,194.2	81,465	40,940.7	85.19	110.34	3.21	34.34
55 to 64 Years	16,942	16,942	53,556	2,003,781	5,674.6	140,983	74,810.3	120.17	118.27	3.16	37.41

	New Users	New Episodes	Dispensings	Total Days Supplied	Years at Risk	Eligible Members	Member-Years	New Users / 1K Eligible Members	Days Supplied/ User	Dispensings / User	Days Supplied/ Dispensing
65 to 74 Years	26,144	26,144	82,966	3,591,007	10,085.2	177,082	100,565.6	147.64	137.35	3.17	43.28
75 to 84 Years	28,493	28,493	93,791	3,992,198	11,213.6	185,507	113,623.3	153.60	140.11	3.29	42.56
85+ Years	11,118	11,118	40,235	1,517,060	4,256.3	117,369	77,201.2	94.73	136.45	3.62	37.70
Exposure of Warfarin, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Insulin Use											
00 to 40 Years	1,030	1,030	3,329	112,428	322.9	28,621	12,885.3	35.99	109.15	3.23	33.77
41 to 54 Years	6,902	6,902	21,988	755,080	2,165.2	84,035	42,564.5	82.13	109.40	3.19	34.34
55 to 64 Years	16,904	16,904	53,180	1,994,785	5,648.9	146,145	78,580.7	115.67	118.01	3.15	37.51
65 to 74 Years	27,197	27,197	86,345	3,756,376	10,546.7	186,622	106,991.6	145.73	138.12	3.17	43.50
75 to 84 Years	32,531	32,531	107,287	4,592,181	12,894.4	204,147	125,713.1	159.35	141.16	3.30	42.80
85+ Years	13,599	13,599	49,012	1,846,869	5,184.2	136,901	91,033.1	99.33	135.81	3.60	37.68
Exposure of Warfarin, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Metformin Use											
00 to 40 Years	1,012	1,012	3,252	109,628	315.2	28,535	12,843.9	35.47	108.33	3.21	33.71
41 to 54 Years	6,678	6,678	21,160	726,572	2,085.3	82,544	41,711.0	80.90	108.80	3.17	34.34
55 to 64 Years	16,257	16,257	50,691	1,889,095	5,358.0	142,563	76,668.5	114.03	116.20	3.12	37.27
65 to 74 Years	25,795	25,795	80,619	3,492,949	9,820.1	181,768	104,386.6	141.91	135.41	3.13	43.33
75 to 84 Years	31,583	31,583	104,395	4,443,435	12,484.7	201,035	124,121.5	157.10	140.69	3.31	42.56
85+ Years	13,525	13,525	48,923	1,832,393	5,144.4	136,649	90,811.0	98.98	135.48	3.62	37.45
Exposure of Warfarin, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Sulfonylureas Use											
00 to 40 Years	1,032	1,032	3,316	111,883	321.7	28,809	12,970.4	35.82	108.41	3.21	33.74
41 to 54 Years	7,035	7,035	22,442	770,514	2,209.1	84,638	42,836.1	83.12	109.53	3.19	34.33
55 to 64 Years	17,187	17,187	53,996	2,017,188	5,711.3	147,368	79,126.2	116.63	117.37	3.14	37.36
65 to 74 Years	26,890	26,890	84,469	3,662,894	10,285.5	185,726	106,431.5	144.78	136.22	3.14	43.36
75 to 84 Years	31,447	31,447	104,126	4,423,413	12,427.8	200,512	123,662.7	156.83	140.66	3.31	42.48
85+ Years	13,201	13,201	47,659	1,784,900	5,012.6	134,407	89,320.6	98.22	135.21	3.61	37.45
Exposure of Warfarin, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Other Diabetes Management Medication Use											
00 to 40 Years	1,046	1,046	3,358	113,778	326.9	28,838	12,986.3	36.27	108.77	3.21	33.88
41 to 54 Years	7,191	7,191	22,883	787,227	2,257.3	85,239	43,053.9	84.36	109.47	3.18	34.40
55 to 64 Years	17,794	17,794	55,841	2,096,708	5,936.5	149,204	79,871.6	119.26	117.83	3.14	37.55
65 to 74 Years	28,806	28,806	91,280	3,962,304	11,120.8	192,423	109,769.3	149.70	137.55	3.17	43.41
75 to 84 Years	33,675	33,675	111,380	4,750,846	13,336.1	208,930	128,344.7	161.18	141.08	3.31	42.65
85+ Years	13,891	13,891	50,156	1,884,858	5,290.7	138,807	92,261.4	100.07	135.69	3.61	37.58

	New Users	New Episodes	Dispensings	Total Days Supplied	Years at Risk	Eligible Members	Member-Years	New Users / 1K Eligible Members	Days Supplied/ User	Dispensings / User	Days Supplied/ Dispensing
Exposure of Warfarin, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of ACEI/ARB Use											
00 to 40 Years	820	820	2,574	86,595	248.5	26,662	11,714.2	30.76	105.60	3.14	33.64
41 to 54 Years	4,749	4,749	14,780	504,697	1,450.7	69,145	34,120.9	68.68	106.27	3.11	34.15
55 to 64 Years	10,243	10,243	31,496	1,154,503	3,290.1	109,853	57,867.1	93.24	112.71	3.07	36.66
65 to 74 Years	14,830	14,830	45,880	1,973,851	5,563.1	136,659	78,518.1	108.52	133.10	3.09	43.02
75 to 84 Years	17,865	17,865	58,418	2,454,306	6,911.6	151,496	94,031.2	117.92	137.38	3.27	42.01
85+ Years	7,955	7,955	29,346	1,067,636	3,004.1	103,887	67,677.0	76.57	134.21	3.69	36.38
Exposure of Warfarin, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Anti-arrhythmic Use											
00 to 40 Years	884	884	2,863	97,099	278.3	27,458	11,590.6	32.19	109.84	3.24	33.92
41 to 54 Years	6,105	6,105	19,810	680,714	1,946.9	78,910	36,423.1	77.37	111.50	3.24	34.36
55 to 64 Years	15,695	15,695	50,184	1,882,504	5,324.5	137,526	66,857.1	114.12	119.94	3.20	37.51
65 to 74 Years	26,229	26,229	84,790	3,657,524	10,257.1	180,896	96,086.6	144.99	139.45	3.23	43.14
75 to 84 Years	31,093	31,093	104,425	4,429,344	12,420.6	199,039	116,138.5	156.22	142.45	3.36	42.42
85+ Years	13,086	13,086	47,694	1,796,514	5,038.4	133,671	85,621.2	97.90	137.29	3.64	37.67
Exposure of Warfarin, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of IV Anticoagulant Use											
00 to 40 Years	974	974	3,117	105,031	302.5	28,459	12,633.8	34.22	107.83	3.20	33.70
41 to 54 Years	6,873	6,873	22,203	763,484	2,185.7	84,839	42,373.4	81.01	111.08	3.23	34.39
55 to 64 Years	17,649	17,649	55,665	2,098,404	5,934.9	150,219	79,360.7	117.49	118.90	3.15	37.70
65 to 74 Years	28,258	28,258	89,484	3,911,997	10,974.4	192,009	107,646.9	147.17	138.44	3.17	43.72
75 to 84 Years	32,878	32,878	108,213	4,646,748	13,044.4	208,160	125,702.4	157.95	141.33	3.29	42.94
85+ Years	13,534	13,534	48,550	1,833,139	5,148.2	138,136	90,548.9	97.98	135.45	3.59	37.76
Exposure of Warfarin, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Antiplatelet Use											
00 to 40 Years	1,036	1,036	3,332	112,937	324.2	28,740	12,898.5	36.05	109.01	3.22	33.89
41 to 54 Years	7,045	7,045	22,500	772,428	2,214.9	83,533	41,892.2	84.34	109.64	3.19	34.33
55 to 64 Years	17,264	17,264	54,364	2,042,415	5,783.3	143,939	76,081.6	119.94	118.30	3.15	37.57
65 to 74 Years	27,130	27,130	85,527	3,740,692	10,501.1	182,423	102,697.9	148.72	137.88	3.15	43.74
75 to 84 Years	31,177	31,177	102,440	4,403,152	12,363.5	194,954	117,965.0	159.92	141.23	3.29	42.98
85+ Years	12,652	12,652	45,365	1,711,994	4,808.0	128,407	83,505.2	98.53	135.31	3.59	37.74
Exposure of Warfarin, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Beta Blocker Use											
00 to 40 Years	646	646	2,055	68,348	196.6	23,833	9,389.3	27.11	105.80	3.18	33.26
41 to 54 Years	3,883	3,883	12,510	419,951	1,208.5	61,656	27,280.4	62.98	108.15	3.22	33.57
55 to 64 Years	8,873	8,873	28,369	1,027,448	2,923.5	100,361	48,371.9	88.41	115.79	3.20	36.22

	New Users	New Episodes	Dispensings	Total Days Supplied	Years at Risk	Eligible Members	Member-Years	New Users / 1K Eligible Members	Days Supplied/ User	Dispensings / User	Days Supplied/ Dispensing
65 to 74 Years	13,108	13,108	42,377	1,774,987	4,998.3	128,418	69,866.7	102.07	135.41	3.23	41.89
75 to 84 Years	15,504	15,504	52,253	2,158,016	6,075.7	142,724	86,148.9	108.63	139.19	3.37	41.30
85+ Years	6,676	6,676	24,785	913,275	2,572.5	95,534	60,318.6	69.88	136.80	3.71	36.85
Exposure of Warfarin, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Calcium Channel Blocker Use											
00 to 40 Years	912	912	2,922	97,906	281.8	27,231	11,618.9	33.49	107.35	3.20	33.51
41 to 54 Years	5,808	5,808	18,426	632,706	1,809.9	76,138	36,437.9	76.28	108.94	3.17	34.34
55 to 64 Years	13,708	13,708	43,072	1,615,328	4,574.4	128,444	65,488.2	106.72	117.84	3.14	37.50
65 to 74 Years	20,949	20,949	65,232	2,840,623	7,977.5	161,404	89,490.3	129.79	135.60	3.11	43.55
75 to 84 Years	23,851	23,851	78,963	3,330,105	9,353.0	173,534	104,551.9	137.44	139.62	3.31	42.17
85+ Years	9,588	9,588	34,198	1,275,722	3,584.3	114,064	73,567.8	84.06	133.05	3.57	37.30
Exposure of Warfarin, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Digoxin Use											
00 to 40 Years	997	997	3,235	109,098	313.2	28,530	12,725.0	34.95	109.43	3.24	33.72
41 to 54 Years	6,837	6,837	21,994	750,190	2,150.2	83,952	41,725.7	81.44	109.73	3.22	34.11
55 to 64 Years	17,095	17,095	54,589	2,028,145	5,743.4	146,937	76,753.0	116.34	118.64	3.19	37.15
65 to 74 Years	27,242	27,242	87,378	3,749,922	10,528.7	186,853	103,893.1	145.79	137.65	3.21	42.92
75 to 84 Years	31,046	31,046	103,961	4,388,997	12,324.4	199,709	119,289.4	155.46	141.37	3.35	42.22
85+ Years	12,433	12,433	45,214	1,684,516	4,730.0	129,394	82,456.2	96.09	135.49	3.64	37.26
Exposure of Warfarin, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Loop Diuretic Use											
00 to 40 Years	937	937	3,028	101,272	291.2	28,448	12,761.0	32.94	108.08	3.23	33.45
41 to 54 Years	6,261	6,261	20,029	686,070	1,967.7	82,343	41,403.5	76.04	109.58	3.20	34.25
55 to 64 Years	14,974	14,974	47,280	1,753,512	4,976.1	141,225	75,094.3	106.03	117.10	3.16	37.09
65 to 74 Years	22,856	22,856	73,104	3,176,311	8,920.6	175,678	99,319.9	130.10	138.97	3.20	43.45
75 to 84 Years	25,380	25,380	84,216	3,589,806	10,080.2	183,271	111,341.8	138.48	141.44	3.32	42.63
85+ Years	9,394	9,394	34,186	1,289,604	3,623.2	113,198	72,308.0	82.99	137.28	3.64	37.72
Exposure of Warfarin, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Potassium-Sparing Diuretic Use											
00 to 40 Years	1,018	1,018	3,273	109,741	315.6	28,708	12,911.4	35.46	107.80	3.22	33.53
41 to 54 Years	7,111	7,111	22,843	784,180	2,246.9	85,149	42,953.5	83.51	110.28	3.21	34.33
55 to 64 Years	17,965	17,965	56,895	2,127,737	6,021.6	150,400	80,228.1	119.45	118.44	3.17	37.40
65 to 74 Years	28,924	28,924	92,593	4,008,280	11,247.4	192,806	109,415.5	150.02	138.58	3.20	43.29
75 to 84 Years	33,509	33,509	111,513	4,743,400	13,312.4	208,454	127,233.6	160.75	141.56	3.33	42.54
85+ Years	13,664	13,664	49,329	1,854,119	5,201.4	137,530	90,625.4	99.35	135.69	3.61	37.59

	New Users	New Episodes	Dispensings	Total Days Supplied	Years at Risk	Eligible Members	Member-Years	New Users / 1K Eligible Members	Days Supplied/ User	Dispensings / User	Days Supplied/ Dispensing
Exposure of Warfarin, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Thiazide Diuretic Use											
00 to 40 Years	979	979	3,133	106,072	304.7	28,055	12,517.4	34.90	108.35	3.20	33.86
41 to 54 Years	6,305	6,305	20,113	690,994	1,983.6	79,430	39,744.7	79.38	109.59	3.19	34.36
55 to 64 Years	15,063	15,063	46,869	1,752,904	4,970.0	135,040	71,647.0	111.54	116.37	3.11	37.40
65 to 74 Years	23,120	23,120	72,388	3,133,548	8,808.6	170,772	97,186.0	135.39	135.53	3.13	43.29
75 to 84 Years	26,960	26,960	88,676	3,761,312	10,569.0	187,924	115,487.6	143.46	139.51	3.29	42.42
85+ Years	11,351	11,351	41,078	1,516,637	4,267.0	126,863	83,407.2	89.47	133.61	3.62	36.92
Exposure of Warfarin, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Amiodarone Use											
00 to 40 Years	1,020	1,020	3,298	111,983	321.3	28,808	12,904.7	35.41	109.79	3.23	33.95
41 to 54 Years	7,029	7,029	22,691	778,459	2,228.9	85,168	42,418.1	82.53	110.75	3.23	34.31
55 to 64 Years	17,724	17,724	56,380	2,109,421	5,970.7	149,490	78,000.2	118.56	119.01	3.18	37.41
65 to 74 Years	28,390	28,390	91,282	3,950,103	11,082.8	190,786	105,457.5	148.81	139.14	3.22	43.27
75 to 84 Years	32,771	32,771	109,633	4,670,643	13,100.7	205,263	122,431.4	159.65	142.52	3.35	42.60
85+ Years	13,488	13,488	49,104	1,849,194	5,188.0	136,052	88,312.9	99.14	137.10	3.64	37.66
Exposure of Warfarin, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Dronedarone Use											
00 to 40 Years	1,031	1,031	3,292	111,776	321.0	28,839	12,888.3	35.75	108.42	3.19	33.95
41 to 54 Years	7,204	7,204	23,099	794,169	2,275.8	85,721	42,641.3	84.04	110.24	3.21	34.38
55 to 64 Years	18,344	18,344	58,064	2,177,798	6,163.1	151,810	79,848.5	120.84	118.72	3.17	37.51
65 to 74 Years	29,829	29,829	94,916	4,114,920	11,549.7	195,756	110,467.8	152.38	137.95	3.18	43.35
75 to 84 Years	34,546	34,546	114,526	4,875,517	13,686.7	212,026	129,379.0	162.93	141.13	3.32	42.57
85+ Years	14,106	14,106	50,970	1,914,846	5,373.3	140,122	92,773.1	100.67	135.75	3.61	37.57

Table 3a. Summary of Incident Dabigatran Use in the MSDD between October 19, 2010 and December 31, 2012, by Pre-Existing Condition Criteria and Sex

	New Users	New Episodes	Dispensings	Total Days Supplied	Years at Risk	Eligible Members	Member-Years	New Users / 1K Eligible Members	Days Supplied/ User	Dispensings / User	Days Supplied/ Dispensing
Exposure of Dabigatran, Pre-Existing Inclusion of Atrial Fibrillation											
Female	10,245	10,245	39,645	1,443,164	4,121.0	342,196	215,412.0	29.94	140.87	3.87	36.40
Male	18,912	18,912	69,556	2,560,429	7,342.8	432,121	265,934.0	43.77	135.39	3.68	36.81
Unknown	0	0	0	0	0.0	13	8.1	0.00	---	---	---
Exposure of Dabigatran, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Anemia											
Female	8,480	8,480	33,517	1,224,809	3,490.7	297,632	183,956.3	28.49	144.44	3.95	36.54
Male	16,717	16,717	62,174	2,292,560	6,569.7	384,522	233,256.1	43.47	137.14	3.72	36.87
Unknown	0	0	0	0	0.0	12	8.5	0.00	---	---	---
Exposure of Dabigatran, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of COPD											
Female	8,460	8,460	33,132	1,208,227	3,448.9	305,558	190,904.5	27.69	142.82	3.92	36.47
Male	16,494	16,494	61,120	2,249,843	6,450.2	390,007	239,210.7	42.29	136.40	3.71	36.81
Unknown	0	0	0	0	0.0	12	6.7	0.00	---	---	---
Exposure of Dabigatran, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Diabetes											
Female	7,445	7,445	29,162	1,060,510	3,026.2	279,967	176,872.2	26.59	142.45	3.92	36.37
Male	13,738	13,738	49,914	1,819,402	5,226.0	349,532	217,041.7	39.30	132.44	3.63	36.45
Unknown	0	0	0	0	0.0	12	7.4	0.00	---	---	---
Exposure of Dabigatran, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Hypertension											
Female	2,015	2,015	7,542	269,218	771.8	215,397	148,573.3	9.35	133.61	3.74	35.70
Male	5,224	5,224	18,166	647,752	1,877.2	290,007	198,009.5	18.01	124.00	3.48	35.66
Unknown	0	0	0	0	0.0	11	6.8	0.00	---	---	---
Exposure of Dabigatran, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Chronic Kidney Failure											
Female	9,132	9,132	35,562	1,293,311	3,696.1	311,832	195,195.1	29.28	141.62	3.89	36.37
Male	17,271	17,271	63,870	2,350,713	6,741.9	392,819	241,088.0	43.97	136.11	3.70	36.80
Unknown	0	0	0	0	0.0	13	8.1	0.00	---	---	---
Exposure of Dabigatran, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Acute Kidney Failure											
Female	9,724	9,724	37,888	1,380,458	3,939.2	325,522	204,258.4	29.87	141.96	3.90	36.44
Male	18,087	18,087	66,712	2,463,379	7,061.7	410,030	251,873.6	44.11	136.20	3.69	36.93
Unknown	0	0	0	0	0.0	13	8.0	0.00	---	---	---
Exposure of Dabigatran, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Peptic Ulcer Disease											
Female	10,202	10,202	39,491	1,437,748	4,105.2	340,648	213,647.9	29.95	140.93	3.87	36.41
Male	18,861	18,861	69,392	2,554,849	7,326.6	430,226	263,780.3	43.84	135.46	3.68	36.82

	New Users	New Episodes	Dispensings	Total Days Supplied	Years at Risk	Eligible Members	Member-Years	New Users / 1K Eligible Members	Days Supplied/ User	Dispensings / User	Days Supplied/ Dispensing
Unknown	0	0	0	0	0.0	13	8.1	0.00	---	---	---
Exposure of Dabigatran, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Hospitalized AMI											
Female	9,915	9,915	38,347	1,397,888	3,992.9	333,480	209,337.3	29.73	140.99	3.87	36.45
Male	18,320	18,320	67,540	2,488,742	7,136.9	419,437	257,856.4	43.68	135.85	3.69	36.85
Unknown	0	0	0	0	0.0	13	7.6	0.00	---	---	---
Exposure of Dabigatran, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Heart Failure											
Female	7,550	7,550	29,325	1,079,352	3,081.0	293,657	184,962.4	25.71	142.96	3.88	36.81
Male	14,716	14,716	54,171	2,004,433	5,748.8	375,928	232,418.2	39.15	136.21	3.68	37.00
Unknown	0	0	0	0	0.0	12	7.2	0.00	---	---	---
Exposure of Dabigatran, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Peripheral Vascular Disease											
Female	9,254	9,254	35,726	1,303,551	3,720.3	322,542	198,580.9	28.69	140.86	3.86	36.49
Male	17,434	17,434	64,144	2,359,726	6,764.7	408,357	247,335.4	42.69	135.35	3.68	36.79
Unknown	0	0	0	0	0.0	13	8.4	0.00	---	---	---
Exposure of Dabigatran, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Stroke											
Female	9,767	9,767	37,487	1,366,891	3,906.9	336,257	211,162.6	29.05	139.95	3.84	36.46
Male	18,352	18,352	66,750	2,455,935	7,049.4	426,378	262,021.9	43.04	133.82	3.64	36.79
Unknown	0	0	0	0	0.0	13	8.1	0.00	---	---	---
Exposure of Dabigatran, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Urinary Catheter											
Female	10,138	10,138	39,217	1,428,607	4,078.9	338,292	211,455.9	29.97	140.92	3.87	36.43
Male	18,723	18,723	68,900	2,535,787	7,271.9	426,023	259,521.6	43.95	135.44	3.68	36.80
Unknown	0	0	0	0	0.0	13	8.1	0.00	---	---	---
Exposure of Dabigatran, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Hospitalized Bleeding											
Female	9,969	9,969	38,642	1,408,278	4,020.8	332,620	206,263.8	29.97	141.27	3.88	36.44
Male	18,543	18,543	68,276	2,516,821	7,215.8	421,569	256,276.1	43.99	135.73	3.68	36.86
Unknown	0	0	0	0	0.0	13	8.1	0.00	---	---	---
Exposure of Dabigatran, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of NSAID Use											
Female	8,724	8,724	33,655	1,228,166	3,506.9	323,601	200,083.1	26.96	140.78	3.86	36.49
Male	16,473	16,473	60,682	2,235,043	6,411.1	413,269	250,113.4	39.86	135.68	3.68	36.83
Unknown	0	0	0	0	0.0	13	8.1	0.00	---	---	---
Exposure of Dabigatran, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of PPI Use											
Female	7,886	7,886	30,634	1,113,629	3,181.7	292,914	179,466.9	26.92	141.22	3.88	36.35
Male	15,806	15,806	58,152	2,124,751	6,105.1	383,260	230,235.4	41.24	134.43	3.68	36.54
Unknown	0	0	0	0	0.0	11	4.9	0.00	---	---	---

	New Users	New Episodes	Dispensings	Total Days Supplied	Years at Risk	Eligible Members	Member-Years	New Users / 1K Eligible Members	Days Supplied/ User	Dispensings / User	Days Supplied/ Dispensing
Exposure of Dabigatran, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of SSRI Antidepressants Use											
Female	8,681	8,681	33,701	1,231,446	3,514.2	305,359	189,891.9	28.43	141.86	3.88	36.54
Male	17,500	17,500	64,362	2,370,524	6,799.1	406,755	247,747.1	43.02	135.46	3.68	36.83
Unknown	0	0	0	0	0.0	13	8.1	0.00	---	---	---
Exposure of Dabigatran, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Thyroid Replacement Use											
Female	7,744	7,744	30,114	1,086,739	3,105.6	284,037	176,709.2	27.26	140.33	3.89	36.09
Male	17,469	17,469	64,089	2,353,042	6,751.7	405,361	246,770.8	43.09	134.70	3.67	36.72
Unknown	0	0	0	0	0.0	11	6.1	0.00	---	---	---
Exposure of Dabigatran, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Insulin Use											
Female	9,680	9,680	37,697	1,370,267	3,914.0	328,256	207,013.1	29.49	141.56	3.89	36.35
Male	17,914	17,914	65,744	2,417,009	6,933.2	413,560	254,894.1	43.32	134.92	3.67	36.76
Unknown	0	0	0	0	0.0	12	7.7	0.00	---	---	---
Exposure of Dabigatran, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Metformin Use											
Female	9,098	9,098	35,046	1,275,847	3,644.5	324,463	204,689.1	28.04	140.23	3.85	36.40
Male	16,519	16,519	60,519	2,218,787	6,368.1	404,810	249,904.7	40.81	134.32	3.66	36.66
Unknown	0	0	0	0	0.0	13	8.1	0.00	---	---	---
Exposure of Dabigatran, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Sulfonylureas Use											
Female	9,566	9,566	36,938	1,345,927	3,843.2	327,619	206,202.9	29.20	140.70	3.86	36.44
Male	17,450	17,450	63,985	2,349,270	6,739.3	409,544	252,225.0	42.61	134.63	3.67	36.72
Unknown	0	0	0	0	0.0	12	6.7	0.00	---	---	---
Exposure of Dabigatran, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Other Diabetes Management Medication Use											
Female	9,806	9,806	37,787	1,376,056	3,929.7	336,203	211,411.1	29.17	140.33	3.85	36.42
Male	17,949	17,949	65,539	2,403,664	6,899.0	421,659	259,191.1	42.57	133.92	3.65	36.68
Unknown	0	0	0	0	0.0	13	8.1	0.00	---	---	---
Exposure of Dabigatran, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of ACEI/ARB Use											
Female	5,295	5,295	19,783	706,299	2,024.7	250,121	154,871.6	21.17	133.39	3.74	35.70
Male	9,834	9,834	33,898	1,210,894	3,504.2	314,739	191,164.0	31.24	123.13	3.45	35.72
Unknown	0	0	0	0	0.0	11	5.0	0.00	---	---	---
Exposure of Dabigatran, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Anti-arrhythmic Use											
Female	8,237	8,237	32,102	1,170,628	3,336.4	319,685	188,181.6	25.77	142.12	3.90	36.47
Male	15,011	15,011	56,071	2,076,123	5,940.9	397,745	227,850.0	37.74	138.31	3.74	37.03
Unknown	0	0	0	0	0.0	13	7.5	0.00	---	---	---
Exposure of Dabigatran, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of IV Anticoagulant Use											

	New Users	New Episodes	Dispensings	Total Days Supplied	Years at Risk	Eligible Members	Member-Years	New Users / 1K Eligible Members	Days Supplied/ User	Dispensings / User	Days Supplied/ Dispensing
Female	9,711	9,711	37,615	1,372,585	3,916.6	334,601	206,920.1	29.02	141.34	3.87	36.49
Male	17,832	17,832	66,000	2,436,921	6,983.4	422,152	255,426.4	42.24	136.66	3.70	36.92
Unknown	0	0	0	0	0.0	13	7.0	0.00	---	---	---
Exposure of Dabigatran, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Antiplatelet Use											
Female	9,148	9,148	35,027	1,267,284	3,623.7	320,076	197,607.3	28.58	138.53	3.83	36.18
Male	16,824	16,824	60,952	2,231,358	6,409.0	399,506	241,405.7	42.11	132.63	3.62	36.61
Unknown	0	0	0	0	0.0	11	6.9	0.00	---	---	---
Exposure of Dabigatran, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Beta Blocker Use											
Female	4,215	4,215	15,885	574,367	1,644.4	229,636	134,026.0	18.36	136.27	3.77	36.16
Male	8,422	8,422	30,330	1,096,306	3,160.1	294,436	168,889.1	28.60	130.17	3.60	36.15
Unknown	0	0	0	0	0.0	12	6.0	0.00	---	---	---
Exposure of Dabigatran, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Calcium Channel Blocker Use											
Female	6,458	6,458	24,604	889,520	2,544.6	277,727	166,462.6	23.25	137.74	3.81	36.15
Male	13,316	13,316	48,485	1,763,129	5,065.2	366,103	217,428.2	36.37	132.41	3.64	36.36
Unknown	0	0	0	0	0.0	8	7.1	0.00	---	---	---
Exposure of Dabigatran, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Digoxin Use											
Female	9,091	9,091	35,452	1,291,297	3,684.5	322,091	194,783.2	28.22	142.04	3.90	36.42
Male	17,196	17,196	63,206	2,322,076	6,661.9	410,481	245,683.0	41.89	135.04	3.68	36.74
Unknown	0	0	0	0	0.0	12	6.7	0.00	---	---	---
Exposure of Dabigatran, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Loop Diuretic Use											
Female	8,006	8,006	31,270	1,138,414	3,250.5	297,605	182,164.6	26.90	142.20	3.91	36.41
Male	15,950	15,950	58,869	2,160,853	6,198.3	386,092	232,902.1	41.31	135.48	3.69	36.71
Unknown	0	0	0	0	0.0	14	6.9	0.00	---	---	---
Exposure of Dabigatran, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Potassium-Sparing Diuretic Use											
Female	9,862	9,862	38,119	1,390,368	3,969.8	334,606	208,965.1	29.47	140.98	3.87	36.47
Male	18,300	18,300	67,195	2,473,659	7,094.0	423,085	258,650.7	43.25	135.17	3.67	36.81
Unknown	0	0	0	0	0.0	13	7.9	0.00	---	---	---
Exposure of Dabigatran, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Thiazide Diuretic Use											
Female	7,457	7,457	28,345	1,023,364	2,928.2	298,326	186,009.2	25.00	137.24	3.80	36.10
Male	15,020	15,020	54,040	1,970,477	5,669.4	389,061	237,455.8	38.61	131.19	3.60	36.46
Unknown	0	0	0	0	0.0	10	6.7	0.00	---	---	---
Exposure of Dabigatran, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Amiodarone Use											
Female	9,618	9,618	37,277	1,357,628	3,872.7	333,672	204,034.5	28.82	141.15	3.88	36.42

	New Users	New Episodes	Dispensings	Total Days Supplied	Years at Risk	Eligible Members	Member-Years	New Users / 1K Eligible Members	Days Supplied/ User	Dispensings / User	Days Supplied/ Dispensing
Male	17,663	17,663	65,332	2,405,365	6,894.4	417,975	249,173.4	42.26	136.18	3.70	36.82
Unknown	0	0	0	0	0.0	13	7.5	0.00	---	---	---

	New Users	New Episodes	Dispensings	Total Days Supplied	Years at Risk	Eligible Members	Member-Years	New Users / 1K Eligible Members	Days Supplied/ User	Dispensings / User	Days Supplied/ Dispensing
Exposure of Dabigatran, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Dronedaron Use											
Female	9,805	9,805	37,967	1,382,738	3,946.8	339,995	211,701.0	28.84	141.02	3.87	36.42
Male	17,951	17,951	65,893	2,430,935	6,967.8	428,471	260,773.9	41.90	135.42	3.67	36.89
Unknown	0	0	0	0	0.0	13	8.1	0.00	---	---	---

Table 3b. Summary of Incident Warfarin Use in the MSDD between October 19, 2010 and December 31, 2012, by Pre-Existing Condition Criteria and Sex

	New Users	New Episodes	Dispensings	Total Days Supplied	Years at Risk	Eligible Members	Member-Years	New Users / 1K Eligible Members	Days Supplied/ User	Dispensings / User	Days Supplied/ Dispensing
Exposure of Warfarin Pre-Existing Inclusion of Atrial Fibrillation											
Female	45,630	45,630	155,070	6,134,225	17,265.2	342,196	213,383.4	133.34	134.43	3.40	39.56
Male	61,225	61,225	195,782	8,088,302	22,765.0	432,121	263,373.7	141.68	132.11	3.20	41.31
Unknown	3	3	7	210	0.7	13	8.1	230.77	70.00	2.33	30.00
Exposure of Warfarin, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Anemia											
Female	32,404	32,404	108,160	4,448,519	12,512.0	297,624	182,852.6	108.88	137.28	3.34	41.13
Male	46,675	46,675	148,611	6,269,036	17,637.8	384,518	231,710.3	121.39	134.31	3.18	42.18
Unknown	2	2	5	150	0.5	12	8.5	166.67	75.00	2.50	30.00
Exposure of Warfarin, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of COPD											
Female	35,664	35,664	119,234	4,807,721	13,535.0	305,557	189,459.6	116.72	134.81	3.34	40.32
Male	48,631	48,631	153,238	6,425,663	18,089.4	390,000	237,317.5	124.69	132.13	3.15	41.93
Unknown	1	1	4	120	0.4	12	6.7	83.33	120.00	4.00	30.00
Exposure of Warfarin, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Diabetes											
Female	30,765	30,765	103,291	4,125,742	11,624.9	279,967	175,525.4	109.89	134.11	3.36	39.94
Male	39,333	39,333	122,871	5,074,524	14,314.0	349,527	215,507.4	112.53	129.01	3.12	41.30
Unknown	1	1	2	60	0.2	12	7.4	83.33	60.00	2.00	30.00
Exposure of Warfarin, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Hypertension											
Female	7,589	7,589	22,938	947,961	2,691.9	215,396	148,277.5	35.23	124.91	3.02	41.33
Male	13,711	13,711	40,945	1,724,440	4,879.4	290,002	197,555.4	47.28	125.77	2.99	42.12
Unknown	0	0	0	0	0.0	11	6.8	0.00	---	---	---
Exposure of Warfarin, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Chronic Kidney Failure											
Female	36,213	36,213	121,949	4,868,650	13,718.1	311,830	193,715.6	116.13	134.44	3.37	39.92
Male	48,321	48,321	153,947	6,402,204	18,023.4	392,815	239,311.0	123.01	132.49	3.19	41.59
Unknown	2	2	3	90	0.3	13	8.1	153.85	45.00	1.50	30.00
Exposure of Warfarin, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Acute Kidney Failure											
Female	40,898	40,898	137,895	5,538,396	15,588.3	325,521	202,540.7	125.64	135.42	3.37	40.16
Male	54,016	54,016	170,892	7,187,912	20,221.7	410,028	249,824.4	131.74	133.07	3.16	42.06
Unknown	3	3	7	210	0.7	13	8.0	230.77	70.00	2.33	30.00
Exposure of Warfarin, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Peptic Ulcer Disease											
Female	45,246	45,246	153,484	6,084,749	17,124.2	340,646	211,672.4	132.82	134.48	3.39	39.64
Male	60,826	60,826	194,346	8,037,367	22,622.9	430,226	261,269.8	141.38	132.14	3.20	41.36

	New Users	New Episodes	Dispensings	Total Days Supplied	Years at Risk	Eligible Members	Member-Years	New Users / 1K Eligible Members	Days Supplied/ User	Dispensings / User	Days Supplied/ Dispensing
Unknown	3	3	7	210	0.7	13	8.1	230.77	70.00	2.33	30.00
Exposure of Warfarin, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Hospitalized AMI											
Female	43,096	43,096	145,895	5,811,994	16,358.4	333,474	207,481.4	129.23	134.86	3.39	39.84
Male	57,335	57,335	182,615	7,603,586	21,396.7	419,432	255,540.0	136.70	132.62	3.19	41.64
Unknown	3	3	7	210	0.7	13	7.6	230.77	70.00	2.33	30.00
Exposure of Warfarin, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Heart Failure											
Female	29,115	29,115	95,365	3,930,546	11,069.8	293,652	183,868.6	99.15	135.00	3.28	41.22
Male	39,812	39,812	124,098	5,262,837	14,820.3	375,923	230,976.5	105.90	132.19	3.12	42.41
Unknown	1	1	4	120	0.4	12	7.2	83.33	120.00	4.00	30.00
Exposure of Warfarin, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Peripheral Vascular Disease											
Female	39,207	39,207	130,102	5,266,048	14,819.6	322,539	196,980.1	121.56	134.31	3.32	40.48
Male	52,604	52,604	166,031	6,932,332	19,518.1	408,355	245,351.2	128.82	131.78	3.16	41.75
Unknown	3	3	7	210	0.7	13	8.4	230.77	70.00	2.33	30.00
Exposure of Warfarin, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Stroke											
Female	42,768	42,768	142,560	5,702,031	16,059.9	336,255	209,258.4	127.19	133.32	3.33	40.00
Male	58,457	58,457	183,983	7,675,203	21,614.0	426,376	259,583.0	137.10	131.30	3.15	41.72
Unknown	3	3	7	210	0.7	13	8.1	230.77	70.00	2.33	30.00
Exposure of Warfarin, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Urinary Catheter											
Female	44,577	44,577	151,158	6,003,949	16,898.8	338,292	209,524.5	131.77	134.69	3.39	39.72
Male	59,620	59,620	189,980	7,880,982	22,181.2	426,021	257,121.5	139.95	132.19	3.19	41.48
Unknown	2	2	5	150	0.5	13	8.1	153.85	75.00	2.50	30.00
Exposure of Warfarin, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Hospitalized Bleeding											
Female	43,280	43,280	146,630	5,858,618	16,479.3	332,614	204,524.0	130.12	135.37	3.39	39.96
Male	58,575	58,575	186,760	7,786,772	21,900.7	421,571	254,034.2	138.94	132.94	3.19	41.69
Unknown	3	3	7	210	0.7	13	8.1	230.77	70.00	2.33	30.00
Exposure of Warfarin, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of NSAID Use											
Female	40,049	40,049	135,579	5,399,957	15,197.1	323,592	198,437.4	123.76	134.83	3.39	39.83
Male	54,723	54,723	174,278	7,229,913	20,348.6	413,269	247,959.7	132.41	132.12	3.18	41.48
Unknown	2	2	6	180	0.6	13	8.1	153.85	90.00	3.00	30.00
Exposure of Warfarin, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of PPI Use											
Female	34,927	34,927	117,779	4,712,235	13,257.3	292,910	178,141.8	119.24	134.92	3.37	40.01
Male	50,297	50,297	160,434	6,671,478	18,770.1	383,257	228,408.6	131.24	132.64	3.19	41.58
Unknown	1	1	2	60	0.2	11	4.9	90.91	60.00	2.00	30.00

	New Users	New Episodes	Dispensings	Total Days Supplied	Years at Risk	Eligible Members	Member-Years	New Users / 1K Eligible Members	Days Supplied/ User	Dispensings / User	Days Supplied/ Dispensing
Exposure of Warfarin, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of SSRI Antidepressants Use											
Female	38,632	38,632	129,752	5,202,006	14,639.0	305,358	188,289.5	126.51	134.66	3.36	40.09
Male	56,008	56,008	179,028	7,434,164	20,923.2	406,756	245,534.4	137.69	132.73	3.20	41.53
Unknown	3	3	7	210	0.7	13	8.1	230.77	70.00	2.33	30.00
Exposure of Warfarin, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Thyroid Replacement Use											
Female	34,781	34,781	117,596	4,632,529	13,049.4	284,034	175,215.1	122.45	133.19	3.38	39.39
Male	55,877	55,877	178,567	7,349,601	20,697.0	405,360	244,516.3	137.85	131.53	3.20	41.16
Unknown	3	3	7	210	0.7	11	6.1	272.73	70.00	2.33	30.00
Exposure of Warfarin, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Insulin Use											
Female	42,128	42,128	142,896	5,675,832	15,976.1	328,256	205,157.9	128.34	134.73	3.39	39.72
Male	56,032	56,032	178,238	7,381,677	20,785.4	413,559	252,602.6	135.49	131.74	3.18	41.41
Unknown	3	3	7	210	0.7	12	7.7	250.00	70.00	2.33	30.00
Exposure of Warfarin, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Metformin Use											
Female	41,035	41,035	138,904	5,484,160	15,451.5	324,462	202,865.4	126.47	133.65	3.39	39.48
Male	53,813	53,813	170,133	7,009,822	19,755.8	404,809	247,669.0	132.93	130.26	3.16	41.20
Unknown	2	2	3	90	0.3	13	8.1	153.85	45.00	1.50	30.00
Exposure of Warfarin, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Sulfonylureas Use											
Female	41,893	41,893	142,023	5,609,251	15,793.1	327,619	204,364.3	127.87	133.89	3.39	39.50
Male	54,897	54,897	173,982	7,161,451	20,174.6	409,541	249,976.6	134.05	130.45	3.17	41.16
Unknown	2	2	3	90	0.3	12	6.7	166.67	45.00	1.50	30.00
Exposure of Warfarin, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Other Diabetes Management Medication Use											
Female	44,045	44,045	149,331	5,915,235	16,651.5	336,202	209,480.0	131.01	134.30	3.39	39.61
Male	58,356	58,356	185,564	7,680,396	21,616.4	421,658	256,799.1	138.40	131.61	3.18	41.39
Unknown	2	2	3	90	0.3	13	8.1	153.85	45.00	1.50	30.00
Exposure of Warfarin, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of ACEI/ARB Use											
Female	24,135	24,135	81,219	3,153,072	8,910.1	250,118	153,961.6	96.49	130.64	3.37	38.82
Male	32,326	32,326	101,274	4,088,486	11,557.9	314,730	189,962.1	102.71	126.48	3.13	40.37
Unknown	1	1	1	30	0.1	11	5.0	90.91	30.00	1.00	30.00
Exposure of Warfarin, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Anti-arrhythmic Use											
Female	40,145	40,145	138,333	5,456,513	15,345.2	319,678	186,694.9	125.58	135.92	3.45	39.44
Male	52,944	52,944	171,426	7,086,976	19,920.0	397,736	226,014.7	133.11	133.86	3.24	41.34
Unknown	3	3	7	210	0.7	13	7.5	230.77	70.00	2.33	30.00
Exposure of Warfarin, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of IV Anticoagulant Use											

	New Users	New Episodes	Dispensings	Total Days Supplied	Years at Risk	Eligible Members	Member-Years	New Users / 1K Eligible Members	Days Supplied/ User	Dispensings / User	Days Supplied/ Dispensing
Female	42,744	42,744	144,285	5,753,996	16,192.2	334,600	205,111.9	127.75	134.62	3.38	39.88
Male	57,420	57,420	182,942	7,604,657	21,397.3	422,148	253,147.4	136.02	132.44	3.19	41.57
Unknown	2	2	5	150	0.5	13	7.0	153.85	75.00	2.50	30.00
Exposure of Warfarin, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Antiplatelet Use											
Female	41,512	41,512	140,337	5,588,425	15,731.8	320,072	195,830.6	129.70	134.62	3.38	39.82
Male	54,789	54,789	173,184	7,194,983	20,262.5	399,504	239,203.0	137.14	131.32	3.16	41.55
Unknown	3	3	7	210	0.7	11	6.9	272.73	70.00	2.33	30.00
Exposure of Warfarin, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Beta Blocker Use											
Female	20,167	20,167	69,878	2,668,474	7,540.5	229,630	133,399.0	87.82	132.32	3.46	38.19
Male	28,522	28,522	92,470	3,693,521	10,434.4	294,428	167,970.8	96.87	129.50	3.24	39.94
Unknown	1	1	1	30	0.1	12	6.0	83.33	30.00	1.00	30.00
Exposure of Warfarin, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Calcium Channel Blocker Use											
Female	30,293	30,293	102,009	4,008,717	11,293.7	277,720	165,362.9	109.08	132.33	3.37	39.30
Male	44,523	44,523	140,804	5,783,673	16,287.2	366,098	215,785.0	121.61	129.90	3.16	41.08
Unknown	0	0	0	0	0.0	8	7.1	0.00	---	---	---
Exposure of Warfarin, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Digoxin Use											
Female	40,517	40,517	138,536	5,438,051	15,309.1	322,092	193,227.9	125.79	134.22	3.42	39.25
Male	55,130	55,130	177,828	7,272,607	20,480.0	410,482	243,607.8	134.31	131.92	3.23	40.90
Unknown	3	3	7	210	0.7	12	6.7	250.00	70.00	2.33	30.00
Exposure of Warfarin, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Loop Diuretic Use											
Female	33,198	33,198	112,647	4,464,534	12,584.3	297,604	180,947.6	111.55	134.48	3.39	39.63
Male	46,601	46,601	149,189	6,131,831	17,273.9	386,085	231,273.9	120.70	131.58	3.20	41.10
Unknown	3	3	7	210	0.7	14	6.9	214.29	70.00	2.33	30.00
Exposure of Warfarin, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Potassium-Sparing Diuretic Use											
Female	43,641	43,641	148,747	5,879,465	16,545.1	334,605	207,084.1	130.43	134.72	3.41	39.53
Male	58,547	58,547	187,692	7,747,782	21,799.6	423,083	256,275.6	138.38	132.33	3.21	41.28
Unknown	3	3	7	210	0.7	13	7.9	230.77	70.00	2.33	30.00
Exposure of Warfarin, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Thiazide Diuretic Use											
Female	34,206	34,206	115,040	4,508,351	12,705.7	298,319	184,584.8	114.66	131.80	3.36	39.19
Male	49,571	49,571	157,215	6,453,056	18,197.1	389,054	235,398.3	127.41	130.18	3.17	41.05
Unknown	1	1	2	60	0.2	10	6.7	100.00	60.00	2.00	30.00
Exposure of Warfarin, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Amiodarone Use											
Female	43,196	43,196	147,923	5,854,475	16,469.2	333,670	202,383.5	129.46	135.53	3.42	39.58

	New Users	New Episodes	Dispensings	Total Days Supplied	Years at Risk	Eligible Members	Member-Years	New Users / 1K Eligible Members	Days Supplied/ User	Dispensings / User	Days Supplied/ Dispensing
Male	57,223	57,223	184,458	7,615,118	21,422.4	417,972	247,133.8	136.91	133.08	3.22	41.28
Unknown	3	3	7	210	0.7	13	7.5	230.77	70.00	2.33	30.00
Exposure of Warfarin, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Dronedaron Use											
Female	44,922	44,922	152,617	6,038,234	16,995.4	339,992	209,735.0	132.13	134.42	3.40	39.56
Male	60,135	60,135	192,243	7,950,582	22,373.5	428,468	258,254.8	140.35	132.21	3.20	41.36
Unknown	3	3	7	210	0.7	13	8.1	230.77	70.00	2.33	30.00

Table 4a. Summary of Incident Dabigatran Use in the MSDD between October 19, 2010 and December 31, 2012, by Pre-Existing Condition Criteria and Year

	New Users	New Episodes	Dispensings	Total Days Supplied	Years at Risk	Eligible Members	Member-Years	New Users / 1K Eligible Members	Days Supplied/ User	Dispensings / User	Days Supplied/ Dispensing
Exposure of Dabigatran, Pre-Existing Inclusion of Atrial Fibrillation											
2010	1,138	1,138	6,067	224,099	632.5	280,461	43,792.1	4.06	196.92	5.33	36.94
2011	16,375	16,375	70,478	2,606,256	7,463.0	481,656	214,251.0	34.00	159.16	4.30	36.98
2012	11,644	11,644	32,656	1,173,238	3,368.3	495,650	223,311.0	23.49	100.76	2.80	35.93
Exposure of Dabigatran, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Anemia											
2010	989	989	5,385	197,864	558.7	244,292	37,726.4	4.05	200.06	5.44	36.74
2011	14,096	14,096	61,849	2,295,073	6,565.8	423,961	185,749.2	33.25	162.82	4.39	37.11
2012	10,112	10,112	28,457	1,024,432	2,936.0	433,944	193,745.3	23.30	101.31	2.81	36.00
Exposure of Dabigatran, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of COPD											
2010	1,009	1,009	5,524	203,211	573.4	250,727	38,908.0	4.02	201.40	5.47	36.79
2011	13,990	13,990	60,849	2,254,429	6,451.1	432,493	191,166.1	32.35	161.15	4.35	37.05
2012	9,955	9,955	27,879	1,000,430	2,874.7	444,775	200,047.7	22.38	100.50	2.80	35.88
Exposure of Dabigatran, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Diabetes											
2010	838	838	4,436	160,907	455.6	227,760	35,378.5	3.68	192.01	5.29	36.27
2011	11,946	11,946	51,196	1,881,777	5,390.4	392,652	175,004.0	30.42	157.52	4.29	36.76
2012	8,399	8,399	23,444	837,228	2,406.3	403,927	183,538.8	20.79	99.68	2.79	35.71
Exposure of Dabigatran, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Hypertension											
2010	303	303	1,776	64,569	182.2	179,811	27,781.3	1.69	213.10	5.86	36.36
2011	4,066	4,066	16,337	588,183	1,698.0	318,004	149,259.4	12.79	144.66	4.02	36.00
2012	2,870	2,870	7,595	264,218	768.9	333,763	169,548.9	8.60	92.06	2.65	34.79
Exposure of Dabigatran, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Chronic Kidney Failure											
2010	1,041	1,041	5,581	205,652	580.4	254,287	39,499.2	4.09	197.55	5.36	36.85
2011	14,834	14,834	64,330	2,376,464	6,808.1	438,612	194,684.9	33.82	160.20	4.34	36.94
2012	10,528	10,528	29,521	1,061,908	3,049.5	448,563	202,107.2	23.47	100.87	2.80	35.97
Exposure of Dabigatran, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Acute Kidney Failure											
2010	1,099	1,099	5,849	216,204	610.1	268,709	41,887.8	4.09	196.73	5.32	36.96
2011	15,615	15,615	67,499	2,502,428	7,161.9	458,902	203,754.0	34.03	160.26	4.32	37.07
2012	11,097	11,097	31,252	1,125,205	3,229.0	469,545	210,498.3	23.63	101.40	2.82	36.00
Exposure of Dabigatran, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Peptic Ulcer Disease											
2010	1,135	1,135	6,057	223,709	631.3	278,921	43,504.9	4.07	197.10	5.34	36.93

	New Users	New Episodes	Dispensings	Total Days Supplied	Years at Risk	Eligible Members	Member-Years	New Users / 1K Eligible Members	Days Supplied/ User	Dispensings / User	Days Supplied/ Dispensing
2011	16,321	16,321	70,262	2,599,103	7,442.2	479,195	212,583.6	34.06	159.25	4.31	36.99
2012	11,607	11,607	32,564	1,169,785	3,358.3	492,849	221,347.9	23.55	100.78	2.81	35.92
Exposure of Dabigatran, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Hospitalized AMI											
2010	1,116	1,116	5,972	220,739	622.6	273,339	42,659.2	4.08	197.79	5.35	36.96
2011	15,851	15,851	68,343	2,531,398	7,249.2	468,598	208,126.7	33.83	159.70	4.31	37.04
2012	11,268	11,268	31,572	1,134,493	3,257.9	481,797	216,415.4	23.39	100.68	2.80	35.93
Exposure of Dabigatran, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Heart Failure											
2010	857	857	4,573	170,725	481.6	241,385	37,414.5	3.55	199.21	5.34	37.33
2011	12,575	12,575	54,365	2,024,174	5,794.2	417,679	185,703.1	30.11	160.97	4.32	37.23
2012	8,834	8,834	24,558	888,886	2,554.0	428,544	194,270.3	20.61	100.62	2.78	36.20
Exposure of Dabigatran, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Peripheral Vascular Disease											
2010	1,039	1,039	5,519	203,157	573.7	260,755	40,342.4	3.98	195.53	5.31	36.81
2011	14,998	14,998	64,531	2,390,088	6,840.2	453,081	198,236.1	33.10	159.36	4.30	37.04
2012	10,651	10,651	29,820	1,070,032	3,071.0	464,875	207,346.3	22.91	100.46	2.80	35.88
Exposure of Dabigatran, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Stroke											
2010	1,102	1,102	5,839	216,149	610.3	276,783	43,212.6	3.98	196.14	5.30	37.02
2011	15,776	15,776	67,191	2,482,948	7,117.6	474,647	210,865.8	33.24	157.39	4.26	36.95
2012	11,241	11,241	31,207	1,123,729	3,228.4	487,657	219,114.3	23.05	99.97	2.78	36.01
Exposure of Dabigatran, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Urinary Catheter											
2010	1,127	1,127	5,934	219,509	619.5	275,989	42,983.9	4.08	194.77	5.27	36.99
2011	16,210	16,210	69,860	2,583,432	7,397.6	474,934	209,796.4	34.13	159.37	4.31	36.98
2012	11,524	11,524	32,323	1,161,453	3,333.6	488,040	218,205.4	23.61	100.79	2.80	35.93
Exposure of Dabigatran, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Hospitalized Bleeding											
2010	1,119	1,119	5,929	219,599	619.8	273,122	42,497.5	4.10	196.25	5.30	37.04
2011	16,031	16,031	69,124	2,560,082	7,329.0	468,631	206,471.1	34.21	159.70	4.31	37.04
2012	11,362	11,362	31,865	1,145,418	3,287.8	480,209	213,579.3	23.66	100.81	2.80	35.95
Exposure of Dabigatran, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of NSAID Use											
2010	983	983	5,372	197,756	557.3	263,171	40,763.7	3.74	201.18	5.46	36.81
2011	14,104	14,104	60,411	2,241,525	6,419.4	456,358	199,825.8	30.91	158.93	4.28	37.10
2012	10,110	10,110	28,554	1,023,928	2,941.2	469,571	209,615.0	21.53	101.28	2.82	35.86
Exposure of Dabigatran, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of PPI Use											
2010	925	925	5,053	184,173	520.5	241,063	37,334.1	3.84	199.11	5.46	36.45

	New Users	New Episodes	Dispensings	Total Days Supplied	Years at Risk	Eligible Members	Member-Years	New Users / 1K Eligible Members	Days Supplied/ User	Dispensings / User	Days Supplied/ Dispensing
2011	13,296	13,296	57,068	2,099,785	6,020.6	419,071	182,714.8	31.73	157.93	4.29	36.79
2012	9,471	9,471	26,665	954,422	2,745.7	428,148	189,658.3	22.12	100.77	2.82	35.79
Exposure of Dabigatran, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of SSRI Antidepressants Use											
2010	1,046	1,046	5,603	207,163	583.9	255,258	39,692.0	4.10	198.05	5.36	36.97
2011	14,728	14,728	63,359	2,348,382	6,725.8	441,325	194,562.8	33.37	159.45	4.30	37.06
2012	10,407	10,407	29,101	1,046,425	3,003.6	454,673	203,392.3	22.89	100.55	2.80	35.96
Exposure of Dabigatran, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Thyroid Replacement Use											
2010	994	994	5,192	191,258	540.6	247,557	38,520.6	4.02	192.41	5.22	36.84
2011	14,134	14,134	60,824	2,239,077	6,416.0	427,342	188,590.0	33.07	158.42	4.30	36.81
2012	10,085	10,085	28,187	1,009,446	2,900.7	439,099	196,375.4	22.97	100.09	2.79	35.81
Exposure of Dabigatran, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Insulin Use											
2010	1,077	1,077	5,706	210,959	595.5	268,711	41,939.2	4.01	195.88	5.30	36.97
2011	15,505	15,505	66,802	2,467,116	7,066.9	461,783	205,633.3	33.58	159.12	4.31	36.93
2012	11,012	11,012	30,933	1,109,201	3,184.8	474,972	214,342.2	23.18	100.73	2.81	35.86
Exposure of Dabigatran, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Metformin Use											
2010	1,011	1,011	5,472	199,814	565.1	264,588	41,308.1	3.82	197.64	5.41	36.52
2011	14,428	14,428	61,628	2,274,377	6,514.6	453,961	202,373.9	31.78	157.64	4.27	36.90
2012	10,178	10,178	28,465	1,020,443	2,932.9	466,597	210,919.9	21.81	100.26	2.80	35.85
Exposure of Dabigatran, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Sulfonylureas Use											
2010	1,059	1,059	5,722	211,210	596.2	265,933	41,518.1	3.98	199.44	5.40	36.91
2011	15,134	15,134	64,912	2,397,085	6,864.3	457,953	203,829.5	33.05	158.39	4.29	36.93
2012	10,823	10,823	30,289	1,086,902	3,122.0	472,411	213,087.0	22.91	100.43	2.80	35.88
Exposure of Dabigatran, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Other Diabetes Management Medication Use											
2010	1,078	1,078	5,782	212,940	601.5	273,463	42,674.3	3.94	197.53	5.36	36.83
2011	15,539	15,539	66,369	2,449,388	7,017.5	470,709	209,225.6	33.01	157.63	4.27	36.91
2012	11,138	11,138	31,175	1,117,392	3,209.7	485,728	218,710.5	22.93	100.32	2.80	35.84
Exposure of Dabigatran, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of ACEI/ARB Use											
2010	572	572	2,675	95,766	272.6	199,739	30,963.0	2.86	167.42	4.68	35.80
2011	8,361	8,361	33,983	1,222,628	3,526.0	347,882	153,124.8	24.03	146.23	4.06	35.98
2012	6,196	6,196	17,023	598,799	1,730.4	360,271	161,952.8	17.20	96.64	2.75	35.18
Exposure of Dabigatran, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Anti-arrhythmic Use											
2010	880	880	4,773	178,469	503.1	248,310	38,021.3	3.54	202.81	5.42	37.39

	New Users	New Episodes	Dispensings	Total Days Supplied	Years at Risk	Eligible Members	Member-Years	New Users / 1K Eligible Members	Days Supplied/ User	Dispensings / User	Days Supplied/ Dispensing
2011	12,949	12,949	56,777	2,108,626	6,025.3	438,053	185,148.4	29.56	162.84	4.38	37.14
2012	9,419	9,419	26,623	959,656	2,748.9	449,984	192,869.4	20.93	101.89	2.83	36.05

	New Users	New Episodes	Dispensings	Total Days Supplied	Years at Risk	Eligible Members	Member-Years	New Users / 1K Eligible Members	Days Supplied/ User	Dispensings / User	Days Supplied/ Dispensing
Exposure of Dabigatran, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of IV Anticoagulant Use											
2010	1,069	1,069	5,773	214,145	603.9	273,133	42,452.3	3.91	200.32	5.40	37.09
2011	15,474	15,474	66,939	2,481,517	7,101.6	469,869	206,451.0	32.93	160.37	4.33	37.07
2012	11,000	11,000	30,903	1,113,844	3,194.5	481,649	213,450.3	22.84	101.26	2.81	36.04
Exposure of Dabigatran, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Antiplatelet Use											
2010	992	992	5,152	190,008	536.1	255,923	39,721.5	3.88	191.54	5.19	36.88
2011	14,469	14,469	61,569	2,259,750	6,481.6	444,688	195,058.4	32.54	156.18	4.26	36.70
2012	10,511	10,511	29,258	1,048,884	3,015.0	459,559	204,240.0	22.87	99.79	2.78	35.85
Exposure of Dabigatran, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Beta Blocker Use											
2010	479	479	2,606	94,824	269.9	178,246	27,218.5	2.69	197.96	5.44	36.39
2011	6,973	6,973	29,150	1,064,540	3,056.3	318,016	134,054.1	21.93	152.67	4.18	36.52
2012	5,185	5,185	14,459	511,309	1,478.2	327,821	141,648.4	15.82	98.61	2.79	35.36
Exposure of Dabigatran, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Calcium Channel Blocker Use											
2010	777	777	4,017	145,910	412.1	225,361	34,740.5	3.45	187.79	5.17	36.32
2011	11,046	11,046	47,062	1,721,704	4,937.3	394,583	170,463.0	27.99	155.87	4.26	36.58
2012	7,951	7,951	22,010	785,035	2,260.5	407,578	178,694.4	19.51	98.73	2.77	35.67
Exposure of Dabigatran, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Digoxin Use											
2010	994	994	5,255	194,525	549.4	257,354	39,786.2	3.86	195.70	5.29	37.02
2011	14,688	14,688	63,561	2,349,273	6,727.0	450,583	195,650.5	32.60	159.95	4.33	36.96
2012	10,605	10,605	29,842	1,069,575	3,070.1	465,451	205,036.3	22.78	100.86	2.81	35.84
Exposure of Dabigatran, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Loop Diuretic Use											
2010	928	928	5,062	188,315	531.2	242,117	37,478.7	3.83	202.93	5.45	37.20
2011	13,393	13,393	58,045	2,143,913	6,139.1	422,505	184,632.3	31.70	160.08	4.33	36.94
2012	9,635	9,635	27,032	967,039	2,778.6	434,823	192,962.7	22.16	100.37	2.81	35.77
Exposure of Dabigatran, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Potassium-Sparing Diuretic Use											
2010	1,094	1,094	5,843	217,154	612.5	273,369	42,582.3	4.00	198.50	5.34	37.16
2011	15,790	15,790	67,907	2,512,780	7,195.1	470,661	208,305.1	33.55	159.14	4.30	37.00
2012	11,278	11,278	31,564	1,134,093	3,256.3	483,655	216,736.3	23.32	100.56	2.80	35.93
Exposure of Dabigatran, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Thiazide Diuretic Use											
2010	875	875	4,510	165,722	468.1	245,109	38,129.8	3.57	189.40	5.15	36.75
2011	12,550	12,550	52,767	1,934,641	5,555.7	425,141	187,735.9	29.52	154.15	4.20	36.66
2012	9,052	9,052	25,108	893,478	2,573.9	440,047	197,606.0	20.57	98.71	2.77	35.59

	New Users	New Episodes	Dispensings	Total Days Supplied	Years at Risk	Eligible Members	Member-Years	New Users / 1K Eligible Members	Days Supplied/ User	Dispensings / User	Days Supplied/ Dispensing
Exposure of Dabigatran, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Amiodarone Use											
2010	1,062	1,062	5,699	210,675	594.5	267,103	41,354.7	3.98	198.38	5.37	36.97
2011	15,333	15,333	66,296	2,452,938	7,020.7	464,088	202,017.7	33.04	159.98	4.32	37.00
2012	10,886	10,886	30,614	1,099,380	3,151.9	476,675	209,843.1	22.84	100.99	2.81	35.91
Exposure of Dabigatran, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Dronedarone Use											
2010	1,061	1,061	5,658	210,451	594.1	277,223	43,145.1	3.83	198.35	5.33	37.20
2011	15,460	15,460	66,688	2,469,547	7,066.6	476,548	210,222.0	32.44	159.74	4.31	37.03
2012	11,235	11,235	31,514	1,133,675	3,253.9	490,012	219,116.0	22.93	100.91	2.80	35.97

Table 4b. Summary of Incident Warfarin Use in the MSDD between October 19, 2010 and December 31, 2012, by Pre-Existing Condition Criteria and Year

	New Users	New Episodes	Dispensings	Total Days Supplied	Years at Risk	Eligible Members	Member-Years	New Users / 1K Eligible Members	Days Supplied/ User	Dispensings / User	Days Supplied/ Dispensing
Exposure of Warfarin Pre-Existing Inclusion of Atrial Fibrillation											
2010	12,776	12,776	47,192	1,987,115	5,587.0	280,461	43,792.1	45.55	155.53	3.69	42.11
2011	47,036	47,036	177,468	7,257,301	20,544.6	479,355	213,389.0	98.12	154.29	3.77	40.89
2012	47,046	47,046	126,199	4,978,321	13,899.3	486,985	219,584.1	96.61	105.82	2.68	39.45
Exposure of Warfarin, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Anemia											
2010	9,781	9,781	35,659	1,541,127	4,329.3	244,292	37,726.4	40.04	157.56	3.65	43.22
2011	34,778	34,778	129,922	5,471,868	15,482.8	422,429	185,177.9	82.33	157.34	3.74	42.12
2012	34,522	34,522	91,195	3,704,710	10,338.2	428,955	191,667.0	80.48	107.31	2.64	40.62
Exposure of Warfarin, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of COPD											
2010	10,351	10,351	37,321	1,605,348	4,515.4	250,727	38,908.0	41.28	155.09	3.61	43.01
2011	37,070	37,070	137,885	5,716,866	16,192.4	430,702	190,500.4	86.07	154.22	3.72	41.46
2012	36,875	36,875	97,270	3,911,290	10,917.0	438,543	197,375.3	84.09	106.07	2.64	40.21
Exposure of Warfarin, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Diabetes											
2010	8,646	8,646	30,945	1,306,224	3,681.8	227,760	35,378.5	37.96	151.08	3.58	42.21
2011	30,990	30,990	114,620	4,693,105	13,309.1	391,131	174,435.5	79.23	151.44	3.70	40.94
2012	30,463	30,463	80,599	3,200,997	8,948.3	398,659	181,226.1	76.41	105.08	2.65	39.72
Exposure of Warfarin, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Hypertension											
2010	2,771	2,771	9,001	397,478	1,122.9	179,811	27,781.3	15.41	143.44	3.25	44.16
2011	9,532	9,532	32,218	1,351,091	3,851.2	317,515	149,088.3	30.02	141.74	3.38	41.94
2012	8,997	8,997	22,664	923,832	2,597.2	332,434	168,970.2	27.06	102.68	2.52	40.76
Exposure of Warfarin, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Chronic Kidney Failure											
2010	10,472	10,472	37,894	1,605,349	4,516.0	254,287	39,499.2	41.18	153.30	3.62	42.36
2011	37,314	37,314	139,475	5,745,868	16,272.0	436,793	194,000.8	85.43	153.99	3.74	41.20
2012	36,750	36,750	98,530	3,919,727	10,953.8	442,581	199,534.8	83.04	106.66	2.68	39.78
Exposure of Warfarin, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Acute Kidney Failure											
2010	11,608	11,608	42,353	1,807,744	5,081.5	268,709	41,887.8	43.20	155.73	3.65	42.68
2011	41,779	41,779	155,884	6,478,152	18,339.4	456,884	203,011.4	91.44	155.06	3.73	41.56
2012	41,530	41,530	110,557	4,440,622	12,389.8	462,467	207,473.9	89.80	106.93	2.66	40.17
Exposure of Warfarin, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Peptic Ulcer Disease											
2010	12,685	12,685	46,887	1,974,351	5,550.8	278,921	43,504.9	45.48	155.64	3.70	42.11

	New Users	New Episodes	Dispensings	Total Days Supplied	Years at Risk	Eligible Members	Member-Years	New Users / 1K Eligible Members	Days Supplied/ User	Dispensings / User	Days Supplied/ Dispensing
2011	46,681	46,681	175,739	7,204,378	20,395.3	476,937	211,740.3	97.88	154.33	3.76	40.99
2012	46,709	46,709	125,211	4,943,597	13,801.7	484,368	217,705.1	96.43	105.84	2.68	39.48
Exposure of Warfarin, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Hospitalized AMI											
2010	12,048	12,048	44,327	1,879,687	5,283.1	273,339	42,659.2	44.08	156.02	3.68	42.41
2011	44,198	44,198	166,171	6,842,032	19,366.3	466,466	207,324.8	94.75	154.80	3.76	41.17
2012	44,188	44,188	118,019	4,694,071	13,106.4	473,931	213,044.9	93.24	106.23	2.67	39.77
Exposure of Warfarin, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Heart Failure											
2010	8,500	8,500	29,834	1,312,300	3,695.8	241,385	37,414.5	35.21	154.39	3.51	43.99
2011	30,165	30,165	110,503	4,647,729	13,174.1	416,205	185,155.6	72.48	154.08	3.66	42.06
2012	30,263	30,263	79,130	3,233,474	9,020.6	423,999	192,282.2	71.38	106.85	2.61	40.86
Exposure of Warfarin, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Peripheral Vascular Disease											
2010	11,082	11,082	40,355	1,719,108	4,838.8	260,755	40,342.4	42.50	155.13	3.64	42.60
2011	40,483	40,483	149,595	6,220,472	17,614.1	451,155	197,525.7	89.73	153.66	3.70	41.58
2012	40,249	40,249	106,190	4,259,010	11,885.5	458,110	204,471.6	87.86	105.82	2.64	40.11
Exposure of Warfarin, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Stroke											
2010	12,168	12,168	43,900	1,871,281	5,263.7	276,783	43,212.6	43.96	153.79	3.61	42.63
2011	44,606	44,606	164,928	6,814,421	19,305.4	472,431	210,033.3	94.42	152.77	3.70	41.32
2012	44,454	44,454	117,722	4,691,742	13,105.5	479,462	215,603.7	92.72	105.54	2.65	39.85
Exposure of Warfarin, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Urinary Catheter											
2010	12,466	12,466	45,681	1,936,691	5,444.0	275,989	42,983.9	45.17	155.36	3.66	42.40
2011	45,876	45,876	172,599	7,086,598	20,062.2	472,715	208,970.8	97.05	154.47	3.76	41.06
2012	45,857	45,857	122,863	4,861,792	13,574.4	479,847	214,699.3	95.57	106.02	2.68	39.57
Exposure of Warfarin, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Hospitalized Bleeding											
2010	12,262	12,262	45,332	1,923,952	5,406.0	273,122	42,497.5	44.90	156.90	3.70	42.44
2011	44,888	44,888	168,598	6,963,459	19,706.1	466,555	205,698.5	96.21	155.13	3.76	41.30
2012	44,708	44,708	119,467	4,758,189	13,268.7	472,659	210,370.3	94.59	106.43	2.67	39.83
Exposure of Warfarin, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of NSAID Use											
2010	11,263	11,263	41,332	1,754,051	4,932.2	263,171	40,763.7	42.80	155.74	3.67	42.44
2011	41,487	41,487	156,018	6,415,984	18,157.6	454,407	199,108.6	91.30	154.65	3.76	41.12
2012	42,024	42,024	112,513	4,460,015	12,456.4	462,249	206,532.9	90.91	106.13	2.68	39.64
Exposure of Warfarin, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of PPI Use											
2010	10,294	10,294	37,961	1,611,599	4,530.5	241,063	37,334.1	42.70	156.56	3.69	42.45

	New Users	New Episodes	Dispensings	Total Days Supplied	Years at Risk	Eligible Members	Member-Years	New Users / 1K Eligible Members	Days Supplied/ User	Dispensings / User	Days Supplied/ Dispensing
2011	37,562	37,562	140,446	5,802,841	16,420.3	417,403	182,102.5	89.99	154.49	3.74	41.32
2012	37,369	37,369	99,808	3,969,333	11,076.8	422,136	187,118.7	88.52	106.22	2.67	39.77
Exposure of Warfarin, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of SSRI Antidepressants Use											
2010	11,317	11,317	41,712	1,771,469	4,981.9	255,258	39,692.0	44.34	156.53	3.69	42.47
2011	41,575	41,575	155,636	6,434,008	18,214.4	439,368	193,836.5	94.62	154.76	3.74	41.34
2012	41,751	41,751	111,439	4,430,903	12,366.6	447,513	200,303.5	93.30	106.13	2.67	39.76
Exposure of Warfarin, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Thyroid Replacement Use											
2010	10,820	10,820	39,704	1,666,726	4,687.1	247,557	38,520.6	43.71	154.04	3.67	41.98
2011	39,958	39,958	149,450	6,098,455	17,280.7	425,431	187,871.3	93.92	152.62	3.74	40.81
2012	39,883	39,883	107,016	4,217,159	11,779.3	432,011	193,345.5	92.32	105.74	2.68	39.41
Exposure of Warfarin, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Insulin Use											
2010	11,841	11,841	43,431	1,834,009	5,159.0	268,711	41,939.2	44.07	154.89	3.67	42.23
2011	43,130	43,130	162,002	6,646,769	18,820.3	459,667	204,838.8	93.83	154.11	3.76	41.03
2012	43,192	43,192	115,708	4,576,941	12,783.0	467,270	210,990.2	92.43	105.97	2.68	39.56
Exposure of Warfarin, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Metformin Use											
2010	11,375	11,375	41,417	1,750,548	4,926.0	264,588	41,308.1	42.99	153.89	3.64	42.27
2011	41,698	41,698	156,086	6,357,421	18,020.7	451,931	201,609.1	92.27	152.46	3.74	40.73
2012	41,777	41,777	111,537	4,386,103	12,260.9	458,966	207,625.3	91.02	104.99	2.67	39.32
Exposure of Warfarin, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Sulfonylureas Use											
2010	11,521	11,521	42,073	1,766,300	4,972.8	265,933	41,518.1	43.32	153.31	3.65	41.98
2011	42,483	42,483	159,294	6,491,019	18,386.4	455,884	203,048.6	93.19	152.79	3.75	40.75
2012	42,788	42,788	114,641	4,513,473	12,608.8	464,745	209,780.9	92.07	105.48	2.68	39.37
Exposure of Warfarin, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Other Diabetes Management Medication Use											
2010	12,187	12,187	44,954	1,895,465	5,329.4	273,463	42,674.3	44.57	155.53	3.69	42.16
2011	44,981	44,981	169,000	6,925,420	19,610.3	468,558	208,414.5	96.00	153.96	3.76	40.98
2012	45,235	45,235	120,944	4,774,836	13,328.5	477,573	215,198.5	94.72	105.56	2.67	39.48
Exposure of Warfarin, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of ACEI/ARB Use											
2010	6,624	6,624	23,771	970,604	2,742.6	199,739	30,963.0	33.16	146.53	3.59	40.83
2011	24,694	24,694	90,976	3,651,391	10,370.8	346,830	152,724.8	71.20	147.87	3.68	40.14
2012	25,144	25,144	67,747	2,619,593	7,354.8	356,317	160,240.9	70.57	104.18	2.69	38.67
Exposure of Warfarin, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Anti-arrhythmic Use											
2010	10,930	10,930	41,218	1,730,946	4,862.6	248,310	38,021.3	44.02	158.37	3.77	41.99

	New Users	New Episodes	Dispensings	Total Days Supplied	Years at Risk	Eligible Members	Member-Years	New Users / 1K Eligible Members	Days Supplied/ User	Dispensings / User	Days Supplied/ Dispensing
2011	40,827	40,827	156,641	6,402,110	18,102.0	436,431	184,548.7	93.55	156.81	3.84	40.87
2012	41,335	41,335	111,907	4,410,643	12,301.2	443,452	190,147.1	93.21	106.70	2.71	39.41

	New Users	New Episodes	Dispensings	Total Days Supplied	Years at Risk	Eligible Members	Member-Years	New Users / 1K Eligible Members	Days Supplied/ User	Dispensings / User	Days Supplied/ Dispensing
Exposure of Warfarin, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of IV Anticoagulant Use											
2010	12,033	12,033	44,021	1,873,507	5,267.0	273,133	42,452.3	44.06	155.70	3.66	42.56
2011	44,008	44,008	165,400	6,802,879	19,256.7	467,798	205,681.0	94.07	154.58	3.76	41.13
2012	44,125	44,125	117,811	4,682,417	13,066.3	473,893	210,133.0	93.11	106.12	2.67	39.75
Exposure of Warfarin, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Antiplatelet Use											
2010	11,499	11,499	41,907	1,779,445	5,005.2	255,923	39,721.5	44.93	154.75	3.64	42.46
2011	42,349	42,349	158,111	6,508,797	18,435.4	442,672	194,303.4	95.67	153.69	3.73	41.17
2012	42,456	42,456	113,510	4,495,376	12,554.3	451,978	201,015.6	93.93	105.88	2.67	39.60
Exposure of Warfarin, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Beta Blocker Use											
2010	5,559	5,559	21,427	848,539	2,391.0	178,246	27,218.5	31.19	152.64	3.85	39.60
2011	21,179	21,179	80,332	3,197,088	9,077.6	317,299	133,770.3	66.75	150.96	3.79	39.80
2012	21,952	21,952	60,590	2,316,398	6,506.5	324,917	140,387.0	67.56	105.52	2.76	38.23
Exposure of Warfarin, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Calcium Channel Blocker Use											
2010	8,879	8,879	32,300	1,357,747	3,815.2	225,361	34,740.5	39.40	152.92	3.64	42.04
2011	32,651	32,651	121,593	4,952,654	14,028.8	393,196	169,946.1	83.04	151.68	3.72	40.73
2012	33,286	33,286	88,920	3,481,989	9,736.9	402,295	176,468.4	82.74	104.61	2.67	39.16
Exposure of Warfarin, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Digoxin Use											
2010	11,182	11,182	41,708	1,733,979	4,885.1	257,354	39,786.2	43.45	155.07	3.73	41.57
2011	42,021	42,021	160,159	6,488,624	18,374.6	448,734	194,960.5	93.64	154.41	3.81	40.51
2012	42,447	42,447	114,504	4,488,265	12,530.2	458,567	202,095.7	92.56	105.74	2.70	39.20
Exposure of Warfarin, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Loop Diuretic Use											
2010	9,540	9,540	35,383	1,479,332	4,166.6	242,117	37,478.7	39.40	155.07	3.71	41.81
2011	34,999	34,999	131,425	5,365,988	15,209.4	420,978	184,044.0	83.14	153.32	3.76	40.83
2012	35,263	35,263	95,035	3,751,255	10,482.9	429,619	190,705.7	82.08	106.38	2.70	39.47
Exposure of Warfarin, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Potassium-Sparing Diuretic Use											
2010	12,225	12,225	45,434	1,909,660	5,366.7	273,369	42,582.3	44.72	156.21	3.72	42.03
2011	44,998	44,998	170,150	6,952,705	19,680.0	468,500	207,489.9	96.05	154.51	3.78	40.86
2012	44,968	44,968	120,862	4,765,092	13,298.6	475,689	213,295.4	94.53	105.97	2.69	39.43
Exposure of Warfarin, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Thiazide Diuretic Use											
2010	9,865	9,865	36,016	1,508,128	4,244.9	245,109	38,129.8	40.25	152.88	3.65	41.87
2011	36,637	36,637	136,431	5,538,971	15,705.3	423,377	187,068.2	86.54	151.19	3.72	40.60
2012	37,276	37,276	99,810	3,914,368	10,952.7	433,498	194,791.9	85.99	105.01	2.68	39.22

	New Users	New Episodes	Dispensings	Total Days Supplied	Years at Risk	Eligible Members	Member-Years	New Users / 1K Eligible Members	Days Supplied/ User	Dispensings / User	Days Supplied/ Dispensing
Exposure of Warfarin, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Amiodarone Use											
2010	11,955	11,955	44,757	1,881,746	5,288.4	267,103	41,354.7	44.76	157.40	3.74	42.04
2011	44,175	44,175	168,259	6,881,489	19,466.9	462,170	201,308.4	95.58	155.78	3.81	40.90
2012	44,292	44,292	119,372	4,706,568	13,137.0	469,629	206,861.8	94.31	106.26	2.70	39.43
Exposure of Warfarin, Pre-Existing Inclusion of Atrial Fibrillation and Exclusion of Dronedaronone Use											
2010	12,495	12,495	46,271	1,949,585	5,481.2	277,223	43,145.1	45.07	156.03	3.70	42.13
2011	46,167	46,167	174,220	7,129,337	20,180.5	474,352	209,399.8	97.33	154.42	3.77	40.92
2012	46,398	46,398	124,376	4,910,104	13,708.0	481,444	215,453.1	96.37	105.83	2.68	39.48

Table 5. Pre-existing Conditions and Prescription Drug Dispensings among Incident Dabigatran and Warfarin Users with Atrial Fibrillation

Condition/Drug Product	Dabigatran N, (%)	Warfarin N, (%)
Atrial fibrillation	29,157(100%)	106,858 (100%)
Age		
0-40	560 (1.9%)	1,062 (1.0%)
41-54	3,755 (12.9%)	7,429 (7.0%)
55-64	8,069 (27.7%)	18,880 (17.7%)
65-74	8,064 (27.7%)	30,344 (28.4%)
75-84	6,533 (22.4%)	34,933 (32.7%)
85+	2,176 (7.5%)	14,210 (13.3%)
Gender		
Female	10,245 (35.1%)	45,630 (42.7%)
Male	18,912 (64.9%)	61,225 (57.3%)
Medical condition		
Anemia	3,960 (13.6%)	27,777 (26.0%)
COPD	4,203 (14.4%)	22,562 (21.1%)
Diabetes	7,974 (27.3%)	36,759 (34.4%)
Hypertension	21,918 (75.2%)	85,558 (80.1%)
Chronic kidney failure	2,754 (9.4%)	22,322 (20.9%)
Acute kidney failure	1,346 (4.6%)	11,941 (11.2%)
Peptic ulcer disease	94 (0.3%)	783 (0.7%)
Hospitalized AMI	922 (3.2%)	6,424 (6.0%)
Heart failure	6,891 (23.6%)	37,930 (35.5%)
Peripheral vascular disease	2,469(8.5%)	15,044 (14.1%)
Stroke	1,038 (3.6%)	5,630 (5.3%)
Urinary catheter	296 (1.0%)	2,659 (2.5%)
Hospitalized bleeding	645 (2.2%)	5,000 (4.7%)
Drug Products		
NSAIDs	3,960 (13.6%)	12,084 (11.3%)
Proton pump inhibitors	5,465 (18.7%)	21,633 (20.2%)
SSRI antidepressants	2,976 (10.2%)	12,215 (11.4%)
Thyroid replacement	3,944 (13.5%)	16,197 (15.2%)
Insulin	1,563 (5.4%)	8,695 (8.1%)
Metformin	3,540 (12.1%)	12,008 (11.2%)
Sulfonyureas	2,141 (7.3%)	10,066 (9.4%)
Other Diabetes medications	1,402 (4.8%)	4,455 (4.2%)
ACEI/ARBs	14,028 (48.1%)	50,396 (47.2%)
Antiarrhythmics	5,909 (20.3%)	13,766 (12.9%)
Injectable anticoagulants	1,614 (5.5%)	6,692 (6.3%)
Anti-platelets	3,185 (10.9%)	10,554 (9.9%)
Beta-blockers	16,520 (56.7%)	58,168 (54.4%)
Calcium channel blockers	9,383 (32.2%)	32,042 (30.0%)
Digoxin	2,870 (9.8%)	11,208 (10.5%)
Loop diuretics	5,201 (17.8%)	27,056 (25.3%)
Potassium-sparing diuretics	995 (3.4%)	4,667 (4.4%)
Thiazide diuretics	6,680 (22.9%)	23,080 (21.6%)
Amiodarone	1,876 (6.4%)	6,436 (6.0%)
Dronedarone	1,401 (4.8%)	1,798 (1.7%)

Appendix A. ICD-9CM Code List for Pre-Existing Conditions

Code	Code Type	Description
Afib		
427.31	ICD-9-CM Diagnosis Code	Afib
Anemia		
280	ICD-9-CM Diagnosis Code	Anemia
280.0	ICD-9-CM Diagnosis Code	Anemia
280.1	ICD-9-CM Diagnosis Code	Anemia
280.8	ICD-9-CM Diagnosis Code	Anemia
280.9	ICD-9-CM Diagnosis Code	Anemia
281	ICD-9-CM Diagnosis Code	Anemia
281.0	ICD-9-CM Diagnosis Code	Anemia
281.1	ICD-9-CM Diagnosis Code	Anemia
281.2	ICD-9-CM Diagnosis Code	Anemia
281.3	ICD-9-CM Diagnosis Code	Anemia
281.4	ICD-9-CM Diagnosis Code	Anemia
281.8	ICD-9-CM Diagnosis Code	Anemia
281.9	ICD-9-CM Diagnosis Code	Anemia
282	ICD-9-CM Diagnosis Code	Anemia
282.0	ICD-9-CM Diagnosis Code	Anemia
282.1	ICD-9-CM Diagnosis Code	Anemia
282.2	ICD-9-CM Diagnosis Code	Anemia
282.3	ICD-9-CM Diagnosis Code	Anemia
282.4	ICD-9-CM Diagnosis Code	Anemia
282.41	ICD-9-CM Diagnosis Code	Anemia
282.42	ICD-9-CM Diagnosis Code	Anemia
282.49	ICD-9-CM Diagnosis Code	Anemia
282.5	ICD-9-CM Diagnosis Code	Anemia
282.6	ICD-9-CM Diagnosis Code	Anemia
282.60	ICD-9-CM Diagnosis Code	Anemia
282.61	ICD-9-CM Diagnosis Code	Anemia
282.62	ICD-9-CM Diagnosis Code	Anemia
282.63	ICD-9-CM Diagnosis Code	Anemia
282.64	ICD-9-CM Diagnosis Code	Anemia
282.68	ICD-9-CM Diagnosis Code	Anemia
282.69	ICD-9-CM Diagnosis Code	Anemia
282.7	ICD-9-CM Diagnosis Code	Anemia
282.8	ICD-9-CM Diagnosis Code	Anemia
282.9	ICD-9-CM Diagnosis Code	Anemia
283	ICD-9-CM Diagnosis Code	Anemia
283.0	ICD-9-CM Diagnosis Code	Anemia
283.1	ICD-9-CM Diagnosis Code	Anemia
283.10	ICD-9-CM Diagnosis Code	Anemia
283.11	ICD-9-CM Diagnosis Code	Anemia
283.19	ICD-9-CM Diagnosis Code	Anemia
283.2	ICD-9-CM Diagnosis Code	Anemia
283.9	ICD-9-CM Diagnosis Code	Anemia
285	ICD-9-CM Diagnosis Code	Anemia
285.0	ICD-9-CM Diagnosis Code	Anemia
285.1	ICD-9-CM Diagnosis Code	Anemia
285.2	ICD-9-CM Diagnosis Code	Anemia
285.21	ICD-9-CM Diagnosis Code	Anemia
285.22	ICD-9-CM Diagnosis Code	Anemia
285.29	ICD-9-CM Diagnosis Code	Anemia
285.3	ICD-9-CM Diagnosis Code	Anemia
285.8	ICD-9-CM Diagnosis Code	Anemia

Code	Code Type	Description
285.9	ICD-9-CM Diagnosis Code	Anemia
COPD		
491	ICD-9-CM Diagnosis Code	COPD
491.0	ICD-9-CM Diagnosis Code	COPD
491.1	ICD-9-CM Diagnosis Code	COPD
491.2	ICD-9-CM Diagnosis Code	COPD
491.20	ICD-9-CM Diagnosis Code	COPD
491.21	ICD-9-CM Diagnosis Code	COPD
491.22	ICD-9-CM Diagnosis Code	COPD
491.8	ICD-9-CM Diagnosis Code	COPD
491.9	ICD-9-CM Diagnosis Code	COPD
492	ICD-9-CM Diagnosis Code	COPD
492.0	ICD-9-CM Diagnosis Code	COPD
492.8	ICD-9-CM Diagnosis Code	COPD
494	ICD-9-CM Diagnosis Code	COPD
494.0	ICD-9-CM Diagnosis Code	COPD
494.1	ICD-9-CM Diagnosis Code	COPD
496	ICD-9-CM Diagnosis Code	COPD
32141	HCPCS	COPD
32491	HCPCS	COPD
G8093	HCPCS	COPD
G8094	HCPCS	COPD
Diabetes		
250	ICD-9-CM Diagnosis Code	Diabetes
250.0	ICD-9-CM Diagnosis Code	Diabetes
250.00	ICD-9-CM Diagnosis Code	Diabetes
250.01	ICD-9-CM Diagnosis Code	Diabetes
250.02	ICD-9-CM Diagnosis Code	Diabetes
250.03	ICD-9-CM Diagnosis Code	Diabetes
250.1	ICD-9-CM Diagnosis Code	Diabetes
250.10	ICD-9-CM Diagnosis Code	Diabetes
250.11	ICD-9-CM Diagnosis Code	Diabetes
250.12	ICD-9-CM Diagnosis Code	Diabetes
250.13	ICD-9-CM Diagnosis Code	Diabetes
250.2	ICD-9-CM Diagnosis Code	Diabetes
250.20	ICD-9-CM Diagnosis Code	Diabetes
250.21	ICD-9-CM Diagnosis Code	Diabetes
250.22	ICD-9-CM Diagnosis Code	Diabetes
250.23	ICD-9-CM Diagnosis Code	Diabetes
250.3	ICD-9-CM Diagnosis Code	Diabetes
250.30	ICD-9-CM Diagnosis Code	Diabetes
250.31	ICD-9-CM Diagnosis Code	Diabetes
250.32	ICD-9-CM Diagnosis Code	Diabetes
250.33	ICD-9-CM Diagnosis Code	Diabetes
250.4	ICD-9-CM Diagnosis Code	Diabetes
250.40	ICD-9-CM Diagnosis Code	Diabetes
250.41	ICD-9-CM Diagnosis Code	Diabetes
250.42	ICD-9-CM Diagnosis Code	Diabetes
250.43	ICD-9-CM Diagnosis Code	Diabetes
250.5	ICD-9-CM Diagnosis Code	Diabetes
250.50	ICD-9-CM Diagnosis Code	Diabetes
250.51	ICD-9-CM Diagnosis Code	Diabetes
250.52	ICD-9-CM Diagnosis Code	Diabetes
250.53	ICD-9-CM Diagnosis Code	Diabetes
250.6	ICD-9-CM Diagnosis Code	Diabetes
250.60	ICD-9-CM Diagnosis Code	Diabetes

Code	Code Type	Description
250.61	ICD-9-CM Diagnosis Code	Diabetes
250.62	ICD-9-CM Diagnosis Code	Diabetes
250.63	ICD-9-CM Diagnosis Code	Diabetes
250.7	ICD-9-CM Diagnosis Code	Diabetes
250.70	ICD-9-CM Diagnosis Code	Diabetes
250.71	ICD-9-CM Diagnosis Code	Diabetes
250.72	ICD-9-CM Diagnosis Code	Diabetes
250.73	ICD-9-CM Diagnosis Code	Diabetes
250.8	ICD-9-CM Diagnosis Code	Diabetes
250.80	ICD-9-CM Diagnosis Code	Diabetes
250.81	ICD-9-CM Diagnosis Code	Diabetes
250.82	ICD-9-CM Diagnosis Code	Diabetes
250.83	ICD-9-CM Diagnosis Code	Diabetes
250.9	ICD-9-CM Diagnosis Code	Diabetes
250.90	ICD-9-CM Diagnosis Code	Diabetes
250.91	ICD-9-CM Diagnosis Code	Diabetes
250.92	ICD-9-CM Diagnosis Code	Diabetes
250.93	ICD-9-CM Diagnosis Code	Diabetes
G0108	HCPCS	Diabetes
G0109	HCPCS	Diabetes
G0245	HCPCS	Diabetes
G0246	HCPCS	Diabetes
G0247	HCPCS	Diabetes
G8015	HCPCS	Diabetes
G8016	HCPCS	Diabetes
G8017	HCPCS	Diabetes
G8018	HCPCS	Diabetes
G8019	HCPCS	Diabetes
G8020	HCPCS	Diabetes
G8021	HCPCS	Diabetes
G8022	HCPCS	Diabetes
G8023	HCPCS	Diabetes
G8024	HCPCS	Diabetes
G8025	HCPCS	Diabetes
G8026	HCPCS	Diabetes
G8332	HCPCS	Diabetes
G8333	HCPCS	Diabetes
G8334	HCPCS	Diabetes
G8335	HCPCS	Diabetes
G8336	HCPCS	Diabetes
G8385	HCPCS	Diabetes
G8386	HCPCS	Diabetes
G8390	HCPCS	Diabetes
Hypertension		
401	ICD-9-CM Diagnosis Code	Hypertension
401.1	ICD-9-CM Diagnosis Code	Hypertension
401.9	ICD-9-CM Diagnosis Code	Hypertension
402	ICD-9-CM Diagnosis Code	Hypertension
402.0	ICD-9-CM Diagnosis Code	Hypertension
402.00	ICD-9-CM Diagnosis Code	Hypertension
402.01	ICD-9-CM Diagnosis Code	Hypertension
402.1	ICD-9-CM Diagnosis Code	Hypertension
402.10	ICD-9-CM Diagnosis Code	Hypertension
402.11	ICD-9-CM Diagnosis Code	Hypertension
402.9	ICD-9-CM Diagnosis Code	Hypertension
402.90	ICD-9-CM Diagnosis Code	Hypertension

Code	Code Type	Description
402.91	ICD-9-CM Diagnosis Code	Hypertension
403	ICD-9-CM Diagnosis Code	Hypertension
403.0	ICD-9-CM Diagnosis Code	Hypertension
403.00	ICD-9-CM Diagnosis Code	Hypertension
403.01	ICD-9-CM Diagnosis Code	Hypertension
403.1	ICD-9-CM Diagnosis Code	Hypertension
403.10	ICD-9-CM Diagnosis Code	Hypertension
403.11	ICD-9-CM Diagnosis Code	Hypertension
403.9	ICD-9-CM Diagnosis Code	Hypertension
403.90	ICD-9-CM Diagnosis Code	Hypertension
403.91	ICD-9-CM Diagnosis Code	Hypertension
404	ICD-9-CM Diagnosis Code	Hypertension
404.0	ICD-9-CM Diagnosis Code	Hypertension
404.00	ICD-9-CM Diagnosis Code	Hypertension
404.01	ICD-9-CM Diagnosis Code	Hypertension
404.02	ICD-9-CM Diagnosis Code	Hypertension
404.03	ICD-9-CM Diagnosis Code	Hypertension
404.1	ICD-9-CM Diagnosis Code	Hypertension
404.10	ICD-9-CM Diagnosis Code	Hypertension
404.11	ICD-9-CM Diagnosis Code	Hypertension
404.12	ICD-9-CM Diagnosis Code	Hypertension
404.13	ICD-9-CM Diagnosis Code	Hypertension
404.9	ICD-9-CM Diagnosis Code	Hypertension
404.90	ICD-9-CM Diagnosis Code	Hypertension
404.91	ICD-9-CM Diagnosis Code	Hypertension
404.92	ICD-9-CM Diagnosis Code	Hypertension
404.93	ICD-9-CM Diagnosis Code	Hypertension
405	ICD-9-CM Diagnosis Code	Hypertension
405.0	ICD-9-CM Diagnosis Code	Hypertension
405.01	ICD-9-CM Diagnosis Code	Hypertension
405.09	ICD-9-CM Diagnosis Code	Hypertension
405.1	ICD-9-CM Diagnosis Code	Hypertension
405.11	ICD-9-CM Diagnosis Code	Hypertension
405.19	ICD-9-CM Diagnosis Code	Hypertension
405.9	ICD-9-CM Diagnosis Code	Hypertension
405.91	ICD-9-CM Diagnosis Code	Hypertension
405.99	ICD-9-CM Diagnosis Code	Hypertension
997.91	ICD-9-CM Diagnosis Code	Hypertension
Chronic Kidney Failure		
585	ICD-9-CM Diagnosis Code	ChronicKidneyFailure
585.1	ICD-9-CM Diagnosis Code	ChronicKidneyFailure
585.2	ICD-9-CM Diagnosis Code	ChronicKidneyFailure
585.3	ICD-9-CM Diagnosis Code	ChronicKidneyFailure
585.4	ICD-9-CM Diagnosis Code	ChronicKidneyFailure
585.5	ICD-9-CM Diagnosis Code	ChronicKidneyFailure
585.6	ICD-9-CM Diagnosis Code	ChronicKidneyFailure
585.9	ICD-9-CM Diagnosis Code	ChronicKidneyFailure
586	ICD-9-CM Diagnosis Code	ChronicKidneyFailure
587	ICD-9-CM Diagnosis Code	ChronicKidneyFailure
Acute Kidney Failure		
584	ICD-9-CM Diagnosis Code	AcuteKidneyFailure
584.5	ICD-9-CM Diagnosis Code	AcuteKidneyFailure
584.6	ICD-9-CM Diagnosis Code	AcuteKidneyFailure
584.7	ICD-9-CM Diagnosis Code	AcuteKidneyFailure
584.8	ICD-9-CM Diagnosis Code	AcuteKidneyFailure
584.9	ICD-9-CM Diagnosis Code	AcuteKidneyFailure

Code	Code Type	Description
Peptic Ulcer Disease		
531.0	ICD-9-CM Diagnosis Code	PepticUlcer
531.00	ICD-9-CM Diagnosis Code	PepticUlcer
531.01	ICD-9-CM Diagnosis Code	PepticUlcer
531.1	ICD-9-CM Diagnosis Code	PepticUlcer
531.10	ICD-9-CM Diagnosis Code	PepticUlcer
531.11	ICD-9-CM Diagnosis Code	PepticUlcer
531.2	ICD-9-CM Diagnosis Code	PepticUlcer
531.20	ICD-9-CM Diagnosis Code	PepticUlcer
531.21	ICD-9-CM Diagnosis Code	PepticUlcer
531.3	ICD-9-CM Diagnosis Code	PepticUlcer
531.30	ICD-9-CM Diagnosis Code	PepticUlcer
531.31	ICD-9-CM Diagnosis Code	PepticUlcer
531.4	ICD-9-CM Diagnosis Code	PepticUlcer
531.40	ICD-9-CM Diagnosis Code	PepticUlcer
531.41	ICD-9-CM Diagnosis Code	PepticUlcer
531.5	ICD-9-CM Diagnosis Code	PepticUlcer
531.50	ICD-9-CM Diagnosis Code	PepticUlcer
531.51	ICD-9-CM Diagnosis Code	PepticUlcer
531.6	ICD-9-CM Diagnosis Code	PepticUlcer
531.60	ICD-9-CM Diagnosis Code	PepticUlcer
531.61	ICD-9-CM Diagnosis Code	PepticUlcer
531.7	ICD-9-CM Diagnosis Code	PepticUlcer
531.70	ICD-9-CM Diagnosis Code	PepticUlcer
531.71	ICD-9-CM Diagnosis Code	PepticUlcer
532.0	ICD-9-CM Diagnosis Code	PepticUlcer
532.00	ICD-9-CM Diagnosis Code	PepticUlcer
532.01	ICD-9-CM Diagnosis Code	PepticUlcer
532.1	ICD-9-CM Diagnosis Code	PepticUlcer
532.10	ICD-9-CM Diagnosis Code	PepticUlcer
532.11	ICD-9-CM Diagnosis Code	PepticUlcer
532.2	ICD-9-CM Diagnosis Code	PepticUlcer
532.20	ICD-9-CM Diagnosis Code	PepticUlcer
532.21	ICD-9-CM Diagnosis Code	PepticUlcer
532.3	ICD-9-CM Diagnosis Code	PepticUlcer
532.30	ICD-9-CM Diagnosis Code	PepticUlcer
532.31	ICD-9-CM Diagnosis Code	PepticUlcer
532.4	ICD-9-CM Diagnosis Code	PepticUlcer
532.40	ICD-9-CM Diagnosis Code	PepticUlcer
532.41	ICD-9-CM Diagnosis Code	PepticUlcer
532.5	ICD-9-CM Diagnosis Code	PepticUlcer
532.50	ICD-9-CM Diagnosis Code	PepticUlcer
532.51	ICD-9-CM Diagnosis Code	PepticUlcer
532.6	ICD-9-CM Diagnosis Code	PepticUlcer
532.60	ICD-9-CM Diagnosis Code	PepticUlcer
532.61	ICD-9-CM Diagnosis Code	PepticUlcer
532.7	ICD-9-CM Diagnosis Code	PepticUlcer
532.70	ICD-9-CM Diagnosis Code	PepticUlcer
532.71	ICD-9-CM Diagnosis Code	PepticUlcer
533.0	ICD-9-CM Diagnosis Code	PepticUlcer
533.00	ICD-9-CM Diagnosis Code	PepticUlcer
533.01	ICD-9-CM Diagnosis Code	PepticUlcer
533.1	ICD-9-CM Diagnosis Code	PepticUlcer
533.10	ICD-9-CM Diagnosis Code	PepticUlcer
533.11	ICD-9-CM Diagnosis Code	PepticUlcer
533.2	ICD-9-CM Diagnosis Code	PepticUlcer

Code	Code Type	Description
533.20	ICD-9-CM Diagnosis Code	PepticUlcer
533.21	ICD-9-CM Diagnosis Code	PepticUlcer
533.3	ICD-9-CM Diagnosis Code	PepticUlcer
533.30	ICD-9-CM Diagnosis Code	PepticUlcer
533.31	ICD-9-CM Diagnosis Code	PepticUlcer
533.4	ICD-9-CM Diagnosis Code	PepticUlcer
533.40	ICD-9-CM Diagnosis Code	PepticUlcer
533.41	ICD-9-CM Diagnosis Code	PepticUlcer
533.5	ICD-9-CM Diagnosis Code	PepticUlcer
533.50	ICD-9-CM Diagnosis Code	PepticUlcer
533.51	ICD-9-CM Diagnosis Code	PepticUlcer
533.6	ICD-9-CM Diagnosis Code	PepticUlcer
533.60	ICD-9-CM Diagnosis Code	PepticUlcer
533.61	ICD-9-CM Diagnosis Code	PepticUlcer
533.7	ICD-9-CM Diagnosis Code	PepticUlcer
533.70	ICD-9-CM Diagnosis Code	PepticUlcer
533.71	ICD-9-CM Diagnosis Code	PepticUlcer
534.0	ICD-9-CM Diagnosis Code	PepticUlcer
534.00	ICD-9-CM Diagnosis Code	PepticUlcer
534.01	ICD-9-CM Diagnosis Code	PepticUlcer
534.1	ICD-9-CM Diagnosis Code	PepticUlcer
534.10	ICD-9-CM Diagnosis Code	PepticUlcer
534.11	ICD-9-CM Diagnosis Code	PepticUlcer
534.2	ICD-9-CM Diagnosis Code	PepticUlcer
534.20	ICD-9-CM Diagnosis Code	PepticUlcer
534.21	ICD-9-CM Diagnosis Code	PepticUlcer
534.3	ICD-9-CM Diagnosis Code	PepticUlcer
534.30	ICD-9-CM Diagnosis Code	PepticUlcer
534.31	ICD-9-CM Diagnosis Code	PepticUlcer
534.4	ICD-9-CM Diagnosis Code	PepticUlcer
534.40	ICD-9-CM Diagnosis Code	PepticUlcer
534.41	ICD-9-CM Diagnosis Code	PepticUlcer
534.5	ICD-9-CM Diagnosis Code	PepticUlcer
534.50	ICD-9-CM Diagnosis Code	PepticUlcer
534.51	ICD-9-CM Diagnosis Code	PepticUlcer
534.6	ICD-9-CM Diagnosis Code	PepticUlcer
534.60	ICD-9-CM Diagnosis Code	PepticUlcer
534.61	ICD-9-CM Diagnosis Code	PepticUlcer
534.7	ICD-9-CM Diagnosis Code	PepticUlcer
534.70	ICD-9-CM Diagnosis Code	PepticUlcer
534.71	ICD-9-CM Diagnosis Code	PepticUlcer
44.4	ICD-9-CM Procedure Code	PepticUlcer
44.40	ICD-9-CM Procedure Code	PepticUlcer
44.41	ICD-9-CM Procedure Code	PepticUlcer
44.42	ICD-9-CM Procedure Code	PepticUlcer
AMI		
410	ICD-9-CM Diagnosis Code	AMI
410.0	ICD-9-CM Diagnosis Code	AMI
410.00	ICD-9-CM Diagnosis Code	AMI
410.01	ICD-9-CM Diagnosis Code	AMI
410.02	ICD-9-CM Diagnosis Code	AMI
410.1	ICD-9-CM Diagnosis Code	AMI
410.10	ICD-9-CM Diagnosis Code	AMI
410.11	ICD-9-CM Diagnosis Code	AMI
410.12	ICD-9-CM Diagnosis Code	AMI
410.2	ICD-9-CM Diagnosis Code	AMI

Code	Code Type	Description
410.20	ICD-9-CM Diagnosis Code	AMI
410.21	ICD-9-CM Diagnosis Code	AMI
410.22	ICD-9-CM Diagnosis Code	AMI
410.3	ICD-9-CM Diagnosis Code	AMI
410.30	ICD-9-CM Diagnosis Code	AMI
410.31	ICD-9-CM Diagnosis Code	AMI
410.32	ICD-9-CM Diagnosis Code	AMI
410.4	ICD-9-CM Diagnosis Code	AMI
410.40	ICD-9-CM Diagnosis Code	AMI
410.41	ICD-9-CM Diagnosis Code	AMI
410.42	ICD-9-CM Diagnosis Code	AMI
410.5	ICD-9-CM Diagnosis Code	AMI
410.50	ICD-9-CM Diagnosis Code	AMI
410.51	ICD-9-CM Diagnosis Code	AMI
410.52	ICD-9-CM Diagnosis Code	AMI
410.6	ICD-9-CM Diagnosis Code	AMI
410.60	ICD-9-CM Diagnosis Code	AMI
410.61	ICD-9-CM Diagnosis Code	AMI
410.62	ICD-9-CM Diagnosis Code	AMI
410.7	ICD-9-CM Diagnosis Code	AMI
410.70	ICD-9-CM Diagnosis Code	AMI
410.71	ICD-9-CM Diagnosis Code	AMI
410.72	ICD-9-CM Diagnosis Code	AMI
410.8	ICD-9-CM Diagnosis Code	AMI
410.80	ICD-9-CM Diagnosis Code	AMI
410.81	ICD-9-CM Diagnosis Code	AMI
410.82	ICD-9-CM Diagnosis Code	AMI
410.9	ICD-9-CM Diagnosis Code	AMI
410.90	ICD-9-CM Diagnosis Code	AMI
410.91	ICD-9-CM Diagnosis Code	AMI
410.92	ICD-9-CM Diagnosis Code	AMI
Heart Failure		
402.01	ICD-9-CM Diagnosis Code	HeartFailure
402.11	ICD-9-CM Diagnosis Code	HeartFailure
402.91	ICD-9-CM Diagnosis Code	HeartFailure
404.01	ICD-9-CM Diagnosis Code	HeartFailure
404.03	ICD-9-CM Diagnosis Code	HeartFailure
404.11	ICD-9-CM Diagnosis Code	HeartFailure
404.13	ICD-9-CM Diagnosis Code	HeartFailure
404.91	ICD-9-CM Diagnosis Code	HeartFailure
404.93	ICD-9-CM Diagnosis Code	HeartFailure
428	ICD-9-CM Diagnosis Code	HeartFailure
428.0	ICD-9-CM Diagnosis Code	HeartFailure
428.1	ICD-9-CM Diagnosis Code	HeartFailure
428.2	ICD-9-CM Diagnosis Code	HeartFailure
428.20	ICD-9-CM Diagnosis Code	HeartFailure
428.21	ICD-9-CM Diagnosis Code	HeartFailure
428.22	ICD-9-CM Diagnosis Code	HeartFailure
428.23	ICD-9-CM Diagnosis Code	HeartFailure
428.3	ICD-9-CM Diagnosis Code	HeartFailure
428.30	ICD-9-CM Diagnosis Code	HeartFailure
428.31	ICD-9-CM Diagnosis Code	HeartFailure
428.32	ICD-9-CM Diagnosis Code	HeartFailure
428.33	ICD-9-CM Diagnosis Code	HeartFailure
428.4	ICD-9-CM Diagnosis Code	HeartFailure
428.40	ICD-9-CM Diagnosis Code	HeartFailure

Code	Code Type	Description
428.41	ICD-9-CM Diagnosis Code	HeartFailure
428.42	ICD-9-CM Diagnosis Code	HeartFailure
428.43	ICD-9-CM Diagnosis Code	HeartFailure
428.9	ICD-9-CM Diagnosis Code	HeartFailure
37.66	ICD-9-CM Procedure Code	HeartFailure
0050T	HCPCS	HeartFailure
33973	HCPCS	HeartFailure
33974	HCPCS	HeartFailure
33975	HCPCS	HeartFailure
33977	HCPCS	HeartFailure
33978	HCPCS	HeartFailure
33980	HCPCS	HeartFailure
92970	HCPCS	HeartFailure
92971	HCPCS	HeartFailure
G8027	HCPCS	HeartFailure
G8028	HCPCS	HeartFailure
G8029	HCPCS	HeartFailure
G8030	HCPCS	HeartFailure
G8031	HCPCS	HeartFailure
G8032	HCPCS	HeartFailure
G8184	HCPCS	HeartFailure
Peripheral Vascular Disease		
249.7	ICD-9-CM Diagnosis Code	PeripheralVascDis
249.70	ICD-9-CM Diagnosis Code	PeripheralVascDis
249.71	ICD-9-CM Diagnosis Code	PeripheralVascDis
250.7	ICD-9-CM Diagnosis Code	PeripheralVascDis
250.70	ICD-9-CM Diagnosis Code	PeripheralVascDis
250.71	ICD-9-CM Diagnosis Code	PeripheralVascDis
250.72	ICD-9-CM Diagnosis Code	PeripheralVascDis
250.73	ICD-9-CM Diagnosis Code	PeripheralVascDis
440.2	ICD-9-CM Diagnosis Code	PeripheralVascDis
440.20	ICD-9-CM Diagnosis Code	PeripheralVascDis
440.21	ICD-9-CM Diagnosis Code	PeripheralVascDis
440.22	ICD-9-CM Diagnosis Code	PeripheralVascDis
440.23	ICD-9-CM Diagnosis Code	PeripheralVascDis
440.24	ICD-9-CM Diagnosis Code	PeripheralVascDis
440.29	ICD-9-CM Diagnosis Code	PeripheralVascDis
440.3	ICD-9-CM Diagnosis Code	PeripheralVascDis
440.30	ICD-9-CM Diagnosis Code	PeripheralVascDis
440.31	ICD-9-CM Diagnosis Code	PeripheralVascDis
440.32	ICD-9-CM Diagnosis Code	PeripheralVascDis
440.4	ICD-9-CM Diagnosis Code	PeripheralVascDis
443.1	ICD-9-CM Diagnosis Code	PeripheralVascDis
443.81	ICD-9-CM Diagnosis Code	PeripheralVascDis
443.9	ICD-9-CM Diagnosis Code	PeripheralVascDis
38.03	ICD-9-CM Procedure Code	PeripheralVascDis
38.05	ICD-9-CM Procedure Code	PeripheralVascDis
38.06	ICD-9-CM Procedure Code	PeripheralVascDis
38.08	ICD-9-CM Procedure Code	PeripheralVascDis
38.13	ICD-9-CM Procedure Code	PeripheralVascDis
38.15	ICD-9-CM Procedure Code	PeripheralVascDis
38.16	ICD-9-CM Procedure Code	PeripheralVascDis
38.18	ICD-9-CM Procedure Code	PeripheralVascDis
39.22	ICD-9-CM Procedure Code	PeripheralVascDis
39.23	ICD-9-CM Procedure Code	PeripheralVascDis
39.24	ICD-9-CM Procedure Code	PeripheralVascDis

Code	Code Type	Description
39.25	ICD-9-CM Procedure Code	PeripheralVascDis
39.26	ICD-9-CM Procedure Code	PeripheralVascDis
39.29	ICD-9-CM Procedure Code	PeripheralVascDis
39.50	ICD-9-CM Procedure Code	PeripheralVascDis
39.90	ICD-9-CM Procedure Code	PeripheralVascDis
34203	HCPCS	PeripheralVascDis
35311	HCPCS	PeripheralVascDis
35321	HCPCS	PeripheralVascDis
35331	HCPCS	PeripheralVascDis
35341	HCPCS	PeripheralVascDis
35351	HCPCS	PeripheralVascDis
35355	HCPCS	PeripheralVascDis
35361	HCPCS	PeripheralVascDis
35363	HCPCS	PeripheralVascDis
35371	HCPCS	PeripheralVascDis
35372	HCPCS	PeripheralVascDis
35381	HCPCS	PeripheralVascDis
35450	HCPCS	PeripheralVascDis
35452	HCPCS	PeripheralVascDis
35454	HCPCS	PeripheralVascDis
35456	HCPCS	PeripheralVascDis
35458	HCPCS	PeripheralVascDis
35459	HCPCS	PeripheralVascDis
35460	HCPCS	PeripheralVascDis
35470	HCPCS	PeripheralVascDis
35471	HCPCS	PeripheralVascDis
35472	HCPCS	PeripheralVascDis
35473	HCPCS	PeripheralVascDis
35474	HCPCS	PeripheralVascDis
35475	HCPCS	PeripheralVascDis
35480	HCPCS	PeripheralVascDis
35481	HCPCS	PeripheralVascDis
35482	HCPCS	PeripheralVascDis
35483	HCPCS	PeripheralVascDis
35484	HCPCS	PeripheralVascDis
35485	HCPCS	PeripheralVascDis
35490	HCPCS	PeripheralVascDis
35491	HCPCS	PeripheralVascDis
35492	HCPCS	PeripheralVascDis
35493	HCPCS	PeripheralVascDis
35494	HCPCS	PeripheralVascDis
35495	HCPCS	PeripheralVascDis
35511	HCPCS	PeripheralVascDis
35512	HCPCS	PeripheralVascDis
35515	HCPCS	PeripheralVascDis
35516	HCPCS	PeripheralVascDis
35518	HCPCS	PeripheralVascDis
35521	HCPCS	PeripheralVascDis
35522	HCPCS	PeripheralVascDis
35523	HCPCS	PeripheralVascDis
35525	HCPCS	PeripheralVascDis
35526	HCPCS	PeripheralVascDis
35531	HCPCS	PeripheralVascDis
35533	HCPCS	PeripheralVascDis
35535	HCPCS	PeripheralVascDis
35536	HCPCS	PeripheralVascDis

Code	Code Type	Description
35537	HCPCS	PeripheralVascDis
35538	HCPCS	PeripheralVascDis
35539	HCPCS	PeripheralVascDis
35540	HCPCS	PeripheralVascDis
35541	HCPCS	PeripheralVascDis
35546	HCPCS	PeripheralVascDis
35548	HCPCS	PeripheralVascDis
35549	HCPCS	PeripheralVascDis
35551	HCPCS	PeripheralVascDis
35556	HCPCS	PeripheralVascDis
35558	HCPCS	PeripheralVascDis
35560	HCPCS	PeripheralVascDis
35563	HCPCS	PeripheralVascDis
35565	HCPCS	PeripheralVascDis
35566	HCPCS	PeripheralVascDis
35570	HCPCS	PeripheralVascDis
35571	HCPCS	PeripheralVascDis
35583	HCPCS	PeripheralVascDis
35585	HCPCS	PeripheralVascDis
35587	HCPCS	PeripheralVascDis
35612	HCPCS	PeripheralVascDis
35616	HCPCS	PeripheralVascDis
35621	HCPCS	PeripheralVascDis
35623	HCPCS	PeripheralVascDis
35626	HCPCS	PeripheralVascDis
35631	HCPCS	PeripheralVascDis
35632	HCPCS	PeripheralVascDis
35633	HCPCS	PeripheralVascDis
35634	HCPCS	PeripheralVascDis
35636	HCPCS	PeripheralVascDis
35637	HCPCS	PeripheralVascDis
35638	HCPCS	PeripheralVascDis
35641	HCPCS	PeripheralVascDis
35646	HCPCS	PeripheralVascDis
35647	HCPCS	PeripheralVascDis
35650	HCPCS	PeripheralVascDis
35651	HCPCS	PeripheralVascDis
35654	HCPCS	PeripheralVascDis
35656	HCPCS	PeripheralVascDis
35661	HCPCS	PeripheralVascDis
35663	HCPCS	PeripheralVascDis
35665	HCPCS	PeripheralVascDis
35666	HCPCS	PeripheralVascDis
35671	HCPCS	PeripheralVascDis
35700	HCPCS	PeripheralVascDis
35721	HCPCS	PeripheralVascDis
35741	HCPCS	PeripheralVascDis
35879	HCPCS	PeripheralVascDis
35881	HCPCS	PeripheralVascDis
Hospitalized Stroke		
430	ICD-9-CM Diagnosis Code	HospitalizedStroke
431	ICD-9-CM Diagnosis Code	HospitalizedStroke
433.01	ICD-9-CM Diagnosis Code	HospitalizedStroke
433.11	ICD-9-CM Diagnosis Code	HospitalizedStroke
433.21	ICD-9-CM Diagnosis Code	HospitalizedStroke
433.31	ICD-9-CM Diagnosis Code	HospitalizedStroke

Code	Code Type	Description
433.81	ICD-9-CM Diagnosis Code	HospitalizedStroke
433.91	ICD-9-CM Diagnosis Code	HospitalizedStroke
434.01	ICD-9-CM Diagnosis Code	HospitalizedStroke
434.11	ICD-9-CM Diagnosis Code	HospitalizedStroke
434.91	ICD-9-CM Diagnosis Code	HospitalizedStroke
436	ICD-9-CM Diagnosis Code	HospitalizedStroke
Urinary Catheter		
996.64	ICD-9-CM Diagnosis Code	UrinaryCatheter
V536	ICD-9-CM Diagnosis Code	UrinaryCatheter
57.94	ICD-9-CM Procedure Code	UrinaryCatheter
57.95	ICD-9-CM Procedure Code	UrinaryCatheter
96.48	ICD-9-CM Procedure Code	UrinaryCatheter
97.64	ICD-9-CM Procedure Code	UrinaryCatheter
51702	HCPCS	UrinaryCatheter
51703	HCPCS	UrinaryCatheter
A4311	HCPCS	UrinaryCatheter
A4312	HCPCS	UrinaryCatheter
A4313	HCPCS	UrinaryCatheter
A4314	HCPCS	UrinaryCatheter
A4315	HCPCS	UrinaryCatheter
A4316	HCPCS	UrinaryCatheter
A4338	HCPCS	UrinaryCatheter
A4344	HCPCS	UrinaryCatheter
A4346	HCPCS	UrinaryCatheter
A4355	HCPCS	UrinaryCatheter
Hospitalized Bleeding		
280.0	ICD-9-CM Diagnosis Code	HospitalizedBleed
285.1	ICD-9-CM Diagnosis Code	HospitalizedBleed
285.9	ICD-9-CM Diagnosis Code	HospitalizedBleed
423.0	ICD-9-CM Diagnosis Code	HospitalizedBleed
430	ICD-9-CM Diagnosis Code	HospitalizedBleed
431	ICD-9-CM Diagnosis Code	HospitalizedBleed
432.0	ICD-9-CM Diagnosis Code	HospitalizedBleed
432.1	ICD-9-CM Diagnosis Code	HospitalizedBleed
432.9	ICD-9-CM Diagnosis Code	HospitalizedBleed
455	ICD-9-CM Diagnosis Code	HospitalizedBleed
455.0	ICD-9-CM Diagnosis Code	HospitalizedBleed
455.1	ICD-9-CM Diagnosis Code	HospitalizedBleed
455.2	ICD-9-CM Diagnosis Code	HospitalizedBleed
455.3	ICD-9-CM Diagnosis Code	HospitalizedBleed
455.4	ICD-9-CM Diagnosis Code	HospitalizedBleed
455.5	ICD-9-CM Diagnosis Code	HospitalizedBleed
455.6	ICD-9-CM Diagnosis Code	HospitalizedBleed
455.7	ICD-9-CM Diagnosis Code	HospitalizedBleed
455.8	ICD-9-CM Diagnosis Code	HospitalizedBleed
455.9	ICD-9-CM Diagnosis Code	HospitalizedBleed
456.0	ICD-9-CM Diagnosis Code	HospitalizedBleed
456.20	ICD-9-CM Diagnosis Code	HospitalizedBleed
459.0	ICD-9-CM Diagnosis Code	HospitalizedBleed
530.1	ICD-9-CM Diagnosis Code	HospitalizedBleed
530.1.0	ICD-9-CM Diagnosis Code	HospitalizedBleed
530.11	ICD-9-CM Diagnosis Code	HospitalizedBleed
530.12	ICD-9-CM Diagnosis Code	HospitalizedBleed
530.13	ICD-9-CM Diagnosis Code	HospitalizedBleed
530.19	ICD-9-CM Diagnosis Code	HospitalizedBleed
530.7	ICD-9-CM Diagnosis Code	HospitalizedBleed

Code	Code Type	Description
535.11	ICD-9-CM Diagnosis Code	HospitalizedBleed
535.20	ICD-9-CM Diagnosis Code	HospitalizedBleed
535.21	ICD-9-CM Diagnosis Code	HospitalizedBleed
535.30	ICD-9-CM Diagnosis Code	HospitalizedBleed
535.31	ICD-9-CM Diagnosis Code	HospitalizedBleed
535.40	ICD-9-CM Diagnosis Code	HospitalizedBleed
535.41	ICD-9-CM Diagnosis Code	HospitalizedBleed
535.50	ICD-9-CM Diagnosis Code	HospitalizedBleed
535.51	ICD-9-CM Diagnosis Code	HospitalizedBleed
535.60	ICD-9-CM Diagnosis Code	HospitalizedBleed
535.61	ICD-9-CM Diagnosis Code	HospitalizedBleed
537.83	ICD-9-CM Diagnosis Code	HospitalizedBleed
562.00	ICD-9-CM Diagnosis Code	HospitalizedBleed
562.01	ICD-9-CM Diagnosis Code	HospitalizedBleed
562.02	ICD-9-CM Diagnosis Code	HospitalizedBleed
562.03	ICD-9-CM Diagnosis Code	HospitalizedBleed
562.10	ICD-9-CM Diagnosis Code	HospitalizedBleed
562.11	ICD-9-CM Diagnosis Code	HospitalizedBleed
562.12	ICD-9-CM Diagnosis Code	HospitalizedBleed
562.13	ICD-9-CM Diagnosis Code	HospitalizedBleed
568.81	ICD-9-CM Diagnosis Code	HospitalizedBleed
569.3	ICD-9-CM Diagnosis Code	HospitalizedBleed
569.85	ICD-9-CM Diagnosis Code	HospitalizedBleed
578.0	ICD-9-CM Diagnosis Code	HospitalizedBleed
578.1	ICD-9-CM Diagnosis Code	HospitalizedBleed
578.9	ICD-9-CM Diagnosis Code	HospitalizedBleed
593.81	ICD-9-CM Diagnosis Code	HospitalizedBleed
599.7	ICD-9-CM Diagnosis Code	HospitalizedBleed
599.70	ICD-9-CM Diagnosis Code	HospitalizedBleed
599.71	ICD-9-CM Diagnosis Code	HospitalizedBleed
599.72	ICD-9-CM Diagnosis Code	HospitalizedBleed
623.8	ICD-9-CM Diagnosis Code	HospitalizedBleed
626.2	ICD-9-CM Diagnosis Code	HospitalizedBleed
626.6	ICD-9-CM Diagnosis Code	HospitalizedBleed
719.1	ICD-9-CM Diagnosis Code	HospitalizedBleed
719.10	ICD-9-CM Diagnosis Code	HospitalizedBleed
719.11	ICD-9-CM Diagnosis Code	HospitalizedBleed
719.12	ICD-9-CM Diagnosis Code	HospitalizedBleed
719.13	ICD-9-CM Diagnosis Code	HospitalizedBleed
719.14	ICD-9-CM Diagnosis Code	HospitalizedBleed
719.15	ICD-9-CM Diagnosis Code	HospitalizedBleed
719.16	ICD-9-CM Diagnosis Code	HospitalizedBleed
719.17	ICD-9-CM Diagnosis Code	HospitalizedBleed
719.18	ICD-9-CM Diagnosis Code	HospitalizedBleed
719.19	ICD-9-CM Diagnosis Code	HospitalizedBleed
784.7	ICD-9-CM Diagnosis Code	HospitalizedBleed
784.8	ICD-9-CM Diagnosis Code	HospitalizedBleed
786.3	ICD-9-CM Diagnosis Code	HospitalizedBleed
790.92	ICD-9-CM Diagnosis Code	HospitalizedBleed